Multispecific antibodies for affinity receptor cross-linking and immunomodulation

By designing multispecific antibodies, using Fv form antigen binding parts and flexible and rigid peptide linkers, the immune response is activated in the tumor microenvironment, solving the problems of insufficient therapeutic activity and side effects in the prior art, and improving the antibody Stability and specificity.

CN119053342APending Publication Date: 2024-11-29LYVGEN BIOPHARMA HOLDINGS LIMITED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380028724.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-21
Filing Date
2023-01-20
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing antibody therapy methods targeting immune cell receptors may not achieve the desired clinical efficacy and have safety issues, making it difficult to develop effective and safe new immunotherapies.

Method used

A multispecific antibody was designed to adopt the antigen binding part of the Fv form, which drives the affinity of the target antigen by the simultaneous binding of multiple target antigens, realizes conditioned immune response regulation, and enhances the antibody's use of flexible and rigid peptide linkers. Stability and reduce Fc-mediated side effects.

Benefits of technology

It realizes the activation of therapeutic activity in the tumor microenvironment, avoids systemic immune responses, reduces undesired side effects, improves the stability and specificity of the antibody, and enhances the binding affinity for target antigens.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119053342A_ABST
    Figure CN119053342A_ABST
Patent Text Reader

Abstract

Immune cell receptors, such as Tumor Necrosis Factor Receptor (TNFR) superfamily members or CD3, play an important role in controlling immune responses to pathogens or diseased cells, including cancer cells and pathogen-infected cells. Antibodies targeting these immune cell receptors have been used to modulate immune responses and treat diseases. A multispecific antibody, optionally a multivalent antibody, comprising at least one antigen binding moiety in the Fv form. Also provided herein are methods for preparing such multispecific antibodies and their use for modulating immune responses and treating diseases such as cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of the filing date of International Patent Application No. PCT / CN2022 / 073220, filed on January 21, 2022, the entire contents of which are incorporated herein by reference.

[0003] Sequence Listing

[0004] This application contains a sequence listing that has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. The XML copy created on January 17, 2023 is named 112238-0101-70011WO01_SEQ.xml and is 715,745 bytes in size. Background Art

[0005] Immune cell receptors (such as tumor necrosis factor receptor (TNFR) superfamily members or immune cell receptors in CD3) play an important role in controlling the immune response to pathogens or diseased cells (including cancer cells and pathogen-infected cells). Antibodies targeting such immune cell receptors have been used to regulate immune responses and disease treatment. However, such treatment methods may not achieve the desired clinical efficacy and / or cause safety issues. Therefore, the development of effective and safe new immunotherapies is of great significance. Summary of the invention

[0006] The present disclosure is based, at least in part, on the design of multispecific, optionally multivalent antibody formats utilizing at least one antigen binding moiety in the form of an Fv. Multispecific antibodies having such a format as provided herein can bind to a variety of immune cell receptors or to both immune cell receptors and tumor-associated antigens (TAAs). For example, a binding moiety in the form of an Fv can bind to an immune cell receptor. Since monovalent Fv fragments generally have relatively low binding affinity to target antigens, especially when Fv fragments are connected to other antibody components via peptide linkers, the multispecific antibodies disclosed herein are expected to cause affinity-driven crosslinking of target antigens (e.g., immune cell receptors) by simultaneous binding of multiple antigen binding moieties to their multiple target antigens, so as to conditionally regulate immune responses. Such affinity-driven crosslinking of desired target receptors will result in therapeutic activity (e.g., anti-tumor cell immune responses), such as in a tumor microenvironment, while avoiding stimulation of systemic immune responses, which may cause undesirable side effects.

[0007] In addition, in some cases, a desired peptide linker, including a flexible peptide linker and a rigid peptide linker, can be used in the multispecific antibodies disclosed herein. Such peptide linkers can have at least the following advantageous features: (a) contribute to the functionality of the Fv fragment, (b) contribute to the proper dimerization (e.g., heterodimerization) of the two polypeptides of the multispecific antibody, thereby stabilizing the entire molecule; and (c) reduce the binding affinity to the Fcγ receptor to reduce or eliminate the effector function mediated by Fc, alone or in combination with additional mutations in the heavy chain constant region (e.g., CH2 and CH3 regions) used in the multispecific antibody.

[0008] It is noteworthy that the advantageous features associated with the specific Fv-containing multispecific antibody formats disclosed herein are not target antigen or antigen binding moiety specific. The multispecific antibody formats, comprising one or more Fv fragments disclosed herein and optionally specific peptide linkers, can be used to construct multispecific antibodies capable of binding to any desired target antigen and will be expected to have the advantageous features disclosed herein, such as affinity-driven cross-linking of the target antigen.

[0009] Thus, provided herein are multispecific antibodies, optionally in multivalent form, comprising at least one antigen binding portion in Fv format (monovalent), methods for producing such multispecific antibodies, and methods of using the multispecific antibodies for modulating immune responses and treating diseases.

[0010] In some aspects, the disclosure features a multispecific antibody comprising a first binding portion having specificity for a first target antigen and a second binding portion having specificity for a second target antigen. The first target antigen is a first immune cell receptor. In some cases, the first immune cell receptor can be a first T cell receptor, such as a T cell activation receptor or a T cell checkpoint receptor. In some cases, the second target antigen is a second immune cell receptor, optionally a second T cell receptor (e.g., a T cell activation receptor or a T cell checkpoint receptor). In some instances, the second immune cell receptor is different from the first immune cell receptor. Alternatively, the second target antigen is a tumor-associated antigen (TAA) (first TAA). The first binding portion is a first Fv fragment, which includes a first heavy chain variable region (V H ) and the first light chain variable region (V L ). The first V H Connected to a first flexible peptide linker and a first rigid peptide linker. LThe first rigid peptide linker and the second rigid peptide linker form one or more disulfide bonds. In some cases, the second binding moiety is connected to the first V through the first flexible peptide linker. H Connected or connected to the first V through the second flexible peptide linker L connect.

[0011] In some embodiments, the first flexible peptide linker and the second flexible peptide linker are the same. Alternatively, the first flexible peptide linker and the second flexible peptide linker are different. In some examples, the first flexible peptide linker, the second flexible peptide linker, or both are G / S-rich peptide linkers. For example, the G / S-rich peptide linker may include the formula (G X S) n , wherein x is an integer between 1-6, inclusive, and n is an integer between 1-10, inclusive. Specific examples are provided in Table 1, any of which can be used for the multispecific antibodies disclosed herein.

[0012] In some embodiments, the first rigid peptide linker, the second rigid peptide linker, or both comprise an amino acid sequence of DKTHTCPPCPAPEAAGP (SEQ ID NO: 21), DKTHTCPPCPAPELLGP (SEQ ID NO: 9), or DKTHTCPPCPAPELLGGP (SEQ ID NO: 27). In some cases, the rigid peptide linker may comprise the sequence just mentioned flanked by a G / S-rich peptide linker at the N-terminus and / or C-terminus. In some instances, the first rigid peptide linker, the second rigid peptide linker, or both comprise (G X S) n A motif, the motif is linked to the N-terminus of DKTHTCPPCPAPEAAGP (SEQ ID NO: 21), wherein x is an integer between 1-6, inclusive, and n is an integer between 1-10, inclusive. In other examples, the first rigid peptide linker, the second rigid peptide linker, or both include (G X S) n A motif linked to the N-terminus of DKTHTCPPCPAPELLGP (SEQ ID NO: 9) or to the N-terminus of DKTHTCPPCPAPELLGGP (SEQ ID NO: 27), wherein x is an integer between 1-6, inclusive, and n is an integer between 1-10, inclusive. Examples of rigid peptide linkers are provided in Table 1, any of which can be used in the multispecific antibodies disclosed herein.

[0013] Any of the multispecific antibodies disclosed herein can further include a third binding moiety that is specific for a third target antigen. In some cases, the third target antigen is the same as the second target antigen, for example, the third binding moiety is the same as the second binding moiety. Alternatively, the third binding moiety is different from the second binding moiety. For example, the third target antigen is a second TAA that is different from the first TAA.

[0014] In some embodiments, the second binding moiety is linked to the first V H The third binding moiety is connected to the first V through the second flexible peptide linker. L connect.

[0015] In some cases, the first V H The first V is further connected to the first Fc fragment via the first rigid peptide linker. L The first Fc fragment and the second Fc fragment may be further connected to the second Fc fragment via the second rigid peptide linker. Each Fc fragment may include a CH2 domain and / or a CH3 domain. In some cases, the Fc fragment may be derived from an IgG1 molecule. In some cases, the first Fc fragment and the second Fc fragment may include a mutation in the CH3 domain that enhances heterodimerization of the first Fc fragment and the second Fc fragment relative to a wild-type counterpart rather than homodimerization and / or reduces protein A binding. For example, the mutation may be a knob-in-hole mutation, a charged mutation, or a ZW1 mutation.

[0016] In some examples, the second binding moiety and / or the third binding moiety are in the form of a single-chain variable fragment (scFv). Alternatively, the second binding moiety and / or the third binding moiety are in the form of a single domain antibody, which is optionally in the form of a heavy chain (VHH); in the form of a Fab; or in the form of a cross-Fab. In a specific example, the second binding moiety is a Fab fragment, which includes a first VH-CH1 fragment and a first VL-CL fragment. In other examples, the second binding moiety is a cross-Fab fragment, which includes a first VH-CL fragment and a first VL-CH1 fragment. Alternatively or in addition, the third binding moiety is a Fab fragment, which includes a second VH-CH1 fragment and a second VL-CL fragment. In other examples, the third binding moiety is a cross-Fab fragment, which includes a second VH-CL fragment and a second VL-CH1 fragment.

[0017] In a specific example, the multispecific antibody disclosed herein comprises: (a) a first polypeptide, wherein the first polypeptide comprises, from N-terminus to C-terminus, the first VH-CH1 fragment or the first VH-CL fragment of the second binding moiety, the first flexible peptide linker, the first V H , the first rigid peptide linker and the first Fc fragment; (b) a second polypeptide, the second polypeptide comprising from N-terminus to C-terminus the second VH-CH1 fragment or the second VH-CL fragment of the third binding moiety, the second flexible peptide linker, the first V L , the second rigid peptide linker and the second Fc fragment; (c) a third polypeptide, the third polypeptide comprising the first VL-CL fragment or the first VL-CH1 fragment of the second binding moiety; and (d) a fourth polypeptide, the fourth polypeptide comprising the second VL-CL fragment or the second VL-CH1 fragment of the third binding moiety. In one example, the third polypeptide and the fourth polypeptide are the same.

[0018] Any of the multispecific antibodies disclosed herein may further include a fourth binding moiety that is specific for a fourth antigen. In some embodiments, the fourth target antigen is a third immune receptor, optionally a third T cell activating receptor. In some instances, the third immune receptor is different from the first immune receptor and / or the second immune receptor. For example, the fourth target antigen is a third TAA, which is optionally different from the first TAA or the second TAA.

[0019] In some embodiments, the fourth binding moiety is a second Fv fragment comprising a second V H and the second V L The second V H The first Fc fragment is connected to the first Fc fragment via a first peptide linker, and the second V L In some embodiments, the first peptide linker is connected with the second Fc fragment. In some cases, the first peptide linker is identical with the second peptide linker. In some instances, the first peptide linker, the second peptide linker or both are G / S-rich peptide linkers. In an example, the G / S-rich peptide linker comprises formula (GxS)n, wherein X is between 1-6, an integer including end values, and n is between 1-10, an integer including end values.

[0020] In some embodiments, the multispecific antibody may further include a third peptide linker and a fourth peptide linker, wherein the third peptide linker and the fourth peptide linker are respectively connected to the second V H and the second V LIn some cases, the third peptide linker and the fourth peptide linker are a pair of rigid peptide linkers that are optionally identical, and the pair of rigid peptide linkers form one or more disulfide bonds. In some examples, the third peptide linker, the fourth peptide linker, or both include an amino acid sequence of DKTHTCPPCPAPEAAGP (SEQ ID NO: 21), DKTHTCPPCPAPELLGP (SEQ ID NO: 9), or DKTHTCPPCPAPELLGGP (SEQ ID NO: 27). Each of the sequences can be connected to a G / S-rich peptide linker. In a specific example, the third peptide linker, the fourth peptide linker, or both include (G X S) n A motif that can be linked to the N-terminus of DKTHTCPPCPAPEAAGP (SEQ ID NO: 21), DKTHTCPPCPAPELLGP (SEQ ID NO: 9) or DKTHTCPPCPAPELLGGP (SEQ ID NO: 27), wherein x is an integer between 1-6, inclusive, and n is an integer between 1-10, inclusive.

[0021] In a specific example, the multispecific antibody disclosed herein may include: (a) a first polypeptide, wherein the first polypeptide includes, from the N-terminus to the C-terminus, the first VH-CH1 fragment or the first VH-CL fragment of the second binding moiety, the first flexible peptide linker, the first V H , the first rigid peptide linker, the first Fc fragment, the first peptide linker, the second V H and optionally the second peptide linker; (b) a second polypeptide, the second polypeptide comprising from N-terminus to C-terminus the second VH-CH1 fragment or the second VH-CL fragment of the third binding moiety, the second flexible peptide linker, the first V L , the second rigid peptide linker, the second Fc fragment, the third peptide linker and the second V L and optionally the fourth peptide linker; (c) a third polypeptide comprising the first VL-CL fragment or the first VL-CH1 fragment of the second binding moiety; and (d) a fourth polypeptide comprising the second VL-CL fragment or the second VL-CH1 fragment of the third binding moiety. In one example, the third polypeptide is the same as the fourth polypeptide.

[0022] In some cases, the multispecific antibodies disclosed herein may further include a first heavy chain constant region fragment and a second heavy chain constant region fragment, the first heavy chain constant region fragment being connected to the first flexible peptide linker, and the second heavy chain constant region fragment being connected to the second flexible peptide linker. In some instances, the first heavy chain constant region fragment and / or the second heavy chain constant region fragment are derived from an IgG1 molecule. Each of the first heavy chain constant region fragment and the second heavy chain constant region fragment includes a hinge domain, a CH2 domain, and a CH3 domain. The second binding moiety is connected to the first heavy chain constant region fragment or the second heavy chain constant region fragment. In some instances, the first heavy chain constant region fragment and the second heavy chain constant region fragment include mutations in the CH3 domain, the mutations enhancing heterodimerization of the first Fc fragment and the second Fc fragment rather than homodimerization and / or reducing protein A binding relative to wild-type counterparts. In some cases, the mutations may be knob-hole mutations, charged mutations, or ZW1 mutations.

[0023] In some examples, the multispecific antibody may further include a third binding moiety that is specific for a third target antigen. The second binding moiety may be connected to the first heavy chain constant region fragment, and the third binding moiety may be connected to the second heavy chain constant region fragment. In some examples, the third binding moiety is different from the second binding moiety. For example, the third target antigen is a second TAA, and the second TAA is different from the first TAA. In other examples, the third target antigen may be the same as the second target antigen. For example, the third binding moiety is the same as the second binding moiety.

[0024] In some examples, the second binding moiety and / or the third binding moiety are in the form of a single-chain variable fragment (scFv). Alternatively, the second binding moiety and / or the third binding moiety are in the form of a single domain antibody, which is optionally in the form of a heavy chain (VHH); in the form of a Fab; or in the form of a cross-Fab. In one example, the second binding moiety is a Fab fragment comprising a first VH-CH1 fragment and a first VL-CL fragment. In another example, the second binding moiety is a cross-Fab fragment comprising a first VH-CL fragment and a first VL-CH1 fragment. Alternatively or in addition, the third binding moiety is a Fab fragment comprising a second VH-CH1 fragment and a second VL-CL fragment. In another example, the third binding moiety is a cross-Fab fragment comprising a second VH-CL fragment and a second VL-CH1 fragment.

[0025] In a specific example, the multispecific antibody disclosed herein may include: (a) a first polypeptide, wherein the first polypeptide includes, from the N-terminus to the C-terminus, the first VH-CH1 fragment or the first VH-CL fragment of the second binding moiety, the first heavy chain constant region fragment, the first flexible peptide linker, the first V H and the first rigid peptide linker; (b) a second polypeptide, the second polypeptide comprising from N-terminus to C-terminus the second VH-CH1 fragment or the second VH-CL fragment of the third binding moiety, the second heavy chain constant region fragment, the second flexible peptide linker and the first V L , the second rigid peptide linker; (c) a third polypeptide, the third polypeptide comprising the first VL-CL fragment or the first VL-CH1 fragment of the second binding moiety; and (d) a fourth polypeptide, the fourth polypeptide comprising the second VL-CL fragment or the second VL-CH1 fragment of the third binding moiety. In one example, the third polypeptide and the fourth polypeptide are the same.

[0026] In other aspects, the disclosure features a multispecific antibody comprising a first binding portion having specificity for a first target antigen and a second binding portion having specificity for a second target antigen. The first target antigen is a first immune cell receptor, which is optionally a first T cell activating receptor; and the second target antigen is (i) a second immune cell receptor, which is optionally a second T cell activating receptor, which is different from the first immune cell receptor, or (ii) a first tumor-associated antigen (TAA). The first binding portion is a first Fv fragment, which comprises a first heavy chain variable region (V H ) and the first light chain variable region (V L ). The first V H is connected to a first peptide linker and a first heavy chain constant region fragment; and the first V L The second binding moiety is connected to the first binding moiety through the first heavy chain constant region fragment or the second heavy chain constant region fragment, each of the first heavy chain constant region and the second heavy chain constant region comprising a hinge domain, a CH2 domain and a CH3 domain. In some examples, the first heavy chain constant region fragment and / or the second heavy chain constant region fragment are derived from an IgG1 fragment.

[0027] In some embodiments, the first peptide linker, the second peptide linker, or both are G / S-rich peptide linkers. For example, the G / S-rich peptide linker comprises a formula (G X S) n(SEQ ID NOs: 29 and 512-516), wherein x is an integer between 1-6, inclusive, and n is an integer between 1-10, inclusive.

[0028] In some embodiments, the multispecific antibody may further include a third binding moiety that is specific for a third target antigen. In some cases, the third target antigen is the same as the second target antigen. For example, the third binding moiety is the same as the second binding moiety. In some cases, the third binding moiety is different from the second binding moiety. For example, the third target antigen is a second TAA, and the second TAA is optionally different from the first TAA. In some instances, the second binding moiety and / or the third binding moiety are in the form of a single-chain variable fragment (scFv); or in the form of a single domain antibody, which is optionally a heavy chain (VHH) form; in the form of a Fab; or in the form of a cross-Fab. In a specific example, the binding moiety is in the form of a scFv and / or a Fab.

[0029] In some embodiments, the first heavy chain constant region fragment and the second heavy chain constant region fragment comprise mutations in the CH3 domain that enhance heterodimerization rather than homodimerization of the first Fc fragment and the second Fc fragment relative to their wild-type counterparts and / or reduce protein A binding. Exemplary mutations include knob-in-hole mutations, charged mutations, and / or ZW1 mutations.

[0030] In any of the multispecific antibodies disclosed herein that contain one or more heavy chain constant region fragments, such as an Fc fragment, such heavy chain constant region fragments may include one or more mutations that alter binding activity to an Fc receptor relative to the wild-type counterpart. In a specific example, the heavy chain constant region fragment may include (i) a deletion at one or more of positions 236-238, (ii) an amino acid substitution at one or more of positions 239, 265, 297, 329, 330, and 332, or a combination thereof. In some examples, the heavy chain constant region fragment may include one or more of the following: (i) a deletion at position 237, (ii) at least two amino acid substitutions selected from L234A, L235A, and P329G, (iii) a deletion at position 237 and an amino acid substitution of D265A and N297A, (iv) amino acid substitutions S239D, A330L, and I332E, and (v) a deletion at position 237 and an amino acid substitution of P329G.

[0031] Any of the multispecific antibodies disclosed herein binds to at least one immune receptor (the first immune receptor), optionally additional immune receptors (the second immune receptor and / or the third immune receptor), which may be CD3, CD28, PD-1, PD-L1, CTLA4, CD47, or a member of the tumor necrosis factor receptor superfamily (TNFRSF). Examples of TNFRSF members include FAS, TNFRSF12A, 4-1BB / CD137, TNFRSF13B, TNFRSF13C, CD27 / TNFRSF7, CD30 / TNFRSF8, CD40 / TNFRSF5, DR3 / TNFRSF25, DR4 / TNFRSF10A, DR5 / TNFRSF10B, DR6 / TNFRSF21, GITR / TNFRSF18, HVEM / TNFRSF14, LTβR, OX40 / TNFRSF4, TROY / TNFRSF19, RELT / TNFRSF19L, TL1A / TNFSF15, TNFRSF17, TNFRSF1A, TNFRSF11B, RANK / TNFRSF11A, TNFRSF11B, NGFR, EDA2R, and TNFRSF1B, TNFRSF6B, TNFRSF10C, TNFRSF10D, or TNFRSF13A.

[0032] In some embodiments, the multispecific antibodies disclosed herein may further bind to at least one TAA (the first TAA), optionally additional TAAs (the second TAA and the third TAA), which TAA may be one or more of the following: B7H3, CD19, CD20, PSMA, HER2, CEA, BCMA, P53 mutant, DLL3, MET, EGFR, MAGE-A4 and PRAME.

[0033] In some embodiments, the multispecific antibodies disclosed herein may bind to at least: (a) CD3 and CD28, (b) CD3 and CD137, (c) CD137 and PD-1, (d) CD40 and PD-1, (e) CD40 and PD-L1, (f) CD137 and GITR, (g) CD137 and PD-L1, (h) CD137 and CD40, (i) CD137 and OX40, (j) CD3 and PD-1, (k) CD3 and PD-L1 or (l) CD3 and CTLA4.

[0034] In some examples, the multispecific antibodies disclosed herein can bind to the following: (1) B7H3, CD3 and CD137; (2) CD19, CD3 and CD137; (3) B7H3, CD3 and CD28; (4) CD19, CD3 and CD28; (5) B7H3, CD137 and PD-1; (6) B7H3, CD40 and PD-1; (7) PMSA, CD3 and CD137; (8) B7H3 and CD3; (9) B7H3 and CD137; (10) CD19 and CD3; (11) CD19 and CD137; (12) B7H4 and CD40; (13) HER2, CD3 and CD137; (14) CEA , CD3 and CD137; (15) BCMA, CD3 and CD137; (16) P53 mutants, CD3 and CD137; (17) PD-1 and CD137; (18) PD-1 and CD40; (19) B7H3 and CD40; (20) PD-L1 and CD40; (21) PD-L1 and CD3; (22) PD-L1, CD3 and CD137; (23) PD-L1, CD3 and CD28; (24) PD-L1, CD137 and B7H3; (25) PD-L1, CD40 and B7H3; (26) PD-1, CD40 and CD137; (27) PD-1, CD137 and GITR; (28 )CD19, CD20, CD3 and CD137; (29) CEA and CD3; (30) CEA and CD137; (31) P53 mutant and CD3; (32) P53 mutant and CD137; (33) PD-L1, CD40 and CD137; (34) PD-L1 and CD137; (35) MET, EGFR and CD47; (36) BCMA and CD3; (37) BCMA and CD137; (38) PSMA and CD3; (39) HER2 and CD3; (40) HER2 and CD40; (41) HER2 and CD137; (42) PSMA and CD137; (43) HER2, MET, C D3 and CD137; (44) MAGE-A4, CD3 and CD137; (45) PRAME, CD3 and CD137; (46) HER2, MET and CD3; (47) MAGE-A4 and CD3; (48) PRAME and CD3; (49) HER2, MET and CD47; (50) B7H3, CD3 and PD-1; (51) B7H3, CD3 and PD-L1; (52) B7H3, CD3, and CTLA4; (53) PSMA, CD3 and CD137; (54) PSMA, CD3 and CD28; (55) HER2, CD3 and CD137; (56) HER2, CD3 and CD28;(57) CEA, CD3 and CD137; (58) CEA, CD3 and CD28; (59) BCMA, CD3 and CD137; (60) BCMA, CD3 and CD28; (61) CD19, CD19, CD3 and CD28. ;

[0035] Any of the multispecific antibodies may include heavy chain complementarity determining regions (CDRs) and light chain CDRs that are identical to the heavy chain CDRs and light chain CDRs in one or more of the parent antibodies listed in Table 1. In some cases, the multispecific antibodies include heavy chain complementarity determining regions (CDRs) and light chain CDRs that are identical to the heavy chain CDRs and light chain CDRs in one or more of the parent antibodies listed in Table 1. H and V L Same V H and V L .

[0036] Any of the multispecific antibodies disclosed herein can be multivalent. In some examples, the multispecific antibody can be trivalent. In other examples, the multispecific antibody can be divalent or tetravalent.

[0037] Exemplary multispecific antibodies provided herein are provided in Table 2.

[0038] On the other hand, the present invention provides a nucleic acid or a nucleic acid group, which together encodes the multispecific antibody disclosed herein. In some embodiments, the nucleic acid or nucleic acid group can be an expression vector or an expression vector group. The present invention also provides a host cell, which includes a nucleic acid or a nucleic acid group encoding the multispecific antibody disclosed herein. In some embodiments, the host cell is a mammalian host cell.

[0039] In yet another aspect, the disclosure features a method for producing a multispecific antibody, the method comprising: (i) culturing a host cell disclosed herein under conditions that allow expression of the antibody; and (ii) harvesting the antibody produced thereby.

[0040] Additionally, the disclosure features a pharmaceutical composition that includes any of the multispecific antibodies disclosed herein or a nucleic acid or set of nucleic acids encoding the multispecific antibodies and a pharmaceutically acceptable carrier.

[0041] In other aspects, the disclosure features a method for modulating an immune response, the method comprising administering to a subject in need thereof an effective amount of a multispecific antibody disclosed herein, a nucleic acid encoding the multispecific antibody, or a pharmaceutical composition comprising the antibody or encoding nucleic acid. In some embodiments, the subject may be a human patient having or suspected of having cancer.

[0042] Furthermore, within the present disclosure are any of the multispecific antibodies disclosed herein for use in immunomodulation and therapy (e.g., cancer therapy), as well as the use of such multispecific antibodies in the manufacture of a medicament for the intended medical use.

[0043] The details of one or more embodiments of the invention are set forth in the following description. Other features and advantages of the invention will become apparent from the following drawings and the following detailed description of several embodiments and also from the appended claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] The following drawings form part of this specification and are included to further illustrate certain aspects of the present disclosure, which may be better understood by reference to the drawings in combination with the detailed description of specific embodiments presented herein.

[0045] Figures 1A-1D Contained are figures showing schematic designs of exemplary multispecific antibodies provided herein. Figure 1A : An exemplary antigen-binding portion in Fv format containing a heavy chain variable domain (V H ) and the light chain variable domain (V L ), each of which is connected to a flexible peptide linker and a rigid peptide linker. Figure 1B : Exemplary design of multispecific antibodies with a central (hidden) Fv fragment. Figure 1C : Exemplary design of multispecific antibodies with terminal Fv fragments. Figure 1D : Exemplary design of a multispecific antibody with one central Fv fragment and one terminal Fv fragment.

[0046] Figure 2A-2B Contains graphs showing the characterization of multispecific antibodies with different flexible peptide linkers. Figure 2A : B7H3 binding activity of Ly2364 [having (G4S)5 motif in the flexible peptide linker (SEQ ID NO:7)], Ly2365 [having (G4S)3 motif in the flexible peptide linker (SEQ ID NO:5)], Ly2366 [having (G4S)2 motif in the flexible peptide linker (SEQ ID NO:4)], Ly2367 (having G4S motif in the flexible peptide linker), Ly2368 (without G4S motif in the flexible peptide linker). B7H3 mAb Ly1612 was used as a positive control. Figure 2B : B7H3 binding activities of Ly2384 (having a G3S motif in a flexible peptide linker), Ly2385 (having a G2S motif in a flexible peptide linker), and the control Ly1612. Figure 2C: CD3 binding activity of Ly2364, Ly2365, Ly2366, Ly2367 and Ly2368. CD3 mAb Ly305 was used as a positive control. Figure 2D : CD3 binding activity of Ly2384, Ly2385 and control Ly305. Figure 2E : B7H3 binding activity of Ly2136 [having a (G4S)5 motif in a flexible peptide linker (SEQ ID NO:7)], Ly2137 [having a (G4S)3 motif in a flexible peptide linker (SEQ ID NO:5)], Ly2138 [having a (G4S)2 motif in a flexible peptide linker (SEQ ID NO:4)], Ly2139 (having a G4S motif in a flexible peptide linker) and the control Ly1612. Figure 2F : CD3 binding activity of Ly2136, Ly2137, Ly2138, Ly2139 and control Ly305.

[0047] Figure 3A-3B Contains graphs showing the characterization of multispecific antibodies with different rigid peptide linkers. Figure 3A : Images of SDS-PAGE analysis of multispecific antibodies with different rigid peptide linkers under both non-reducing and reducing conditions are shown. Lanes 1 and 2: Clone Ly1891 under reducing and non-reducing conditions, respectively. Lanes 3 and 4: Clone Ly1899 under reducing and non-reducing conditions, respectively. Lanes 5 and 6: Clone Ly1963 under reducing and non-reducing conditions, respectively. Lanes 7 and 8: Clone Ly1800 under reducing and non-reducing conditions, respectively. Lanes 9 and 10: Clone Ly1803 under reducing and non-reducing conditions, respectively. Lanes 11 and 12: Clone Ly1961 under reducing and non-reducing conditions, respectively. M: Molecular weight marker. Figure 3B : A graph showing the CD3 binding activity of the indicated exemplary multispecific antibodies. Parental CD3 mAb Ly305 was used as a positive control.

[0048] Figures 4A-4C Contains a graph showing the CD3 binding activity of the exemplary multispecific antibodies shown. Figure 4A : CD3 binding activity of Ly2125 (without G4S motif in the rigid peptide linker) and Ly2128 (with G4S motif in the rigid peptide linker). Clone Ly305 was used as a positive control CD3 mAb. Figure 4B : CD3 binding activity of Ly2157 (without G4S motif in the rigid peptide linker) and Ly1963 (with G4S motif in the rigid peptide linker). Figure 4C: CD3 binding activity of Ly2167 (without G4S motif in the rigid peptide linker) and Ly1967 (with G4S motif in the rigid peptide linker).

[0049] Figures 5A-5I Contains a graph showing the CD3 agonistic activity of the indicated exemplary multispecific antibodies comprising a central Fv fragment that binds to CD3. Agonistic activity was measured at various concentrations when incubated alone or co-cultured with CHO cells expressing the target antigen. Figure 5A : CD3 agonistic activity of clones Ly2128 and Ly305 (reference CD3 mAbs) assessed individually. Figure 5B : CD3 agonistic activity of clones Ly2128 and Ly305 when co-cultured with CHO cells overexpressing B7H3. Figure 5C : CD3 agonistic activity of clones Ly1966, Ly1967 and Ly305 assessed individually. Figure 5D : CD3 agonistic activity of clones Ly1966, Ly1967 and Ly305 when co-cultured with CHO cells overexpressing CD137. Figure 5E : CD3 agonistic activity of clones Ly1963, Ly1965 and Ly305 assessed individually. Fig. 5F : CD3 agonistic activity of clones Ly1963, Ly1965 and Ly305 when co-cultured with CHO cells overexpressing CD137. Figure 5G : CD3 agonistic activity of clones Ly1963, Ly1965 and Ly305 when co-cultured with CHO cells overexpressing B7H3. Figure 5H : CD3 agonistic activity of clones Ly2278 and Ly305 assessed individually. Fig.5I : CD3 agonistic activity of clones Ly2278 and Ly305 when co-cultured with CHO cells overexpressing CD19.

[0050] Figure 6A-6B Contains figures showing cytotoxicity assays using target tumor cells, effector PBMCs, and exemplary multispecific antibodies as indicated. Lactate dehydrogenase (LDH) release was used as an indicator of cytotoxicity. Fig. 6A : Cytotoxicity of clones Ly1963, Ly1965 and Ly2128. Figure 6B : Cytotoxicity of Ly1967 and Ly2278.

[0051] Figure 7A-7B Contains figures showing characterization of exemplary multispecific antibodies having a central Fv fragment that binds to CD137. Fig. 7A : CD137 binding activity of clone Ly2118 relative to the parental clone Ly1630. Figure 7B: CD137 binding activity of clone Ly2281 relative to the parental clone Ly1630.

[0052] Figures 8A-8E Contains a graph showing activation of human CD137 signaling as shown by IL-8 secretion by exemplary multispecific antibodies co-cultured with CHO or Jurkat overexpressing the target antigen in a reporter gene assay. Parental clone Ly1630 (anti-CD137) and control anti-CD137 clone TM173 were used as controls. Fig. 8A : Agonist activity of individual clones Ly2118 and Ly1630. Figure 8B : Agonist activity of clones Ly2118 and Ly1630 co-cultured with Jurkat cells overexpressing PD-1. Figure 8C : Agonist activity of clones Ly2118 and Ly1630 co-cultured with CHO cells overexpressing B7H3. Fig.8D : Agonist activity of individual clones Ly2281 and TM173. Fig. 8E : Agonist activity of clones Ly2281 and TM173 co-cultured with CHO cells overexpressing PD-1.

[0053] Figures 9A-9B Contains a graph showing the CD40 binding activity of exemplary multispecific antibodies. Fig.9A : CD40 binding activity of Ly2121 relative to the parental CD40 mAb clone TM383. Fig. 9B : CD40 binding activity of Ly2279 and Ly2280 relative to the parental CD40 mAb clone TM383.

[0054] Figures 10A-10F Contains a graph showing activation of human CD40 signaling as shown by IL8 secretion by an exemplary multispecific antibody in a reporter gene assay.

[0055] The agonistic activity of these multispecific antibodies was evaluated alone or in co-culture with CHO cells overexpressing other target antigens.Clone TM383 is the parental CD40 mAb, which was used as a control. Fig. 10A : Activation of human CD40 signaling by clone Ly2121 relative to TM383 alone. Fig. 10B : Activation of human CD40 signaling by clone Ly2121 relative to TM383 when co-cultured with PD-1 expressing CHO cells. Fig. 10C : Activation of human CD40 signaling by clone Ly2121 relative to TM383 when co-cultured with B7H3-expressing CHO cells. Fig. 10D : Activation of human CD40 signaling by clones Ly2279 and Ly2280 relative to TM383 alone. Fig.10E : Activation of human CD40 signaling by clone Ly2279 relative to TM383 when co-cultured with B7H3-expressing CHO cells. Fig.10F : Activation of human CD40 signaling by clone Ly2280 relative to TM383 when co-cultured with PD-1 expressing CHO cells.

[0056] Fig.11 is a graph showing the CD28 binding activity of exemplary multispecific antibodies Ly2132, Ly2133, Ly2134, Ly2135 and Ly2128 comprising different peptide linkers attached to a CD28 binding moiety.

[0057] Figures 12A-12B Contains a graph showing activation of human CD3 / CD28 signaling. The agonistic activity of the exemplary multispecific antibodies alone or co-cultured with CHO cells overexpressing other target antigens was evaluated. Clone Ly305 is the parent anti-CD3 antibody and was used as a control. Fig. 12A : Agonist activity of Ly2132, Ly2133, Ly2134, Ly2135 and Ly2128 alone. Fig. 12B : Agonist activity of Ly2132, Ly2133, Ly2134, Ly2135 and Ly2128 in co-culture with CHO cells expressing B7H3.

[0058] Figures 13A-13N Contains figures showing characterization of exemplary multispecific antibodies with terminal Fv fragments that bind to CD28. Fig.13A : CD28 binding activity of clone Ly2956 and parental clone Ly224. Fig. 13B : CD28 binding activity of clone Ly3103 and parental clone Ly224. Fig. 13C : CD28 binding activity of clone Ly3169 and parental clone Ly224. Fig.13D : CD28 binding activity of clones Ly3190, Ly3196 and parental clone Ly224. Figures 13E-13N Contains a diagram showing activation of a Jurkat T cell reporter gene. The agonistic activity of exemplary multispecific antibodies alone or co-cultured with additional target expressing cells was evaluated. Parent anti-CD28 mAb Ly224 was used as a control. Also included are corresponding multispecific antibodies Ly1965, Ly2951, Ly3098, Ly2915, and Ly3152 without CD28 binding terminal Fv fragments. Fig.13E : Agonist activity of individual clones Ly2128, Ly1965 and Ly224. Fig.13F : Agonist activity of clones Ly2128, Ly1965 and Ly224 co-cultured with CHO cells overexpressing B7H3. Figure 13G : Agonist activity of individual clones Ly2956, Ly2951 and Ly224. Fig.13H : Agonist activity of clones Ly2956, Ly2951 and Ly224 co-cultured with BCMA-expressing H929 cells. Fig.13I : Agonist activity of individual clones Ly3103, Ly3098 and Ly224. Fig.13J : Agonist activity of clones Ly3103, Ly3098 and Ly224 co-cultured with BCMA-expressing H929 cells. Figure 13K : Agonist activity of individual clones Ly2915, Ly3169 and Ly224. Figure 13L : Agonist activity of clones Ly2915, Ly3169 and Ly224 co-cultured with HEK293 cells overexpressing CEA. Figure 13M : Agonist activity of individual clones Ly3152, Ly3190, Ly3196 and Ly224. Fig.13N : Agonist activity of clones Ly3152, Ly3190, Ly3196 and Ly224 co-cultured with HER2-overexpressing CHO cells.

[0059] Figures 14A-14C Contains figures showing characterization of exemplary multispecific antibodies with terminal Fv fragments that bind to PD-L1. Fig.14A : PD-L1 binding activity of clones Ly2846, Ly2847 and parental clones Ly076 and Ly2530. Figures 14B-14C Contains a graph showing blocking activity of human PD-1 / PD-L1 signaling. Blocking activity of exemplary multispecific antibodies alone or in co-culture with CHO cells overexpressing B7H3 was evaluated. Fig. 14B : Blocking activity of individual clones Ly2846, Ly2847, Ly076 and Ly2530. Fig. 14C : Blocking activity of clones Ly2846, Ly2847, Ly076 and Ly2530 co-cultured with CHO cells overexpressing B7H3.

[0060] Figures 15A-15D Contains a graph showing the tumor antigen binding activity of exemplary multispecific anti-CD19 / CD20 antibodies. Parental anti-CD19 mAb Ly238 and parental anti-CD20 mAb Ly238 were used as controls. Fig.15A : Binding of clones Ly1966, Ly1967, Ly2326, Ly2278 and Ly238 to CHO cells overexpressing CD19. Fig. 15B: Binding of clones Ly2800, Ly2802, Ly2943, Ly2944, Ly238 and Ly239 to CHO cells overexpressing CD19. Fig. 15C : Binding of clones Ly2800, Ly2802, Ly2943, Ly2944, Ly238 and Ly239 to CHO cells overexpressing CD20. Fig.15D : Binding of clones Ly2800, Ly2802, Ly2943, Ly2944, Ly238 and Ly239 to Raji cells.

[0061] Figures 16A-16B Contains a graph showing the central Fv target binding activity of exemplary multispecific anti-CD19 / CD20 antibodies. Parental anti-CD3 mAb Ly305 was used as a control. Fig.16A : CD3 binding activity of clones Ly1967, Ly2326, Ly2278 and Ly305. Fig. 16B : CD3 binding activity of clones Ly2800, Ly2802, Ly2943, Ly2944 and Ly305.

[0062] Figures 17A-17B Contains a graph showing terminal Fv target binding activity of exemplary multispecific anti-CD19 / CD20 antibodies. Parental anti-CD137 mAb Ly1630 was used as a control. Fig.17A : CD137 binding activity of clones Ly1966, Ly1967, Ly2326, Ly2278 and Ly1630. Fig. 17B : CD137 binding activity of clones Ly2800, Ly2802, Ly2943, Ly2944 and Ly1630.

[0063] Figures 18A-18H Contains a graph showing central Fv target activation activity of exemplary multispecific anti-CD19 / CD20 antibodies. Parental anti-CD3 mAb Ly305 was used as a control. Fig.18A : Activation of human CD3 signaling by individual clones Ly1966, Ly1967, Ly2278, Ly2326 and Ly305. Fig.18B : Activation of human CD3 signaling by clones Ly1966, Ly1967, Ly2278, Ly2326, and Ly305 co-cultured with CD19-expressing cells. Fig. 18C : Activation of human CD3 signaling by clones Ly1966, Ly1967, Ly2278, Ly2326, and Ly305 co-cultured with cells expressing CD137. Fig.18D: Activation of human CD3 signaling by individual clones Ly2800, Ly2802, Ly2943, Ly2944 and Ly305. Fig.18E : Activation of human CD3 signaling by clones Ly2800, Ly2802, Ly2943, Ly2944, and Ly305 co-cultured with CD19-expressing cells. Fig.18F : Activation of human CD3 signaling by clones Ly2800, Ly2802, Ly2943, Ly2944, and Ly305 co-cultured with CD20-expressing cells. Figure 18G : Activation of human CD3 signaling by clones Ly2800, Ly2802, Ly2943, Ly2944, and Ly305 co-cultured with Raji cells. Fig.18H : Activation of human CD3 signaling by clones Ly2800, Ly2802, Ly2943, Ly2944, and Ly305 co-cultured with cells expressing CD137.

[0064] Figures 19A-19G Contains a graph showing terminal Fv target activation activity of exemplary multispecific anti-CD19 / CD20 antibodies. Reference anti-CD137 mAb TM173 was used as a control. Fig.19A : Activation of human CD137 signaling by individual clones Ly1967, Ly2278, Ly2326 and TM173. Fig.19B : Activation of human CD137 signaling by clones Ly1967, Ly2278, Ly2326, and TM173 co-cultured with CD19-expressing cells. Fig.19C : Activation of human CD137 signaling by individual clones Ly2800, Ly2802, Ly2943, Ly2944 and TM173. Fig.19D : Activation of human CD137 signaling by clones Ly2800, Ly2802, Ly2943, Ly2944, and TM173 co-cultured with CD19-expressing cells. Fig.19E : Activation of human CD137 signaling by clones Ly2800, Ly2802, Ly2943, Ly2944, and TM173 co-cultured with CD20-expressing cells. Fig.19F : Activation of human CD137 signaling by clones Ly2800, Ly2802, Ly2943, Ly2944, and TM173 co-cultured with Raji cells. Figure 19G : Activation of human CD137 signaling by clones Ly2800, Ly2802, Ly2943, Ly2944, and TM173 co-cultured with Jurkat cells.

[0065] Figures 20A-20BContains graphs showing the cytotoxic activity of exemplary multispecific antibodies. Fig. 20A : Lactate dehydrogenase (LDH) release cytotoxicity assay for clones Ly1963, Ly1966 and Ly1967. Fig. 20B : Cytotoxicity assay of tumor cells transfected with luciferase against clones Ly2800, Ly2802, Ly1967, Ly2943, Ly2944, Ly2948 and Ly2309.

[0066] Fig.21 is a graph showing serum concentrations of the CD19 / CD3 / CD137 multispecific antibody clone Ly1967 in mice administered a single intraperitoneal dose of 5 mg / kg.

[0067] Figures 22A-22C Contains graphs showing the anti-tumor activity of exemplary multispecific antibody clones. Fig.22A : Antitumor activity of clones Ly1967 and Ly2278 in a mouse model transplanted with human PBMCs bearing Raji tumor cells. Fig. 22B : Antitumor activity of Ly1967 and Ly531 in a MC38-huCD19-bearing mouse model transplanted with bone marrow from CD3 and CD137 knock-in mice. Fig. 22C : Antitumor activity of Ly1967 and Ly2278 in a B16F10-huCD19-bearing mouse model transplanted with bone marrow from CD3 and CD137 knock-in mice. Fig.22D : Antitumor activity of clones Ly2800, Ly2802, Ly2307 and Ly531 in a human PBMC-transplanted mouse model bearing Raji tumor cells. Fig.22E : Antitumor activity of clones Ly2943, Ly2944, Ly2307 and Ly531 in a mouse model transplanted with human PBMCs bearing Raji tumor cells.

[0068] Figures 23A-23H The B7H3 binding activity of exemplary multispecific antibodies is shown. Fig.23A : B7H3 binding activity of clones Ly1963, Ly1965, Ly2122 and parental anti-B7H3 clone Ly1612. Fig. 23B : B7H3 binding activity of cloned Ly2600 and Ly1612. Fig.23C : B7H3 binding activity of clones Ly2936, Ly2937, Ly2939, Ly2940 and Ly1612. Fig.23D : B7H3 binding activity of clones Ly2823 and Ly1612. Fig.23E: B7H3 binding activity of clones Ly2846, Ly2847, Ly2936 and Ly1612. Fig.23F : B7H3 binding activity of clones Ly2904, Ly2936 and Ly1612. Figure 23G : B7H3 binding activity of clones Ly2938 and Ly1612. Fig.23H : B7H3 binding activity of clones Ly2901, Ly2902, Ly2903, Ly2936 and Ly1612.

[0069] Figures 24A-24H is a graph showing the CD3 binding activity of multispecific antibody clones comprising an anti-B7H3 binding portion. Parental anti-CD3 mAb Ly305 was used as a control. Fig.24A : CD3 binding activity of clones Ly1963 and Ly1965. Fig. 24B : CD3 binding activity of clones Ly2600 and Ly2936. Fig.24C : CD3 binding activity of clones Ly2936, Ly2937 and Ly2939. Fig.24D : CD3 binding activity of clone Ly2823. Fig.24E : CD3 binding activity of clones Ly2846, Ly2847 and Ly2936. Fig.24F : CD3 binding activity of clones Ly2904 and Ly2936. Figure 24G : CD3 binding activity of clones Ly2938, Ly2939 and Ly2940. Fig.24H : CD3 binding activity of Ly2901, Ly2902, Ly2903 and Ly2936.

[0070] Figures 25A-25C is a graph showing the CD137 binding activity of exemplary B7H3 binding multispecific antibody clones. The parental anti-CD137 clone Ly1630 was used as a control. Fig.25A : CD137 binding activity of clones Ly1963 and Ly2122. Fig.25B : CD137 binding activity of clones Ly2936, Ly2937, Ly2940 and Ly2600. Fig.25C : CD137 binding activity of clone Ly2823.

[0071] Fig.26 is a graph showing the CD28 binding activity of the exemplary anti-B7H3 / CD3 / CD28 clone Ly2938.

[0072] Fig. 27 is a graph showing the PD-1 binding activity of an exemplary anti-B7H3 / CD3 / PD-1 clone Ly2904.

[0073] Fig.28 is a graph showing the PD-L1 binding activity of exemplary anti-B7H3 / CD3 / PD-L1 clones Ly2846, Ly2847 and parental anti-PD-L1 clone Ly2530.

[0074] Fig.29 is a graph showing the CTLA-4 binding activity of exemplary anti-B7H3 / CD3 / CTLA4 clones Ly2901, Ly2902, Ly2903, and reference anti-CTLA4 mAb Ly2896.

[0075] Figures 30A-30Q Contains a graph showing activation of human CD3 signaling by the exemplary multispecific antibodies shown. The agonistic activity of these multispecific antibodies alone or in co-culture with additional target-expressing cells was assessed. Figures 30A-30C : Agonist activity of clones Ly1963, Ly1965 and parental clone Ly305 alone (A), co-cultured with CHO cells expressing CD137 (B) or CHO cells expressing B7H3 (C). Figures 30D-30F : Agonist activity of clones Ly2600, Ly2936, Ly2937, Ly2939, Ly2940, Ly305 and Ly1761 alone (D), co-cultured with CHO cells expressing B7H3 (E) or CHO cells expressing CD137 (F). Figures 30G-30I : Agonist activity of clones Ly2600, Ly2823 and Ly305 alone (G), co-cultured with CHO cells expressing B7H3 (H) or CHO cells expressing CD137 (I). Figures 30J-30L : Agonist activity of clones Ly2846, Ly2847 and Ly305 alone (J), co-cultured with B7H3-expressing CHO cells (K) or PD-L1-expressing CHO cells (L). Figures 30M-30O : Agonist activity of clones Ly2904 and Ly305 alone (M), co-cultured with CHO cells expressing B7H3 (N) or CHO cells expressing PD-1 (O). Figure 30P-30Q : Agonist activity of clones Ly2901, Ly2902, Ly2903 and Ly305 alone (P) and co-cultured with B7H3-expressing CHO cells (Q).

[0076] Fig.31A -31Q contains a graph showing activation of human CD137 signaling by the exemplary multispecific antibodies shown. The agonistic activity of these multispecific antibodies alone or in co-culture with additional target-expressing cells was assessed. IL-8 levels or luminescence produced by reporter cells indicated CD137 activation. Figures 31A-31C: Agonist activity of clone Ly1963 and reference anti-CD137 mAb TM173 alone (A), co-cultured with B7H3-expressing CHO cells (B) or CD3-expressing cells (C). Figures 31D-31F : Agonist activity of clones Ly2600, Ly2936, Ly2937, Ly2823, parental anti-CD137 clone Ly1630 and reference anti-CD137 mAb TM173 alone (D), co-cultured with B7H3-expressing CHO cells (E) or CD3-expressing cells (F).

[0077] Figures 32A-32L Contains graphs showing cytotoxic activity and IFN-γ secretion of exemplary multispecific antibodies. Fig.32A : Killing of B7H3-expressing A375 cells by human PBMCs when treated with clones Ly1963, Ly1965 and Ly2128. Fig.32B : IFN-γ secretion by PBMCs when co-cultured with B7H3-expressing A375 cells and treated with clones Ly1963, Ly1965, and Ly2128. Fig.32C : Killing of A375-Luc cells by human PBMCs when treated with clones Ly2600, Ly2936, Ly2937, Ly2939 and Ly1963. Fig.32D : IFN-γ secretion by PBMCs when co-cultured with A375-Luc cells and treated with clones Ly2600, Ly2936, Ly2937, Ly2939 and Ly1963. Fig.32E : Killing of A375-Luc cells by human PBMCs when treated with clones Ly2938 and Ly1963. Fig.32F : IFN-γ secretion by PBMCs when co-cultured with A375-Luc cells and treated with clones Ly2938 and Ly1963. Figure 32G : Killing of A375-Luc cells by human PBMCs when treated with clones Ly2846, Ly2847 and Ly1963. Fig.32H : IFN-γ secretion by PBMCs when co-cultured with A375-Luc cells and treated with clones Ly2846, Ly2847 and Ly1963. Fig.32I : Killing of A375-Luc cells by human PBMCs when treated with clones Ly2904 and Ly1963. Fig.32J : IFN-γ secretion by PBMCs when co-cultured with A375-Luc cells and treated with clones Ly2904 and Ly1963. Figure 32K : Killing of A375-Luc cells by human PBMCs when treated with clones Ly2901, Ly2902, Ly2903 and Ly1963. Figure 32L: IFN-γ secretion by PBMCs when co-cultured with A375-Luc cells and treated with clones Ly2901, Ly2902, Ly2903 and Ly1963.

[0078] Fig.33 is a graph showing serum concentrations of multispecific antibody Ly1963 comprising an anti-B7H3 binding portion in mice administered a single intraperitoneal dose of 5 mg / kg.

[0079] Figures 34A-34L Contains graphs showing the anti-tumor activity of exemplary multispecific antibodies. Fig.34A : Antitumor activity of Ly1963, Ly1965, and Ly2122 in a mouse model carrying LL2-huB7H3 transplanted with bone marrow from CD3 and CD137 knock-in mice. Figures 34B-34L : Antitumor activity of Ly2823, Ly2936, Ly2937, Ly2600, Ly2846, Ly2847, Ly2938, Ly2939, and Ly2940 in a human PBMC-engrafted mouse model bearing A375 tumor cells, Fig.34B and Figures 34C-34L The mean and individual tumor volumes of each group are shown in . DETAILED DESCRIPTION

[0080] The present disclosure provides multispecific antibodies that are optionally in a multivalent form, and the multispecific antibodies utilize a form that includes one or more monovalent Fv fragments. Such monovalent Fv fragments have relatively low binding affinity to target antigens (e.g., immune cell receptors). In some cases, the multispecific antibodies disclosed herein may further include one or more high-affinity binding moieties that are specific to tumor-associated antigens and / or immune cell receptors (such as T cell activation receptors or inhibitory receptors (e.g., checkpoint receptors). Therefore, the multispecific antibodies disclosed herein can bind to the target immune receptor at a minimum level, thereby not stimulating the target immune receptor in the absence of the target antigen bound by the high-affinity binding moiety, thereby minimizing undesirable immune responses and potential side effects.

[0081] It is reported herein that multispecific antibodies comprising an Fv binding portion will activate signaling pathways mediated by immune cell receptors bound by the Fv fragment only in the presence of additional target antigens (e.g., in a tumor microenvironment). In addition, two or more Fv fragments contained in a multispecific antibody allow for simultaneous binding to two or more immune cell receptors, thereby providing a potential synergistic effect specific for those targets. Alternatively or in addition, the use of peptide linkers (comprising flexible peptide linkers and / or rigid peptide linkers) disclosed herein (alone or in combination with engineered Fc fragments) allows for reduction or elimination of undesirable Fc effector functions, reduction of undesirable polypeptide aggregation or homodimerization, and / or enhancement of the stability of multispecific antibodies comprising such.

[0082] Without being bound by theory, such multispecific antibodies can modulate desired immune responses and therapeutic activities by cross-linking multiple target antigens. Advantageous features of multispecific antibodies with specific Fv formats as disclosed herein have been demonstrated in a variety of exemplary antibodies targeting different antigens. See, for example, the following examples. Therefore, such advantageous features can be attributed to the specific design of the multispecific antibody formats disclosed herein, i.e., utilizing one or more antigen binding portions in the form of Fv fragments, and optionally desired peptide linkers, and engineered Fc fragments. In other words, such advantageous features are not antigen-specific and / or antibody sequence-specific.

[0083] As used herein, a multispecific antibody refers to an antibody that is capable of binding to two or more target antigens. In some instances, the multispecific antibodies disclosed herein may be bispecific antibodies, i.e., binding to two different target antigens or binding to two different epitopes of a target antigen. In some instances, the multispecific antibodies disclosed herein may be trispecific antibodies, e.g., binding to three different target antigens or epitopes. Alternatively, the multispecific antibodies disclosed herein may be tetraspecific antibodies, e.g., binding to four different target antigens or epitopes.

[0084] As used herein, a multivalent antibody refers to an antibody having two or more antigen binding sites. In some instances, the multispecific antibodies disclosed herein may have two antigen binding sites. In some instances, the multispecific antibodies disclosed herein may have three antigen binding sites. In some instances, the multispecific antibodies disclosed herein may have four antigen binding sites.

[0085] Thus, provided herein are multispecific antibodies having specific designs as disclosed herein, nucleic acids encoding the multispecific antibodies, host cells carrying the encoding nucleic acids, methods for producing the multispecific antibodies, and methods for using the multispecific antibodies for immune response regulation and treatment of target diseases (such as cancer).

[0086] I. Multispecific Antibodies

[0087] The multispecific antibodies disclosed herein include two or more antigen binding moieties, which may be linked by a peptide linker (e.g., a flexible peptide linker or a rigid peptide linker as provided herein) or a heavy chain constant region fragment (e.g., an Fc fragment as also disclosed herein). At least one antigen binding moiety in the disclosed multispecific antibodies is in the form of an Fv.

[0088] A. Antigen binding part

[0089] Each antigen-binding portion in any of the multispecific antibodies disclosed herein can be an antigen-binding portion in any form, including but not limited to intact (i.e., full-length) antibodies, antigen-binding fragments thereof (such as Fab, Fab', F(ab')2, Fv, triabodies, triFab, tandemly linked Fab, Fab-Fv, tandemly linked V domains, tandemly linked scFv and other forms), single-chain antibodies (scFv antibodies), single domain antibodies (such as VHH), crossover Fabs, and tetravalent antibodies.

[0090] At least one antigen binding portion in the multispecific antibodies disclosed herein is in Fv form. Other antigen binding portions in the multispecific antibodies may be in scFv form, in single domain antibody form (e.g., VHH), in Fab form, in cross-Fab form, or a combination thereof. In some examples, at least one antigen binding portion in the multispecific antibodies disclosed herein is in Fab form. In other examples, at least one antigen binding portion in the multispecific antibodies disclosed herein is in cross-Fab form. Alternatively or in addition, at least one antigen binding portion in the multispecific antibodies disclosed herein is in scFv form.

[0091] Any scFv fragment of a bispecific or multispecific antibody can be in the form of a V H →V L Alternatively, it can be V L →V H Orientation. The antigen binding portion in Fab format contains two separate chains, one chain comprising a VH-CH1 fragment and the other chain comprising a VL-CL fragment. The CL domain can be a Ck domain or a Cl domain.

[0092] Single domain antibodies (sdAbs), also known as nanobodies, are antibody fragments consisting of a single monomeric variable antibody domain. In some embodiments, single domain antibodies may be heavy chain only (VHH) fragments, which may be derived from camelid antibodies.

[0093] The Fab fragment typically contains two separate chains, one chain containing the heavy chain variable region (VH) connected to a heavy chain constant region fragment (such as CH1), and the other chain containing the light chain variable region (VL) connected to a light chain constant region (eg, CK or Cλ).

[0094] The crossover Fab fragment has a double-chain structure similar to that of the Fab fragment, but the connection between the VH / VL and the heavy / light chain constant region fragments is interchanged. The crossover Fab fragment comprises a first chain and a second chain, wherein the first chain contains a VH connected to a light chain constant region (e.g., Cκ or Cλ), and the second chain contains a VL connected to a heavy chain constant region fragment (e.g., CH1).

[0095] The antigen binding portion of the multispecific antibodies disclosed herein can specifically bind to a variety of immune cell receptors (e.g., immune cell activation receptors, such as T cell activation receptors) or specifically bind to at least one immune cell receptor and at least one TAA. Exemplary immune cell receptor antigens include, but are not limited to, CD3, CD28, PD-1, PD-L1, CTLA4, CD47, and members of the tumor necrosis factor receptor superfamily (TNFRSF). Examples of TNFRSF family members include, but are not limited to, FAS, TNFRSF12A, 4-1BB / CD137, TNFRSF13B, TNFRSF13C, CD27 / TNFRSF7, CD30 / TNFRSF8, CD40 / TNFRSF5, DR3 / TNFRSF25, DR4 / TNFRSF10A, DR5 / TNFRSF10B, DR6 / TNFRSF21, GITR / TNFRSF18, HVEM / TNFRSF14, LTBR, ​​OX40 / TNFRSF4, TROY / TNFRSF19, RELT / TNFRSF19L, TNFRSF12A, TNFRSF13B, TL1A / TNFSF15, TNFRSF17, TNFRSF1A, TNFRSF11B, RANK / TNFRSF11A, TNFRSF11B, NGFR, EDA2R, and TNFRSF1B.

[0096] In some cases, the antigen-binding portion of the multispecific antibodies disclosed herein can specifically bind to multiple immune cell receptors (such as immune cell checkpoint receptors), including but not limited to PD-1, PD-L1, and CD47.

[0097] Tumor associated antigen (TAA) refers to an antigen produced by tumor cells. TAA is a tumor marker used to identify tumor cells and therapeutic targets for cancer therapy. Exemplary TAA include but are not limited to B7H3, CD19, CD20, PSMA, HER2, CEA, BCMA, p53, p53 mutants, DLL3, MET, EGFR, B7H4, CD20, FGF, HER2, HER3, BCMA, p53 mutants, MSLN, EPCAM, ROR1, MAGE (e.g., MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10, MAGE-A12, MAGE-B or MAGE-C), SSX2, CAGE, GAGE, NY-ESO-1, SPANX-A, SPANX-C, SPANX-D, PRAME, PECAM, ICAM-3 and HLA-DR, PI3K, RAS, RAF, MEK and ERK.

[0098] The Fv fragment (e.g., a central or hidden Fv fragment) in a multispecific antibody can specifically bind to an immune cell receptor, such as a T cell receptor (e.g., a T cell activation receptor or a T cell checkpoint receptor). For example, the central (hidden) Fv fragment in the multispecific antibodies disclosed herein may be specific for CD3, CD137, CD40, and CD28. In some cases, a multispecific antibody may contain a central Fv fragment and a terminal Fv fragment. In some instances, two Fv fragments may be specific for a pair of immune cell receptors, for example, CD3 and CD28, CD3 and CD137, CD3 and PD-1, CD3 and PD-L1, CD3 and CTLA4, CD137 and PD-1, CD40 and PD-1, CD40 and PD-L1, CD137 and GITR, CD137 and PD-L1, CD137 and CD40, CD137 and OX40. For example, the central Fv fragment may be specific for CD3, and the terminal Fv fragments may be specific for different immune cell receptors, e.g., CD40, CD137, CD28, PD-1, PD-L1, CTLA4, FAS, TNFRSF12A, 4-1BB / CD137, TNFRSF13B, TNFRSF13C, CD27 / TNFRSF7, CD30 / TNFRSF8, CD40 / TNFRSF5, DR3 / TNFRSF25, DR4 / TNFRSF10A, DR5 / TNFRSF10A. FRSF10B, DR6 / TNFRSF21, GITR / TNFRSF18, HVEM / TNFRSF14, LTBR, ​​OX40 / TNFRSF4, TROY / TNFRSF19, RELT / TNFRSF19L, TNFRS F12A, TNFRSF13B, TL1A / TNFSF15, TNFRSF17, TNFRSF1A, TNFRSF11B, RANK / TNFRSF11A, TNFRSF11B, NGFR, EDA2R, or TNFRSF1B. In other examples, the central Fv fragment may be specific for an immune cell receptor (such as CD3, CD137, CD40, CD47 or CD28), and the terminal Fv fragment may be specific for a TAA (e.g., any of B7H3, CD19, CD20, MAGE-A4, PRAME, PSMA, HER2, CEA, BCMA, P53 mutants, DLL3, MET and EGFR).

[0099] In addition to the Fv fragment, the multispecific antibodies disclosed herein may further include additional antigen binding moieties (e.g., in scFv format; in single domain antibodies such as heavy chain only (VHH) format; in Fab format; or in cross-Fab format), which may be specific for different immune cell receptors or different TAAs. In general, multispecific antibodies may bind to two or more immune cell receptors or to at least one immune cell receptor and at least one TAA.

[0100] In some embodiments, the multispecific antibodies disclosed herein can be bispecific antibodies that bind to two different immune cell receptors or to one immune cell receptor (e.g., CD3, CD40, CD137, PD-1, CD47, or PD-L1) and one TAA (e.g., CD19, CD20, MAGE-A4, PRAME, B7H3, CEA, P53 mutant, PSMA, or HER2). Examples include, but are not limited to, CD3 and B7H3, CD137 and B7H3, CD3 and CD19, CD137 and CD19, CD137 and PD-1, CD40 and PD-1, CD40 and B7H3, CD40 and PD-L1, CD3 and PD-L1, CD3 and CEA, CD3 and P53 mutant, CD137 and P53 mutant, CD137 and PD-L1, CD3 and BCMA, CD137 and BCMA, CD3 and PSMA, CD137 and PSMA, CD3 and HER2, CD137 and HER2, CD40 and HER2, B7H3 and CD137, B7H3 and CD3, B7H3 and CD28, CD19 and CD3, CEA and CD137, PD-1 and CD137, PD-1 and CD40, or PMSA and CD3.

[0101] In some embodiments, the multispecific antibodies disclosed herein can be trispecific antibodies that bind to a mixture of three different antigens, which can be immune cell receptors and TAAs, for example, immune cell receptors and TAAs disclosed herein. In some cases, trispecific antibodies bind to two different immune cell receptors and one TAA. In other cases, trispecific antibodies bind to two different TAAs and one immune cell receptor. Examples of antigen combinations include, but are not limited to: B7H3, CD3, and CD137; CD19, CD3, and CD137; B7H3, CD3, and CD28; CD19, CD3, and CD28; B7H3, CD137, and PD-1; B7H3, CD40, and PD-1; PMSA, CD3, and CD137; CD20, CD3, and CD137; HER2, CD3, and CD137; CEA, CD3, and CD137; BCMA, CD3, and CD137; P53 mutants, CD3, and CD137; PD-L1 , CD3 and CD137; PD-L1, CD3 and CD28; PD-L1, CD137 and B7H3; PD-L1, CD40 and B7H3; PD-1, CD40 and CD137; PD-1, CD137 and GITR; CD19, CD20, CD3 and CD137; PD-L1, CD40 and CD137; MET, EGFR and CD47; CD19, CD3 and CD137; B7H3, CD3 and PD-1; B7H3, CD3 and PD-L; B7H3, CD3 and CTLA4.

[0102] An antibody that "specifically binds" to an antigen or epitope is a term well known in the art. If a molecule reacts more frequently, more quickly, longer, and / or with greater affinity to a specific target antigen than to an alternative target, the molecule is said to exhibit "specific binding". If an antibody binds with greater affinity, higher affinity, more easily, and / or longer duration than it binds to other substances, the antibody "specifically binds" to the target antigen or epitope. For example, an antibody that specifically (or preferentially) binds to an antigen (e.g., those listed above) or an antigenic epitope therein is an antibody that binds with greater affinity, higher affinity, more easily, and / or longer duration than it binds to other epitopes in other antigens or the same antigen. It should also be understood using this definition that, for example, an antibody that specifically binds to a first target antigen may or may not specifically bind to or preferentially bind to a second or third target antigen. Therefore, "specific binding" or "preferential binding" does not necessarily require (although it may include) exclusive binding. In some examples, an antibody that "specifically binds" to a target antigen or an epitope thereof may not bind to other antigens or other epitopes in the same antigen (i.e., only baseline binding activity may be detected in conventional methods). Alternatively or in addition, the antibodies described herein may specifically bind to a human antigen or a fragment thereof relative to a monkey counterpart, or vice versa (e.g., the binding affinity for one antigen is at least 10 times the binding affinity for another antigen as determined in the same assay under the same assay conditions). In other cases, the antibodies described herein may cross-react with human and non-human antigens (e.g., monkeys), such as having a binding affinity for human and non-human antigens that differs by less than 5 times, such as less than 2 times, or is substantially similar.

[0103] In some embodiments, the antigen binding portion of any of the bispecific or multispecific antibodies described herein has a suitable binding affinity for the target antigen (e.g., an immune cell receptor or TAA as disclosed herein) or an antigenic epitope thereof. As used herein, "binding affinity" refers to the apparent association constant or K A . K A is the dissociation constant (K D The binding affinity (K) of the antibodies described herein for the target antigen or antigenic epitope is the reciprocal of . D ) can be at least 10 -5 , 10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 M or lower. Increased binding affinity corresponds to decreased K DHigher affinity binding of an antibody to a first antigen relative to a second antigen can be achieved by having a higher K for binding to the second antigen. A (or value K D ) Higher K for binding to the first antigen A (or a smaller value K D ). In such cases, the antibody is specific for a first antigen (e.g., a first protein in a first conformation or a mimetic thereof) relative to a second antigen (e.g., the same first protein in a second conformation or a mimetic thereof; or a second protein). The difference in binding affinity (e.g., for specificity or other comparisons) can be at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 15-fold, 20-fold, 37.5-fold, 50-fold, 70-fold, 80-fold, 91-fold, 100-fold, 500-fold, 1000-fold, 10,000-fold, or 10 5 In some embodiments, any antibody can be further affinity matured to increase the binding affinity of the antibody to the target antigen or its antigenic epitope.

[0104] Binding affinity (or binding specificity) can be determined by various methods, including equilibrium dialysis, equilibrium binding, gel filtration, ELISA, surface plasmon resonance or spectroscopy (e.g., using fluorescence measurement). Exemplary conditions for assessing binding affinity are in HBS-P buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 0.005% (v / v) surfactant P20). These techniques can be used to measure the concentration of bound binding protein as a function of the concentration of target protein. The concentration of bound binding protein ([Bound]) is generally related to the concentration of free target protein ([Free]) by the following equation:

[0105] [Bound] = [Free] / (Kd + [Free]).

[0106] However, it is not always necessary to A The affinity of a protein is determined precisely because sometimes activity in a functional assay, such as an in vitro or in vivo assay, is sufficient to obtain a quantitative measure of affinity, to obtain a qualitative measure of affinity, or to obtain an inference of affinity, such as that determined using methods such as ELISA or FACS analysis, and K A is directly proportional and can therefore be used for comparisons, such as determining whether a higher affinity is, for example, 2-fold higher.

[0107] Exemplary Parent Antibodies

[0108] The antigen binding portion of the multispecific antibodies as disclosed herein can be derived from a parent antibody specific for any of the immune cell receptors or TAA target antigens as disclosed herein. Exemplary parent antibodies from which any of the antigen binding portions are derived are provided in Table 1 below (heavy and light chain CDRs based on the Kabat scheme are identified in boldface).

[0109] As used herein, an antigen-binding portion in a multispecific antibody "derived from" a parent antibody means that the parent antibody is used as a starting material for preparing one antigen-binding portion in the multispecific antibody. The antigen-binding portion may include the same heavy chain and / or light chain CDRs as those in the parent antibody. The two antibodies have the same V H and / or V L A CDR means that its CDRs are identical when they are defined by the same method (eg, the Kabat definition, the Chothia definition, the AbM definition, and / or the contact definition as known in the art).

[0110] In some cases, the antigen-binding portion derived from a parent antibody may be a functional variant of the parent antibody. Such functional variants are substantially similar to the reference antibody in both structure and function. Functional variants include V and V sequences that are substantially the same as the reference antibody. H and V L CDR. For example, it may include only up to 5 (e.g., 4, 3, 2, or 1) amino acid residue variations in the total heavy chain CDR region of the reference antibody, and / or include only up to 5 (e.g., 4, 3, 2, or 1) amino acid residue variations in the total light chain CDR region of the reference antibody. In some examples, the functional variant may include up to 8 (e.g., 7, 6, 5, 4, 3, 2, or 1) amino acid residue variations in the total heavy and light chain CDRs relative to those of the reference antibody. Such functional variants may be expressed with substantially similar affinity (e.g., with the same order of K D Value) binds to the same epitope of B7H3. Alternatively or additionally, the amino acid residue variation is a conservative amino acid residue substitution as disclosed herein.

[0111] In some embodiments, the V H The antigen-binding portion of the multispecific antibodies disclosed herein may include heavy chain CDRs that individually or collectively have at least 80% (e.g., 85%, 90%, 95%, or 98%) sequence identity compared to the V CDRs of the parent antibody. L The antigen binding portion can include light chain CDRs that individually or collectively have at least 80% (e.g., 85%, 90%, 95%, or 98%) sequence identity compared to the CDRs.

[0112] In some embodiments, the V H The antigen binding portion may include heavy chain CDRs that individually or collectively have at least 80% (e.g., 85%, 90%, 95% or 98%) sequence identity compared to the V CDRs of the parent antibody. L The antigen binding portion can include light chain CDRs that individually or collectively have at least 80% (e.g., 85%, 90%, 95%, or 98%) sequence identity compared to the CDRs.

[0113] The "percent identity" of two amino acid sequences is determined using the algorithm of Karlin and Altschul, Proc. Natl. Acad. Sci. USA, 87:2264-68, 1990, as modified in Karlin and Altschul, Proc. Natl. Acad. Sci. USA, 90:5873-77, 1993. Such algorithms are incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul et al., J. Mol. Biol., 215:403-10, 1990. BLAST protein searches can be performed with the XBLAST program (score = 50, wordlength = 3) to obtain amino acid sequences homologous to protein molecules of the invention. In the case where there is a gap between the two sequences, Gapped BLAST can be used as described in Altschul et al., Nucleic Acids Res. 25(17):3389-3402, 1997. When utilizing BLAST programs and Gapped BLAST programs, the default parameters of the corresponding programs (e.g., XBLAST and NBLAST) can be used.

[0114] Alternatively or in addition, amino acid residue variation can be conservative amino acid residue substitution.As used herein, "conservative amino acid substitution" refers to the amino acid substitution that does not change the relative charge or size characteristics of the protein subjected to amino acid substitution.Variants can be prepared according to the method for changing the known polypeptide sequence of a person of ordinary skill in the art, as found in the reference for compiling such methods, such as, "Molecular Cloning: Laboratory Manual (Molecular Cloning: A Laboratory Manual)", J.Sambrook et al., ed., 2nd edition, Cold Spring Harbor Laboratory Press (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York), 1989 or "Current Protocols in Molecular Biology", FM Ausubel et al., ed., John Wiley & Sons, Inc., New York, 1989. Conservative substitutions of amino acids include substitutions between amino acids in the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

[0115] B. Multispecific antibody formats

[0116] The multispecific antibodies disclosed herein are multichain molecules including two or more antigen binding moieties, at least one of which is in the form of an Fv. The other antigen binding moieties in the multispecific antibody (if any) may be in a suitable form, for example, in the form of an scFv, a single domain antibody (e.g., a heavy chain antibody or VHH), Fab, or a cross Fab or a combination thereof. In other examples, one or more antigen binding moieties used to construct the multispecific antibodies disclosed herein may be in the form of a BCR or TCR.

[0117] In some embodiments, multispecific antibodies may include an Fv antigen binding portion and one or more other antigen binding portions in the form of scFv and / or Fab. For example, a multispecific antibody may include an Fv fragment and two Fab fragments. The two Fab fragments may have different structures for binding to different epitopes of different antigens or target antigens. Alternatively, the two Fab fragments may be identical. In other examples, a multispecific antibody may include an Fv fragment and a Fab fragment.

[0118] In other embodiments, the multispecific antibody may include two Fv antigen binding moieties specific for different target antigens and one or more additional antigen binding moieties optionally in the form of scFv and / or Fab. In some cases, the multispecific antibody may include two Fv fragments and two Fab fragments. The two Fab fragments may have different structures for binding to different epitopes of different antigens or target antigens. Alternatively, the two Fab fragments may be identical. In other examples, the multispecific antibody may include two Fv fragments and one Fab fragment.

[0119] The multiple antigen-binding portions in the multispecific antibodies disclosed herein can be connected by a peptide linker, such as the flexible peptide linker and the rigid peptide linker disclosed herein.

[0120] In some cases, the disulfide bond formation characteristics of such fragments (e.g., at the hinge domain) can be utilized to connect two antigen binding portions through a heavy chain constant region fragment (e.g., a fragment including a hinge domain, CH2, and CH3) to form a dimer between two polypeptides of the multispecific antibody. In some cases, the multispecific antibodies disclosed herein may further include a heavy chain constant region fragment such as an Fc fragment (generally including CH2 and CH3 of a heavy chain constant chain) to promote the formation of the entire antibody molecule through disulfide bond formation and / or further regulate the immune response through its Fc receptor binding activity.

[0121] (a) Fv binding part

[0122] As used herein, an Fv fragment refers to a fragment containing the heavy chain variable domains (V H ) and the light chain variable domain (V L ). See, e.g. Figure 1A In some embodiments, the Fv fragment in the multispecific antibodies disclosed herein can be located in the middle of the antibody molecule, i.e., V H and V L Each of the fragments is located in the middle of a polypeptide, wherein the N-terminus and C-terminus of the polypeptide are connected to other components of the antibody (e.g., other antigen binding moieties). Such Fv fragments are also referred to as central or hidden Fv as disclosed herein. See, e.g. Figure 1B In other embodiments, the Fv fragment in the multispecific antibodies disclosed herein may be located at one end of the antibody molecule. H and V LEach of the fragments is located in the middle of the polypeptide, wherein one of the N-terminus and the C-terminus is connected to other components of the antibody (such as other antigen binding moieties). The other end may be the end of the entire polypeptide, or may be connected to a peptide linker but not to any other antigen binding moiety or heavy chain constant region fragment such as an Fc fragment. Such Fv fragments are also referred to as terminal Fv as disclosed herein. See, e.g. Figure 1C .

[0123] In some cases, the multispecific antibodies disclosed herein contain a central Fv fragment, which may be specific to an immune cell receptor of interest, such as an immune cell receptor disclosed herein (e.g., CD3, CD137, CD40, GITR, OX40, CD47, PD-1, or CD28). In some cases, the multispecific antibodies disclosed herein may contain a terminal Fv fragment, which may be specific to an immune cell receptor of interest, such as an immune cell receptor disclosed herein (e.g., CD3, CD137, CD40, GITR, OX40, CD47, CD28, PD-1, PD-L1, CTLA4). In some cases, the multispecific antibodies disclosed herein may include at least two Fv fragments (e.g., 2 Fv fragments), one Fv fragment is the central Fv and the other Fv fragment is the terminal Fv. See, e.g. Figure 1D . The two Fv fragments can be specific for two different immune cell receptors (e.g., two immune cell receptors that provide complementary signaling for optimal immunomodulation). Alternatively, one of the two Fv fragments (e.g., the central Fv) can be specific for an immune cell receptor of interest such as an immune cell receptor disclosed herein (e.g., CD3, CD137, CD40, GITR, OX40, CD47, or CD28), and the other Fv fragment (e.g., the terminal Fv) can be specific for a TAA (such as a TAA provided herein). Alternatively, another Fv fragment (e.g., the terminal Fv) can be specific for a second immune cell receptor such as an immune cell receptor disclosed herein.

[0124] It is expected that in the absence of other antigens bound by other antigen-binding moieties in the same multispecific antibody, the Fv fragments in the multispecific antibody, in particular the central Fv, have relatively low binding affinity for the target antigen (e.g., an immune cell receptor, such as an immune cell receptor disclosed herein, such as CD3, CD137, CD40, GITR, OX40, CD47, PD-1, PD-L1, CTLA4, or CD28). Without being bound by theory, the presence of other antigens can in some cases rescue or enhance the Fv fragment binding affinity and activation potency to levels similar to or even higher than those of its parent mAb clone. As shown in the following examples, the terminal Fv alone exhibits at least a 2-10-fold reduced binding affinity or activation potency compared to its parent mAb clone. As for the central Fv, it alone exhibits an even lower 10-100-fold reduced or ineffective binding affinity or activation potency compared to the binding affinity or activation potency of its parent mAb clone. However, when co-cultured with other cells expressing the target antigen, the binding affinity and activation potency of these central or terminal Fvs were enhanced in some cases to levels similar to or higher than those of their parental mAb clones.

[0125] Adopting this approach in designing the multispecific antibodies disclosed herein will provide one or more binding arms to one or more target immune cell receptors or TAs of interest, but avoid eliciting an immune response in the absence of high affinity target antigens, which may be accompanied by undesirable clinical side effects. Multispecific antibodies will generate synthetic biology to activate the signaling pathway mediated by the immune cell receptor bound by the Fv fragment through affinity-driven cross-linking of multiple target antigens only in the presence of additional target antigens in the tumor microenvironment, thereby achieving therapeutic efficacy.

[0126] (b) Peptide linker

[0127] A peptide linker can be positioned between two fragments in a polypeptide of a multispecific antibody as disclosed herein, for example, a V in a scFv fragment. H Part with V L Between the parts, the V H or V L Between the chains of another antigen-binding moiety, or between the VH or VL of an Fv fragment and a heavy chain constant region fragment such as an Fc fragment.

[0128] Any peptide linker in the peptide linker described herein can include naturally occurring amino acids and / or non-naturally occurring amino acids. Naturally occurring amino acids include alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine ​​(Cys), glutamic acid (Glu), glutamine (Gin), glycine (Gly), histidine (His), isoleucine (He), leucine (Leu), lysine (Lys), methionine (Met), ornithine (Orn), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr) and valine (Val). Non-naturally occurring amino acids can include protected amino acids, such as naturally occurring amino acids protected by groups such as acetyl, formyl, tosyl, nitro, etc. Non-limiting examples of non-naturally occurring amino acids include azidohomoalanine, homopropargylglycine, homoallylglycine, p-bromophenylalanine, p-iodophenylalanine, azidophenylalanine, acetylphenylalanine or ethynylphenylalanine, amino acids containing an internal olefin, such as trans-crotyl olefin, serine allyl ether, allylglycine, propargylglycine, vinylglycine, pyrrolysine, N-σ-o-azidobenzyloxycarbonyl-L-lysine (AzZLys), N-σ-propargyloxycarbonyl- L-lysine, N-σ-2-azidoethoxycarbonyl-L-lysine, N-σ-tert-butoxycarbonyl-L-lysine (BocLys), N-σ-allyloxycarbonyl-L-lysine (AlocLys), N-σ-acetyl-L-lysine (AcLys), N-σ-benzyloxycarbonyl-L-lysine (ZLys), N-σ-cyclopentyloxycarbonyl-L-lysine (CycLys), N-σ-D-prolyl-L-lysine, N-σ-nicotinoyl-L-lysine NicLys, N-σ-N-Me-o-aminobenzoyl-L-lysine (NmaLys), N-σ-biotin-L-lysine, N-σ-9-fluorenylmethoxycarbonyl-L-lysine, N-σ-methyl-L-lysine, N-σ-dimethyl-L-lysine, N-σ-polymethyl-L-lysine, N-σ-isopropyl-L-lysine, N-σ-dansyl-L-lysine, N-σ-o, p-dinitrophenyl-L-lysine, N-σ-p-toluenesulfonyl- L-lysine, N-σ-DL-2-amino-2-carboxyethyl-L-lysine, N-σ-phenylpyruvamide-L-lysine, N-σ-pyruvamide-L-lysine, azidohomoalanine, homopropargylglycine, homoallylglycine, p-bromophenylalanine, p-iodophenylalanine, azidophenylalanine, acetylphenylalanine or ethynylphenylalanine, amino acids containing internal olefins such as trans-crotyl olefin, serine allyl ether, allylglycine, propargylglycine and vinylglycine.

[0129] The peptide linkers provided herein can contain about 5-160 amino acid residues, e.g., about 10-120 amino acid residues, about 10-100 amino acid residues, about 10-80 amino acid residues, about 10-60 amino acid residues, about 10-50 amino acid residues, about 10-40 amino acid residues, about 10-30 amino acid residues, or about 10-20 amino acid residues.

[0130] In some embodiments, the peptide linker can be a flexible peptide linker, which generally contains small flexible amino acid residues, so as to connect the various domains in the multispecific antibody without affecting its binding activity. In some examples, the flexible peptide linker is a Gly-rich linker, for example, a motif comprising (GxS)n, wherein X is an integer of 1, 2, 3, 4, 5 or 6 and n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. Exemplary flexible peptide linkers are provided in Table 1 below, any of which can be used to construct the multispecific antibodies disclosed herein.

[0131] In some embodiments, the peptide linker can be a so-called rigid peptide linker, which contains at least one cysteine ​​residue (e.g., 1 or 2 cysteine ​​residues), such as it can form a disulfide bond with another rigid peptide linker. The use of one or more pairs of rigid peptide linkers in the multispecific antibodies disclosed herein can promote dimer formation of multiple polypeptides across antibodies through disulfide formation, thereby forming a complete multi-chain antibody molecule.

[0132] In some cases, the rigid peptide linker can be derived from the hinge domain (positions 216-230 or a fragment thereof, following the EU numbering system) of an IgG molecule (e.g., an IgG1 molecule) utilizing the disulfide bond forming ability of such fragments. In some instances, such peptide linkers are fragments of wild-type IgG molecules (e.g., human IgG1 molecules). Alternatively, the rigid peptide linker can contain one or more mutations relative to the wild-type counterpart.

[0133] In some examples, the rigid peptide linker may contain only the hinge domain of an IgG molecule or a fragment thereof. In other examples, the rigid peptide linker may contain a hinge domain or a fragment thereof and a Gly-rich fragment (e.g., a Gly-rich fragment disclosed herein), which may be linked to the N-terminus and / or C-terminus of the hinge domain or a fragment thereof. Examples of rigid peptide linkers for any of the multispecific antibodies disclosed herein are provided in Table 1 below.

[0134] (c) Heavy chain constant region fragment and Fc fragment

[0135] In some embodiments, the multispecific antibodies disclosed herein may contain a pair of heavy chain constant region fragments, such as Fc fragments, each located on a separate polypeptide.

[0136] In some instances, the heavy chain constant region fragment contains a hinge domain, a CH2 domain, and a CH3 domain of a suitable immunoglobulin (Ig) molecule (e.g., an IgG molecule). In some cases, the heavy chain constant region fragment is derived from an IgG1 molecule. In some instances, the heavy chain constant region fragment can be an Fc fragment containing a CH2 domain and a CH3 domain of a suitable Ig molecule (e.g., IgG, such as IgG1). In some instances, the heavy chain constant region fragment is a fragment of a wild-type Ig molecule (e.g., IgG, such as IgG1). Alternatively, relative to a wild-type counterpart, the heavy chain constant region fragment can contain more or more mutations.

[0137] In some cases, a heavy chain constant region fragment, such as an Fc fragment, may contain one or more mutations that enhance heterodimer formation. Examples include "knob-in-hole" (Ridgway et al., Protein Engineering, 9(7), pp. 617-21 (1996); Merchant et al., Nature Biotechnology, 16(7), pp. 677-681 (1998)), electrostatics (Gunasekaran et al., Journal of Biological Chemistry, 285(25), pp. 19637-19646 (2010)), or negative design (Kreudenstein et al., mAbs, 5(5), pp. 646-654 (2013); Leaver-Fay et al., Structure, 24(4), pp. 641-651 (2016)) (charged mutations). Further examples can be found, for example, in Brinkmann et al., Monoclonal Antibodies (2017), 9(2): 182-212, the relevant disclosure of which is incorporated by reference for the subject matter and purposes cited herein.

[0138] In some examples, the mutation may be at position 366 (e.g., T366W or T366S), 368 (e.g., L368A), and / or 407 (e.g., G407V). In a specific example, one heavy chain constant region fragment in a multispecific antibody may contain mutations at positions 366 (e.g., T366W) and 407 (e.g., G407V), and a second heavy chain constant region fragment in the same multispecific antibody may contain mutations at positions 366 (e.g., T366S), 368 (e.g., L368A), and 407 (G407V). Unless explicitly stated, all numbers referring to positions in Ig molecules follow the EU numbering system.

[0139] In some cases, mutations that reduce binding affinity to protein A can be introduced into one or both heavy chain Fc regions in the heavy chain Fc region of the multispecific antibody to facilitate purification of the multispecific. Such mutations are known in the art. See, e.g., Tustian et al., Monoclonal Antibodies 8:828-838 (2016), the relevant disclosures of which are incorporated herein by reference for the purposes and subject matter cited herein.

[0140] Alternatively or in addition, mutations at positions related to Fc receptor binding can be introduced into heavy chain constant region fragments. Such mutations can regulate binding affinity and selectivity to Fc receptors. Unless otherwise clearly stated, position numbering in antibody heavy chain or light chain is according to EU index numbering. In some cases, heavy chain constant region fragments such as Fc fragments can contain amino acid replacements at one or more positions in position 267, 273, 328 and 329. In some cases, the one or more mutations can be amino acid replacements at one or more positions in position 239, 265, 297, 329, 330 and 332. In an example, heavy chain constant region fragments such as Fc fragments can contain (i) deletions at position 237, and (ii) two amino acid replacements at position 234 (e.g., L234A) and 235 (e.g., L235A). In another example, the heavy chain constant region fragment can include one or more of the following: (i) a deletion at position 237, (ii) two amino acid substitutions selected from L234A, L235A and P329G, (iii) a deletion at position 237 and amino acid substitutions of D265A and N297A, (iv) amino acid substitutions S239D, A330L and I332E, and (v) a deletion at position 237 and an amino acid substitution of P329G. In some examples, an Fc fragment as disclosed herein can include (i) an amino acid substitution at position 329, which is optionally P329G, (ii) amino acid substitutions at positions 265 and 297, which are optionally D265A and N297A, (iii) amino acid substitutions at positions 239, 330 and 332, which are optionally S239D, A330L and I332E, or a combination of any one of (i)-(iii).

[0141] Additional mutations in the Fc fragment for modulating Fc receptor binding activity can be found, for example, in US-2020-0392227, the relevant disclosure of which is incorporated by reference for the subject matter and purposes cited herein.

[0142] C. Exemplary multispecific antibodies

[0143] Exemplary designs of the multispecific antibodies disclosed herein are provided below.

[0144] (a) Multispecific antibodies with central Fv

[0145] In some embodiments, the multispecific antibodies disclosed herein are multi-chain molecules comprising a first Fv fragment comprising a first V H and the first V L . V H and V LEach of the chains is linked at one end to a flexible peptide linker (flexible peptide linkers disclosed herein, see Table 1 as an example) and at the other end to a rigid peptide linker (rigid peptide linkers disclosed herein, see Table 1 as an example). Figure 1A Such multispecific antibodies include a first polypeptide and a second polypeptide, wherein the first polypeptide includes a first flexible peptide linker, a V H and a first rigid peptide linker, the second polypeptide comprising a second flexible peptide linker, V L and a second rigid peptide linker. In some cases, the first flexible peptide linker and the second flexible peptide linker are the same. Alternatively, the first flexible peptide linker and the second flexible peptide linker are different. The first rigid peptide linker and the second rigid peptide linker form one or more disulfide bonds, such as the first polypeptide and the second polypeptide can form a heterodimer.

[0146] The multispecific antibody may further comprise a second antigen binding portion, optionally a third antibody binding portion, which may be coupled to the V domain via a first flexible peptide linker and / or a second flexible peptide linker. H and / or V L The second antigen binding moiety and optionally the third antigen binding moiety may be in the form of a scFv or a Fab.

[0147] In some examples, the multispecific antibody contains a second antigen-binding portion in the form of a Fab containing a VH-CH1 fragment and a VL-CL fragment. The VH-CH1 fragment or the VL-CL fragment is connected to a first flexible peptide linker and forms an N-terminal fragment of the first polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody). Alternatively, the VH-CH1 fragment or the VL-CL fragment is connected to a second flexible peptide linker and forms an N-terminal fragment of the second polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody).

[0148] In some examples, the multispecific antibody contains a second antigen-binding portion (first Fab) in the form of Fab and a third antigen-binding portion (second Fab) which may also be in the form of Fab. The first Fab contains a first VH-CH1 fragment and a first VL-CL fragment, and the second Fab contains a second VH-CH1 fragment and a second VL-CL fragment. The first VH-CH1 fragment or the first VL-CL fragment is connected to the first flexible peptide linker and forms the N-terminal fragment of the first polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody). In addition, the second VH-CH1 fragment or the second VL-CL fragment is connected to the second flexible peptide linker and forms the N-terminal fragment of the second polypeptide, and the other fragment exists as a separate polypeptide (the fourth polypeptide of the multispecific antibody). In some cases, the second antigen-binding portion and the third antigen-binding portion are the same (the third polypeptide and the fourth polypeptide are the same).

[0149] In some examples, the multispecific antibody contains a second antigen-binding portion in the form of a cross-Fab and a third antigen-binding portion that may be in the form of a Fab. The first cross-Fab contains a VH-CL (Cλ or Cκ) fragment and a first VL-CH1 fragment, and the Fab contains a VH-CH1 fragment and a VL-CL (Cλ or Cκ) fragment. The VH-CL fragment or the VL-CH1 fragment is connected to the first flexible peptide linker and forms the N-terminal fragment of the first polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody). In addition, the VH-CH1 fragment or the VL-CL fragment is connected to the second flexible peptide linker and forms the N-terminal fragment of the second polypeptide, and the other fragment exists as a separate polypeptide (the fourth polypeptide of the multispecific antibody). In some cases, the second antigen-binding portion and the third antigen-binding portion are the same (the third polypeptide and the fourth polypeptide are the same).

[0150] In some examples, the multispecific antibody contains a second antigen-binding portion (first cross Fab) in the form of a cross Fab and a third antigen-binding portion (second cross Fab) which may also be in the form of a cross Fab. The first cross Fab contains a first VH-CL (Cλ or Cκ) fragment and a first VL-CH1 fragment, and the second cross Fab contains a second VH-CL (Cλ or Cκ) fragment and a second VL-CH1 fragment. The first VH-CL fragment or the first VL-CH1 fragment is connected to the first flexible peptide linker and forms the N-terminal fragment of the first polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody). In addition, the second VH-CL fragment or the second VL-CH1 fragment is connected to the second flexible peptide linker and forms the N-terminal fragment of the second polypeptide, and the other fragment exists as a separate polypeptide (the fourth polypeptide of the multispecific antibody). In some cases, the second antigen-binding portion and the third antigen-binding portion are the same (the third polypeptide and the fourth polypeptide are the same).

[0151] The multispecific antibodies disclosed herein may further include a first Fc fragment and a second Fc fragment, wherein the first Fc fragment is linked to the first Vc fragment via a first rigid peptide linker. H The second Fc fragment is connected to the first V L The Fc fragment may contain a mutation disclosed herein, such as a knob-in-hole mutation, to promote the formation of a heterodimer between the first polypeptide and the second polypeptide. See, e.g. Figure 1B .

[0152] (b) Multispecific Antibodies with Terminal Fv

[0153] In some embodiments, the multispecific antibodies disclosed herein are multi-chain molecules comprising a first Fv fragment comprising a first V H and the first V L . V H and V L Each of the chains is connected at one end to a first peptide linker, such as a first flexible peptide linker (a first flexible peptide linker disclosed herein, see Table 1 as an example), and at the other end is optionally connected to another peptide linker, such as a rigid peptide linker (a rigid peptide linker disclosed herein, see Table 1 as an example). See, e.g. Figure 1A Such a multispecific antibody comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises a first peptide linker (eg, a first flexible peptide linker), a V H and a second peptide linker (e.g., a first rigid peptide linker), the second polypeptide comprising a third peptide linker (e.g., a second flexible peptide linker), V LIn some cases, the first peptide linker and the third peptide linker are identical. Alternatively, the first peptide linker and the third peptide linker are different. The second peptide linker (e.g., the first rigid peptide linker) and the fourth peptide linker (e.g., the second rigid peptide linker) can form one or more disulfide bonds, such as the first polypeptide and the second polypeptide can form a heterodimer.

[0154] The multispecific antibodies disclosed herein may further include a first heavy chain constant region fragment and a second heavy chain constant region fragment, wherein the first heavy chain constant region fragment is linked to the first V chain constant region fragment via a first peptide linker. H The second heavy chain constant region fragment is connected to the first V H The heavy chain constant region fragment may contain a mutation disclosed herein, such as a knob-in-hole mutation, to promote the formation of a heterodimer between the first polypeptide and the second polypeptide.

[0155] The multispecific antibody may further comprise a second antigen binding portion, optionally a third antibody binding portion, which may bind to the V domain via the first heavy chain constant region fragment and / or the second heavy chain constant region fragment. H and / or V L The second antigen binding moiety and optionally the third antigen binding moiety may be in the form of scFv, or in the form of Fab or cross-Fab. Alternatively, the second antigen binding moiety and / or the third antigen binding moiety may be in the form of BCR or TCR.

[0156] In some examples, the multispecific antibody contains a second antigen-binding portion in the form of a Fab containing a VH-CH1 fragment and a VL-CL fragment. The VH-CH1 fragment or the VL-CL fragment is connected to the first heavy chain constant region fragment and forms the N-terminal fragment of the first polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody). Alternatively, the VH-CH1 fragment or the VL-CL fragment is connected to the second heavy chain constant region fragment and forms the N-terminal fragment of the second polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody).

[0157] In other examples, the multispecific antibody contains a second antigen-binding portion containing a VH-Cκ or VH-Cλ fragment and a VL-CH1 fragment in the form of a crossover Fab. The VH-Cκ or VH-Cλ fragment or the VL-CH1 fragment is linked to the first heavy chain constant region fragment and forms the N-terminal fragment of the first polypeptide, and the other fragment is present as a separate polypeptide (the third polypeptide of the multispecific antibody). Alternatively, the VH-Cκ or VH-Cλ fragment or the VL-CH1 fragment is linked to the second heavy chain constant region fragment and forms the N-terminal fragment of the second polypeptide, and the other fragment is present as a separate polypeptide (the third polypeptide of the multispecific antibody).

[0158] In some examples, the multispecific antibody contains a second antigen binding portion (first Fab) in the form of a Fab and a third antigen binding portion (second Fab) which may also be in the form of a Fab. The first Fab contains a first VH-CH1 fragment and a first VL-CL fragment, and the second Fab contains a second VH-CH1 fragment and a second VL-CL fragment. The first VH-CH1 fragment or the first VL-CL fragment is connected to the first heavy chain constant region fragment and forms an N-terminal fragment of the first polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody). In addition, the second VH-CH1 fragment or the second VL-CL fragment is connected to the second heavy chain constant region fragment and forms an N-terminal fragment of the second polypeptide, and the other fragment exists as a separate polypeptide (the fourth polypeptide of the multispecific antibody). In some cases, the second antigen binding portion and the third antigen binding portion are the same (the third polypeptide and the fourth polypeptide are the same). See, e.g. Figure 1C .

[0159] In other examples, the multispecific antibody contains a second antigen-binding portion in the form of a cross-Fab and a third antigen-binding portion that may be in the form of a Fab. The cross-Fab contains a VH-Cκ or VH-Cλ fragment and a VL-CH1 fragment, and the Fab contains a VH-CH1 fragment and a VL-CL fragment. The VH-Cκ or VH-Cλ fragment or the VL-CH1 fragment is connected to the first heavy chain constant region fragment and forms the N-terminal fragment of the first polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody). In addition, the VH-CH1 fragment or the VL-CL fragment is connected to the second heavy chain constant region fragment and forms the N-terminal fragment of the second polypeptide, and the other fragment exists as a separate polypeptide (the fourth polypeptide of the multispecific antibody). In some cases, the second antigen-binding portion and the third antigen-binding portion are the same (the third polypeptide and the fourth polypeptide are the same).

[0160] In other examples, the multispecific antibody contains a second antigen-binding portion (first cross Fab) in the form of a cross Fab and a third antigen-binding portion (second cross Fab) which may also be in the form of a cross Fab. The first cross Fab contains a first VH-Cκ or a first VH-Cλ fragment and a first VL-CH1 fragment, and the second cross Fab contains a second VH-Cκ or a second VH-Cλ fragment and a second VL-CH1 fragment. The first VH-Cκ or the first VH-Cλ fragment or the first VL-CH1 fragment is connected to the first heavy chain constant region fragment and forms the N-terminal fragment of the first polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody). In addition, the second VH-Cκ or the second VH-Cλ fragment and the second VL-CH1 fragment are connected to the second heavy chain constant region fragment and form the N-terminal fragment of the second polypeptide, and the other fragment exists as a separate polypeptide (the fourth polypeptide of the multispecific antibody). In some cases, the second antigen-binding portion and the third antigen-binding portion are the same (the third polypeptide and the fourth polypeptide are the same).

[0161] Alternatively, the first Fv fragment contains a first V H and the first V L . V H and V L Each of the chains is connected to a flexible peptide linker (flexible peptide linkers disclosed herein, see Table 1 as an example) at one end and does not contain a peptide linker at the other end. Figure 1C .

[0162] (c) Multispecific Antibodies Having Both Central Fv and Terminal Fv

[0163] In some embodiments, the multispecific antibodies disclosed herein are multi-chain molecules comprising a first Fv fragment (central Fv) containing a first V H and the first V L . V H and V L Each of the chains is linked at one end to a flexible peptide linker (flexible peptide linkers disclosed herein, see Table 1 as an example) and at the other end to a rigid peptide linker (rigid peptide linkers disclosed herein, see Table 1 as an example). Figure 1A Such multispecific antibodies include a first polypeptide and a second polypeptide, wherein the first polypeptide includes a first flexible peptide linker, a V H and a first rigid peptide linker, the second polypeptide comprising a second flexible peptide linker, V Land a second rigid peptide linker. In some cases, the first flexible peptide linker and the second flexible peptide linker are the same. Alternatively, the first flexible peptide linker and the second flexible peptide linker are different. The first rigid peptide linker and the second rigid peptide linker form one or more disulfide bonds, such as the first polypeptide and the second polypeptide can form a heterodimer.

[0164] The multispecific antibody may further include a second Fv fragment (terminal Fv), wherein the second Fv fragment includes a second V H and the second V L . Second V H and the second V L Each of V is connected to a peptide linker at its N-terminus. The peptide linker can be a flexible peptide linker as disclosed herein (see, e.g., Table 1 as an example). In some cases, the second V H The peptide linker connected to VL and the peptide linker connected to the second VL can be the same. H and the second V L Can be connected with different peptide linkers. In some cases, the second V H and the second V L It can be connected to a peptide linker at its C-terminus. Such a C-terminal peptide linker can be a rigid peptide linker to form a disulfide bond. Examples are provided in Table 1 below. Alternatively, the second V H and the second V L It is not connected to any peptide linker at its C-terminus.

[0165] The first Fv fragment and the second Fc fragment in the multispecific antibody can be connected by the Fc fragment, for example, H -first rigid peptide linker-first Fc fragment-peptide linker-second V H and the first V L -Second rigid peptide linker-Second Fc fragment-Peptide linker-Second V L In some cases, the first V H and the second VL can be located on one polypeptide and the first V L and the second V H Can be located on a polypeptide, for example, with the first V H -first rigid peptide linker-first Fc fragment-peptide linker-second V L and the first V L -Second rigid peptide linker-Second Fc fragment-Peptide linker-Second V H in the form of.

[0166] The multispecific antibody may further include a second antigen binding portion, optionally a third antibody binding portion, which may be attached to the first V region of the first Fv (central Fv) via a first flexible peptide linker and / or a second flexible peptide linker. Hand / or the first V L The second antigen binding moiety and optionally the third antigen binding moiety may be in the form of scFv; in the form of a single domain antibody such as VHH; in the form of Fab; or in the form of a cross-Fab. Alternatively, the second antigen binding moiety and optionally the third antigen binding moiety may be in the form of BCR or TCR.

[0167] In some examples, the multispecific antibody contains a second antigen-binding portion in the form of a Fab containing a VH-CH1 fragment and a VL-CL fragment. The VH-CH1 fragment or the VL-CL fragment is connected to a first flexible peptide linker and forms an N-terminal fragment of the first polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody). Alternatively, the VH-CH1 fragment or the VL-CL fragment is connected to a second flexible peptide linker and forms an N-terminal fragment of the second polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody).

[0168] In other examples, the multispecific antibody contains a second antigen-binding portion in the form of a crossover Fab containing a VH-Cκ or a second VH-Cλ fragment and a VL-CH1 fragment. The VH-Cκ or the second VH-Cλ fragment or the VL-CH1 fragment is connected to a first flexible peptide linker and forms an N-terminal fragment of the first polypeptide, and the other fragment is present as a separate polypeptide (the third polypeptide of the multispecific antibody). Alternatively, the VH-Cκ or the second VH-Cλ fragment or the VL-CH1 fragment is connected to a second flexible peptide linker and forms an N-terminal fragment of the second polypeptide, and the other fragment is present as a separate polypeptide (the third polypeptide of the multispecific antibody).

[0169] In some examples, the multispecific antibody contains a second antigen-binding portion (first Fab) in the form of a Fab and a third antigen-binding portion (second Fab) which may also be in the form of a Fab. The first Fab contains a first VH-CH1 fragment and a first VL-CL fragment, and the second Fab contains a second VH-CH1 fragment and a second VL-CL fragment. The first VH-CH1 fragment or the first VL-CL fragment is connected to the first flexible peptide linker and forms an N-terminal fragment of the first polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody). In addition, the second VH-CH1 fragment or the second VL-CL fragment is connected to the second flexible peptide linker and forms an N-terminal fragment of the second polypeptide, and the other fragment exists as a separate polypeptide (the fourth polypeptide of the multispecific antibody). In some cases, the second antigen-binding portion and the third antigen-binding portion are the same (the third polypeptide and the fourth polypeptide are the same). See, e.g. Figure 1D .

[0170] In some examples, the multispecific antibody contains a second antigen-binding portion in the form of a cross-Fab and a third antigen-binding portion that may be in the form of a Fab. The cross-Fab contains a VH-Cκ or VH-Cλ fragment and a VL-CH1 fragment, and the Fab contains a VH-CH1 fragment and a VL-CL fragment. The VH-Cκ or VH-Cλ fragment or the VL-CH1 fragment is connected to the first flexible peptide linker and forms an N-terminal fragment of the first polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody). In addition, the VH-CH1 fragment or the VL-CL fragment is connected to the second flexible peptide linker and forms an N-terminal fragment of the second polypeptide, and the other fragment exists as a separate polypeptide (the fourth polypeptide of the multispecific antibody). In some cases, the second antigen-binding portion and the third antigen-binding portion are the same (the third polypeptide and the fourth polypeptide are the same).

[0171] In yet other examples, the multispecific antibody contains a second antigen-binding portion (first cross Fab) in the form of a cross Fab and a third antigen-binding portion (second cross Fab) which may also be in the form of a cross Fab. The first cross Fab contains a first VH-Cκ or VH-Cλ fragment and a first VL-CH1 fragment, and the second cross Fab contains a second VH-Cκ or VH-Cλ fragment and a second VL-CH1 fragment. The first VH-Cκ / VH-Cλ fragment or the first VL-CH1 fragment is connected to the first flexible peptide linker and forms the N-terminal fragment of the first polypeptide, and the other fragment exists as a separate polypeptide (the third polypeptide of the multispecific antibody). In addition, the second VH-Cκ / VH-Cλ fragment or the second VL-CH1 fragment is connected to the second flexible peptide linker and forms the N-terminal fragment of the second polypeptide, and the other fragment exists as a separate polypeptide (the fourth polypeptide of the multispecific antibody). In some cases, the second antigen-binding portion and the third antigen-binding portion are the same (the third polypeptide and the fourth polypeptide are the same).

[0172] Exemplary multispecific antibodies as disclosed herein are provided in Table 2 below.

[0173] III. Methods for Antibody Preparation

[0174] Any of the multispecific antibodies, including bispecific antibodies and trispecific antibodies as described herein, can be prepared by any method known in the art. See, e.g., Harlow and Lane, (1998) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York.

[0175] In some embodiments, multispecific antibodies can be produced by conventional recombinant techniques, e.g., as exemplified below.

[0176] The nucleic acid of multiple chains of multi-specific antibodies as described herein can be cloned into an expression vector, and each nucleotide sequence is operably connected to a suitable promoter. In an example, each nucleotide sequence in the nucleotide sequence encoding heavy chain and light chain is operably connected to different promoters. Alternatively, the nucleotide sequence encoding multiple chains can be operably connected to a single promoter so that both heavy chain and light chain are expressed from the same promoter. If necessary, an internal ribosome entry site (IRES) can be inserted between the heavy chain and light chain coding sequence.

[0177] In some examples, the nucleotide sequences encoding multiple chains of antibodies are cloned into two or more vectors, which can be introduced into the same or different cells. When multiple chains are expressed in different cells, each chain can be isolated from the host cell expressing such chain, and the separated multiple chains can be mixed and incubated under suitable conditions that allow the formation of multi-chain antibodies.

[0178] Usually, methods known in the art can be used to clone the nucleotide sequence of one or all chains of the encoding antibody into a suitable expression vector, operably connected to a suitable promoter. For example, the nucleotide sequence and the carrier can be contacted with a restriction enzyme under suitable conditions to produce complementary ends that can be paired with each other and connected together with a ligase on each molecule. Alternatively, a synthetic nucleic acid joint can be connected to the end of the gene. These synthetic joints contain the nucleotide sequence corresponding to the specific restriction site in the carrier. The selection of the expression vector / promoter will depend on the type of the host cell used to produce the antibody.

[0179] Various promoters can be used to express the antibodies described herein, including but not limited to the cytomegalovirus (CMV) intermediate early promoter, viral LTRs such as Rous sarcoma virus LTR, HIV-LTR, HTLV-1 LTR, simian virus 40 (SV40) early promoter, Escherichia coli (E. coli) lac UV5 promoter, and herpes simplex tk virus promoter.

[0180] Regulatable promoters may also be used. These include those that use the lac repressor from E. coli as a transcriptional regulator to regulate transcription from a mammalian cell promoter carrying the lac operator (Brown, M. et al., Cell, 49:603-612 (1987)), those that use the tetracycline repressor (tetR) (Gossen, M. and Bujard, H., Proc. Natl. Acad. Sci. USA 89:5547-5551 (1992); Yao, F. et al., Human Gene Therapy, 9:1939-1950 (1998); Shockelt, P. et al., Proc. Natl. Acad. Sci. USA 92:6522-6526 (1995)). Other systems include FK506 dimer, VP16 or p65 using astradiol, RU486, diphenol murislerone, or rapamycin. Inducible systems are available from Invitrogen, Clontech, and Ariad.

[0181] An adjustable promoter comprising a repressor with an operon can be used. In one embodiment, the lac repressor from Escherichia coli can serve as a transcription modulator to regulate the transcription of a mammalian cell promoter carrying a lac operator (M. Brown et al., Cell, 49: 603-612 (1987); Gossen and Bujard (1992); M. Gossen et al., Proceedings of the National Academy of Sciences, 89: 5547-5551 (1992)), the mammalian cell promoter carrying the lac operator combines a tetracycline repressor (tetR) with a transcription activator (VP 16) to produce a tetR-mammalian cell transcription activator fusion protein tTa (tetR-VP 16), and the mammalian promoter carrying tetO is derived from the human cytomegalovirus (hCMV) major immediate early promoter for use in producing a tetR-tet operator system to control gene expression in mammalian cells. In one embodiment, a tetracycline inducible switch is used. A single tetracycline repressor (tetR), rather than a tetR-mammalian cell transcription factor fusion derivative, can act as a potent trans-regulator to regulate gene expression in mammalian cells when the tetracycline operator is appropriately located downstream of the TATA element of the CMVIE promoter (Yao et al., Human Gene Therapy, 10(16):1392-1399 (2003)). A particular advantage of this tetracycline-inducible switch is that it does not require the use of a tetracycline repressor-mammalian cell transactivator or repressor fusion protein to achieve its regulatable effect, which in some cases may be toxic to cells (Gossen et al., Proceedings of the National Academy of Sciences of the United States of America, 89:5547-5551 (1992); Shockett et al., Proceedings of the National Academy of Sciences of the United States of America, 92:6522-6526 (1995)) to achieve its regulatable effect.

[0182] In addition, the vector may contain, for example, some or all of the following: a selectable marker gene, such as the neomycin gene for selecting stable or transient transfectants in mammalian cells; an enhancer / promoter sequence from the immediate early gene of human CMV for high-level transcription; transcription termination and RNA processing signals from SV40 for mRNA stability; the SV40 polyoma replication origin and ColE1 for appropriate episomal replication; an internal ribosome binding site (IRES); a universal multiple cloning site; and T7 and SP6 RNA promoters for in vitro transcription of sense and antisense RNA. Suitable vectors and methods for producing vectors containing transgenes are well known and available in the art.

[0183] Examples of polyadenylation signals that can be used to practice the methods described herein include, but are not limited to, the human collagen I polyadenylation signal, the human collagen II polyadenylation signal, and the SV40 polyadenylation signal.

[0184] One or more vectors (e.g., expression vectors) comprising nucleic acids encoding any antibody can be introduced into a host cell suitable for producing the antibody. Host cells can be cultured under suitable conditions for expressing the antibody or any of its polypeptide chains. Such antibodies or their polypeptide chains can be recovered by conventional methods, such as affinity purification by cultured cells (e.g., from cells or culture supernatant). If necessary, the polypeptide chains of the antibody can be incubated under suitable conditions within a suitable time period allowing the production of the antibody.

[0185] In some embodiments, the method for preparing the antibodies described herein relates to recombinant expression vectors encoding all multiple chains of multi-specific antibodies as described herein. The recombinant expression vector can be introduced into a suitable host cell (e.g., dhfr-CHO cell) by conventional methods, such as calcium phosphate-mediated transfection. Positive transformant host cells can be selected and cultured under suitable conditions allowing expression of multiple polypeptide chains (e.g., three or four) of the antibody, which can be recovered from the cell or from the culture medium. When necessary, multiple chains recovered from the host cell can be incubated under suitable conditions allowing the formation of multi-chain antibodies.

[0186] In one example, two or more recombinant expression vectors are provided, and the two or more recombinant expression vectors encode one or more chains in the multiple chains of antibodies respectively. The two or more recombinant expression vectors can be introduced into suitable host cells (for example, dhfr-CHO cells) by conventional methods, such as calcium phosphate-mediated transfection. Alternatively, each expression vector in the expression vector can be introduced into a suitable host cell. Positive transformants can be selected and cultivated under the appropriate conditions of allowing the polypeptide chain of the expression antibody to be expressed. When the two or more expression vectors are introduced into the same host cell, the antibody produced therein can be recovered from the host cell or from the culture medium. If necessary, the polypeptide chain can be recovered from the host cell or from the culture medium, and then the polypeptide chain can be incubated under the appropriate conditions of allowing the formation of antibodies. When the two or more expression vectors are introduced into different host cells, each expression vector in the two or more expression vectors can be recovered from the corresponding host cell or from the corresponding culture medium. Multiple polypeptide chains can then be incubated under appropriate conditions for forming antibodies.

[0187] Standard molecular biology techniques are used to prepare recombinant expression vectors, transfect host cells, select transformants, culture host cells and recover antibodies from the culture medium. For example, some antibodies can be separated by affinity chromatography using protein A or protein G coupled matrices.

[0188] Any of the nucleic acids encoding multiple chains of a multispecific antibody as disclosed herein, vectors (eg, expression vectors) containing the nucleic acids, and host cells comprising the vectors are within the scope of the present disclosure.

[0189] IV. Pharmaceutical Compositions

[0190] Any of the multispecific antibodies as described herein, including bispecific antibodies and trispecific antibodies disclosed herein, as well as encoding nucleic acids or nucleic acid groups, vectors comprising the nucleic acids or nucleic acid groups, or host cells comprising the vectors, can be mixed with a pharmaceutically acceptable carrier (excipient) to form a pharmaceutical composition for treating a target disease. "Acceptable" means that the carrier must be compatible with the active ingredient of the composition (and preferably, capable of stabilizing the active ingredient) and harmless to the subject to be treated. Pharmaceutically acceptable excipients (carriers) include buffers, which are well known in the art. See, for example, Remington: The Science and Practice of Pharmacy, 20th edition (2000), Lippincott Williams & Wilkins, edited by KE Hoover.

[0191] Pharmaceutical compositions used in the methods of the invention may include pharmaceutically acceptable carriers, excipients or stabilizers in the form of lyophilized formulations or aqueous solutions. (Remington: The Science and Practice of Pharmacy, 20th edition (2000), Lippincott Williams & Wilkins, ed. KE Hoover). Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations used, and may include buffers such as phosphates, citrates and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins such as Serum albumin, gelatin or immunoglobulin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose or dextran; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn protein complexes); and / or nonionic surfactants such as TWEEN, PLURONICS or polyethylene glycol (PEG).

[0192] In some examples, the pharmaceutical compositions described herein include liposomes containing antibodies (or encoding nucleic acids), which can be prepared by methods known in the art, such as those described in Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556. Particularly useful liposomes can be generated by reverse phase evaporation using a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through a filter having a defined pore size to produce liposomes with a desired diameter.

[0193] Antibodies or one or more encoding nucleic acids can also be embedded in microcapsules (e.g., hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively) prepared, for example, by coacervation techniques or by interfacial polymerization, colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or in coarse emulsions. These techniques are known in the art, see, for example, Remington: The Science and Practice of Pharmacy, 20th edition, Mack Publishing (2000).

[0194] In other examples, the pharmaceutical compositions described herein can be formulated in a sustained release format. Suitable examples of sustained release formulations include semi-permeable matrices of solid hydrophobic polymers containing antibodies, and the matrix is ​​in the form of molded articles, such as films or microcapsules. Examples of sustained release matrices include polyesters, hydrogels (e.g., poly (2-hydroxyethyl-methacrylate) or poly (vinyl alcohol)), polylactides (U.S. Patent No. 3,773,919), copolymers of L-glutamic acid and 7-ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, such as LUPRON DEPOT (injectable microspheres consisting of lactic acid-glycolic acid copolymers and leuprorelin acetate), degradable lactic acid-glycolic acid copolymers, sucrose acetate isobutyrate, and poly-D-(-)-3-hydroxybutyric acid.

[0195] Pharmaceutical compositions for in vivo administration must be sterile. This is easily achieved by, for example, filtration through a sterile filtration membrane. The therapeutic antibody composition is usually placed in a container with a sterile inlet port, for example, an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic injection needle.

[0196] The pharmaceutical compositions described herein may be in unit dosage form such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration or administration by inhalation or insufflation.

[0197] In order to prepare solid compositions such as tablets, the main active ingredient can be mixed with a pharmaceutical carrier such as conventional tableting ingredients (such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gum) and other pharmaceutical diluents such as water to form a homogeneous mixture solid pre-formulated composition containing the compound of the present invention or a pharmaceutically acceptable non-toxic salt thereof. When these pre-formulated compositions are called homogeneous, it means that the active ingredient is evenly dispersed throughout the composition so that the composition can be easily subdivided into equivalent unit dosage forms, such as tablets, pills and capsules. This solid pre-formulated composition is then subdivided into unit dosage forms of the above type, and the unit dosage form contains 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the new composition can be coated or otherwise compounded to provide a dosage form that gives the advantage of prolonged action. For example, a tablet or pill can include an inner dosage component and an outer dosage component, the latter being in the form of a coating on the former. The two components can be separated by an enteric layer, which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, including a variety of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

[0198] Suitable surfactants specifically include nonionic agents such as polyoxyethylene sorbitan (e.g., TWEEN 20, 40, 60, 80 or 85) and other sorbitans (e.g., SPAN 20, 40, 60, 80 or 85). Compositions with surfactants will conveniently include between 0.05 and 5% surfactant, and may be between 0.1 and 2.5%. It should be understood that other ingredients, such as mannitol or other pharmaceutically acceptable vehicles, may be added if necessary.

[0199] Suitable emulsions can be prepared using commercially available fat emulsions such as INTRALIPID, LIPOSYN, INFONUTROl, LIPOFUNDIN and LIPIPHYSAN. The active ingredient can be dissolved in a premixed emulsion composition, or alternatively, the active ingredient can be dissolved in an oil (e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and in an emulsion formed by mixing with phospholipids (e.g., egg phospholipid, soybean phospholipid or soybean lecithin) and water. It should be understood that other ingredients, such as glycerol or glucose, can be added to adjust the tension of the emulsion. Suitable emulsions will generally contain up to 20% of oil, for example, between 5 and 20%. Fat emulsions can include fat droplets between 0.1 and 1.0 μm, specifically between 0.1 and 0.5 μm, and a pH range of 5.5 to 8.0.

[0200] Emulsion compositions may be those prepared by mixing the antibody with INTRALIPID or its components (soybean oil, lecithin, glycerol and water).

[0201] Pharmaceutical compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof, and powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as listed above. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect.

[0202] Compositions in preferably sterile pharmaceutically acceptable solvents may be nebulized by the use of gases. Nebulized solutions may be breathed directly from the nebulizing device, or the nebulizing device may be attached to a mask, tent, or intermittent positive pressure breathing machine. Solutions, suspensions, or powder compositions may be administered, preferably orally or nasally, from a device that delivers the formulation in an appropriate manner.

[0203] V. Therapeutic Applications

[0204] Any of the multispecific antibodies disclosed herein can be used in a clinical setting (eg, therapy) or in a non-clinical setting (eg, for research purposes).

[0205] In some aspects, the present invention provides a method for using any antibody disclosed herein for regulating immune response or for treating a targeted disease of a subject in need of treatment. In order to practice the method disclosed herein, the pharmaceutical composition described herein of effective amount can be applied to a subject in need of treatment (e.g., people) by suitable approach, the suitable approach is such as intravenous application (e.g., such as bolus injection or by continuous infusion over a period of time), by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intraarticular, intrasynovial, intrathecal, oral, inhalation or local approach. The commercially available nebulizer for liquid formulations including jet nebulizers and ultrasonic nebulizers can be used for application. Liquid formulations can be directly atomized and lyophilized powder can be atomized after reconstruction. Alternatively, antibodies described herein can be atomized using fluorocarbon formulations and metered dose inhalers or inhaled as lyophilized powder and abrasive powder.

[0206] The subject to be treated by the methods described herein can be a mammal, more preferably a human. Mammals include, but are not limited to, livestock, sport animals, pets, primates, horses, dogs, cats, mice, and rats. The human subject in need of treatment can be a human patient suffering from, at risk of suffering from, or suspected of suffering from a target disease / disorder (such as cancer or an immune disorder, such as an autoimmune disease).

[0207] Examples of cancer include, but are not limited to, breast cancer; biliary tract cancer; bladder cancer; brain cancer, including glioblastoma and medulloblastoma; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; hematological neoplasms, including acute lymphocytic and myeloid leukemias, such as B-cell CLL; T-cell acute lymphocytic leukemia / lymphoma; hairy cell leukemia; chronic myeloid leukemia; multiple myeloma; AIDS-related leukemia and adult T-cell leukemia / lymphoma; intraepithelial neoplasms, including Bowen's disease and Paget's disease; liver cancer; lung cancer; lymphomas, including Hodgkin's disease (Hodgkin's disease) and lymphocytic lymphoma; neuroblastoma; oral cancer, including squamous cell carcinoma; ovarian cancer, including those arising from epithelial cells, stromal cells, germ cells, and stromal cells; pancreatic cancer; prostate cancer; rectal cancer; sarcomas, including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, and osteosarcoma; skin cancer, including melanoma, Merkel cell carcinoma, Kaposi's sarcoma, basal cell carcinoma, and squamous cell carcinoma; testicular cancer, including reproductive tumors such as seminoma, non-germinoma (teratoma, choriocarcinoma), stromal tumor, and germ cell tumor; thyroid cancer, including thyroid adenocarcinoma and medullary carcinoma; and renal cancer, including adenocarcinoma and Wilms tumor.

[0208] In some cases, the multispecific antibodies used in the treatment methods disclosed herein contain a binding arm that is specific for a TAA, and the patient used for treatment carries cancer cells that express the target TAA. For example, the multispecific antibody is specific for CD19, and the patient carries CD19+ cancer. In other examples, the multispecific antibody is specific for CD20, and the patient carries CD20+ cancer. In other examples, the multispecific antibody is specific for BCMA, and the patient carries BCMA+ cancer. In other examples, the multispecific antibody is specific for B7H3, and the patient carries B7H3+ cancer. In some examples, the multispecific antibody is specific for HER2, and the patient carries HER2+ cancer. In some examples, the multispecific antibody is specific for p53 mutants, and the patient carries P53 mutant+ cancer. In some examples, the multispecific antibody is specific for MET, and the patient carries MET+ cancer. In some examples, the multispecific antibody is specific for PSMA, and the patient carries PSMA+ cancer. In some examples, the multispecific antibody is specific for CEA, and the patient carries CEA+ cancer. In some instances, the multispecific antibody is specific for EGFR and the patient has EGFR+ cancer. In some instances, the multispecific antibody is specific for DLL3 and the patient has DLL3+ cancer. In some instances, the multispecific antibody is specific for MAGE-A4 and the patient has MAGE-A4+ cancer. In some instances, the multispecific antibody is specific for PRAME and the patient has PRAME+ cancer.

[0209] In some cases, the multispecific antibodies used in the treatment methods disclosed herein contain a binding arm that is specific for an immune cell receptor, and the patient used for treatment carries immune cells that express this immune cell receptor. For example, the multispecific antibody is specific for PD-(L)1, and the patient carries PD-(L)1+ immune cells. In some instances, the multispecific antibody is specific for CD137, and the patient carries CD137+ immune cells. In some instances, the multispecific antibody is specific for CD3, and the patient carries CD3+ immune cells. In some instances, the multispecific antibody is specific for CTLA4, and the patient carries CTLA4+ immune cells. In some instances, the multispecific antibody is specific for CD40, and the patient carries CD40+ immune cells. In some instances, the multispecific antibody is specific for GITR, and the patient carries GITR+ immune cells. In some examples, the multispecific antibody is specific for at least two of the immune cell receptors (e.g., PD-1, CD137, CD3, CTLA4, CD40, OX40, GITR), and the patient carries immune cells that express at least two of such immune cell receptors.

[0210] Subjects with target cancer can be identified by routine medical examinations, such as laboratory tests, organ function tests, CT scans, ultrasound and / or genetic testing. In some embodiments, the subject to be treated by the methods described herein can be a human cancer patient who has undergone or is undergoing anti-cancer therapy (e.g., chemotherapy, radiotherapy, immunotherapy, or surgery).

[0211] An immune disorder refers to a malfunction of the immune system. Examples include autoimmune diseases, immunodeficiency, or allergies. In some embodiments, the target disease for treatment is an autoimmune disease. Examples include, but are not limited to, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), myasthenia gravis (MG), Graves' Disease, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre Syndrome, autoimmune myocarditis, membranous glomerulonephritis, high IgM syndrome, diabetes, type I or type II diabetes, multiple sclerosis, Reynaud's syndrome, syndrome), autoimmune thyroiditis, gastritis, celiac disease, vitiligo, hepatitis, primary biliary cirrhosis, inflammatory bowel disease, spondyloarthropathies, experimental autoimmune encephalomyelitis, immune neutropenia, juvenile diabetes, and immune responses associated with delayed-type hypersensitivity reactions mediated by cytokines, T lymphocytes, common in tuberculosis, sarcoidosis, and polymyositis, polyarteritis, cutaneous vasculitis, pemphigus, pemphigold, Goodpasture's syndrome, Kawasaki's disease, systemic sclerosis, antiphospholipid syndrome, Sjogren's syndrome, graft-versus-host (GVH) disease, and immune thrombocytopenia.

[0212] Subjects suffering from target autoimmune diseases can be identified by conventional medical examinations, e.g., the presence of antinuclear antibodies, antimitochondrial autoantibodies, antineutral cytoplasmic antibodies, antiphospholipid antibodies, anticitrullinated peptides (anti-CCP), anti-rheumatoid factor, immunoglobulin A, C-reactive protein test, complement test, erythrocyte sedimentation rate (ESR) test, blood coagulation spectrum and protein electrophoresis / immunofixation electrophoresis and / or genetic testing. In some embodiments, the subject to be treated by the methods described herein can be a human subject suffering from an autoimmune disease, and the human subject has experienced or is undergoing autoimmune disease treatment, e.g., immunosuppressive mediation, hormone replacement therapy, blood transfusion, anti-inflammatory drugs and / or pain medications.

[0213] A subject suspected of having any such target disease / disorder may display one or more symptoms of the disease / disorder. A subject at risk of having a disease / disorder may be a subject having one or more of the risk factors for the disease / disorder.

[0214] As used herein, "effective amount" refers to the amount of each active agent required to confer a therapeutic effect on a subject, either alone or in combination with one or more other active agents. It will be apparent to those skilled in the art to determine whether the amount of the antibody achieves a therapeutic effect. As recognized by those skilled in the art, the effective amount varies, depending on the specific condition being treated, the severity of the condition, individual patient parameters including age, physical condition, size, sex and weight, duration of treatment, nature of concurrent therapy (if any), specific routes of administration and similar factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be resolved only by routine experimentation. It is generally preferred to use the maximum dose of the individual components or their combination, i.e., the highest safe dose according to reasonable medical judgment.

[0215] Empirical considerations such as half-life will generally help determine dosage. For example, antibodies compatible with the human immune system such as humanized antibodies or fully human antibodies can be used to extend the half-life of the antibody and prevent the antibody from being attacked by the host's immune system. The frequency of administration can be determined and adjusted during the therapy, and is usually but not necessarily based on the treatment and / or suppression and / or improvement and / or delay of the target disease / disorder. Alternatively, a sustained continuous release formulation of the antibody may be appropriate. Various formulations and devices for achieving sustained release are known in the art.

[0216] In one example, the dosage of an antibody as described herein can be determined empirically in an individual who has been given one or more administrations of the antibody. Increasing doses of the agonist are given to the individual. In order to assess the efficacy of the agonist, indicators of the disease / disorder can be followed.

[0217] Typically, for the administration of any antibody described herein, the initial candidate dose can be about 2 mg / kg. For the purposes of this disclosure, the range of typical daily doses can be about 0.1 μg / kg to 3 μg / kg, to 30 μg / kg, to 300 μg / kg, to 3 mg / kg, to 30 mg / kg, to any dose in 100 mg / kg or more according to the above factors. For repeated administration in several days or longer, treatment is continued according to the condition until the desired symptom suppression occurs or until the treatment level sufficient to alleviate the target disease or disorder or its symptoms is reached. An exemplary dosing regimen includes administering an initial dose of about 2 mg / kg, followed by a weekly maintenance dose of about 1 mg / kg antibody or a maintenance dose of about 1 mg / kg administered every other week. However, other dosage regimens may be useful according to the pharmacokinetic decay pattern that practitioners wish to achieve. For example, it is envisioned that administration is given once to four times per week. In some embodiments, the dosage range that can be used is about 3 μg / mg to about 2 mg / kg (such as about 3 μg / mg, about 10 μg / mg, about 30 μg / mg, about 100 μg / mg, about 300 μg / mg, about 1 mg / kg and about 2 mg / kg). In some embodiments, the dosing frequency is once a week, once every 2 weeks, once every 4 weeks, once every 5 weeks, once every 6 weeks, once every 7 weeks, once every 8 weeks, once every 9 weeks or once every 10 weeks; or once a month, once every 2 months, or once every 3 months or longer. The progress of this therapy is easily monitored by conventional techniques and assays. The dosing regimen (including the antibody used) can change over time.

[0218] In some embodiments, for adult patients of normal weight, the dosage range that can be applied is about 0.003 to 5.00 mg / kg. In some instances, the dosage of the antibodies described herein can be 10 mg / kg. The specific dosing regimen, i.e., dosage, timing, and repetition, will depend on the specific individual and the individual's medical history and the properties of the individual agent (such as the half-life of the agent and other considerations known in the art).

[0219] For the purposes of this disclosure, the appropriate dosage of an antibody as described herein will depend on the specific antibody, antibody and / or non-antibody peptide (or a combination thereof) employed, the type and severity of the disease / disorder, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to agonists, and the judgment of the attending physician. Clinicians will typically administer the antibody until a dose that achieves the desired result is reached. In some embodiments, the desired result is an increase in the anti-tumor immune response in the tumor microenvironment. Methods for determining whether a dose produces a desired result will be apparent to those skilled in the art. Administration of one or more antibodies may be continuous or intermittent, depending on, for example, the physiological condition of the recipient, whether the purpose of administration is therapeutic or preventive, and other factors known to skilled practitioners. Administration of the antibody may be substantially continuous over a preselected time period, or a series of interval doses may be used, for example, before, during, or after the development of the target disease or disorder.

[0220] As used herein, the term "treat" refers to applying or administering a composition comprising one or more active agents to a subject suffering from a target disease or condition, symptoms of a disease / condition, or susceptibility to a disease / symptom, for the purpose of treating, curing, alleviating, alleviating, altering, remedying, ameliorating, improving, or affecting the condition, symptoms of a disease, or susceptibility to a disease or condition.

[0221] Alleviate the target disease / illness and comprise delaying the development or progress of the disease or reducing the severity of the disease or prolonging the survival period. Alleviate the disease or prolong the survival period and do not necessarily need to cure the result. As used herein, "delaying" the development of the target disease or illness means to postpone, hinder, slow down, slow down, stabilize and / or delay the progress of the disease. This delay can have different time lengths, depending on the history of the disease and / or the individual being treated. "Delaying" or alleviating the development of the disease or delaying the onset of the disease is a method of reducing the possibility of one or more symptoms of the disease in a given time frame and / or reducing the degree of symptoms in a given time frame compared to not using the method. This comparison is usually based on clinical research, using many subjects sufficient to give statistically significant results.

[0222] "Development" or "progression" of a disease means the initial manifestation and / or subsequent progression of the disease. The progression of a disease may be detectable and can be assessed using standard clinical techniques as are well known in the art. However, progression also refers to progression that may not be detectable. For purposes of this disclosure, development or progression refers to the biological course of symptoms. "Development" encompasses occurrence, recurrence, and onset. As used herein, "onset" or "occurrence" of a target disease or condition encompasses initial onset and / or recurrence.

[0223] According to the type of disease to be treated or the site of disease, conventional methods known to those of ordinary skill in the medical field can be used to apply pharmaceutical compositions to the subject.This composition can also be used by other conventional routes, for example, oral, parenteral, by inhalation spray, local, rectal, nasal cavity, cheek, vagina or by implantable drug reservoir.As used herein, the term "parenteral" comprises subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion technology.In addition, compositions can be applied to the subject by injectable reservoir administration route, such as using 1 month, 3 months or 6 months reservoir injectable or biodegradable materials and methods.In some instances, pharmaceutical compositions are applied intraocularly or intravitreally.

[0224] Injectable compositions can contain various carriers, such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol and polyols (glycerol, propylene glycol, liquid polyethylene glycol, etc.). For intravenous injection, water-soluble antibodies can be administered by a drip method, thereby infusing a pharmaceutical formulation containing an antibody and a physiologically acceptable excipient. A physiologically acceptable excipient can include, for example, 5% glucose, 0.9% saline, Ringer's solution, or other suitable excipients. Intramuscular preparations (e.g., sterile formulations of suitable soluble salt forms of antibodies) can be dissolved and administered in pharmaceutical excipients such as water for injection, 0.9% saline or 5% glucose solution.

[0225] In one embodiment, the antibody is administered by site-specific or targeted local delivery technology. Examples of site-specific or targeted local delivery technology include various implantable reservoir sources or local delivery catheters (e.g., infusion catheters, indwelling catheters or needle catheters, synthetic grafts, adventitial wraps, shunts and stents or other implantable devices) of the antibody; site-specific carriers; direct injection or direct application. See, e.g., PCT Publication No. WO 00 / 53211 and U.S. Patent No. 5,981,568.

[0226] Targeted delivery of therapeutic compositions containing antisense polynucleotides, expression vectors or subgenomic polynucleotides can also be used. Receptor-mediated DNA delivery technology is described in, for example, Findeis et al., Trends Biotechnol. (1993) 11: 202; Chiou et al., Gene Therapeutics: Methods and Applications Of Direct Gene Transfer (JA Wolff, ed.) (1994); Wu et al., J. Biol. Chem. (1988) 263: 621; Wu et al., J. Biol. Chem. (1994) 269: 542; Zenke et al., PNAS (1990) 87: 3655; Wu et al., J. Biol. Chem. (1991) 266: 338.

[0227] For local administration in a gene therapy regimen, a therapeutic composition containing a polynucleotide (e.g., a polynucleotide encoding an antibody described herein) is administered in the range of about 100 ng to about 200 mg DNA. In some embodiments, a concentration range of about 500 ng to about 50 mg, about 1 μg to about 2 mg, about 5 μg to about 500 μg, and about 20 μg to about 100 μg or more of DNA may also be used during a gene therapy regimen.

[0228] The therapeutic polynucleotides and polypeptides described herein can be delivered using a gene delivery vehicle. The gene delivery vehicle can be viral or non-viral in origin (see generally Jolly, "Cancer Gene Therapy (Cancer Gene Therapy)" (1994) 1:51; Kimura, "Human Gene Therapy" (1994) 5:845; Connelly, "Human Gene Therapy" (1995) 1:185; and Kaplitt, "Nature Genetics (Nature Genetics)" (1994) 6:148). The expression of this coding sequence can be induced using endogenous mammals or heterologous promoters and / or enhancers. The expression of the coding sequence can be constitutive or regulated.

[0229] Viral-based vectors for delivery of a desired polynucleotide and expression in a desired cell are well known in the art. Exemplary viral-based vehicles include, but are not limited to, recombinant retroviruses (see, e.g., PCT Publication Nos. WO 90 / 07936; WO 94 / 03622; WO 93 / 25698; WO 93 / 25234; WO 93 / 11230; WO 93 / 10218; WO 91 / 02805; U.S. Pat. Nos. 5,219,740 and 4,777,127; British Patent No. 2,200,651; and European Patent No. 0 345 242); alphavirus-based vectors (e.g., Sindbis virus vectors, Semliki Forest virus (ATCC VR-67; ATCC VR-1247), Ross River virus (ATCC VR-373; ATCC VR-1246), and Venezuelan equine encephalitis virus (ATCC VR-923; ATCC VR-1250; ATCC VR-1251); 1249; ATCC VR-532)); and adeno-associated virus (AAV) vectors (see, e.g., PCT Publication Nos. WO 94 / 12649, WO 93 / 03769; WO 93 / 19191; WO 94 / 28938; WO 95 / 11984 and WO 95 / 00655). Administration of DNA linked to a killed adenovirus (as described in Curiel, Human Gene Therapy (1992) 3:147) can also be used.

[0230] Non-viral delivery vehicles and methods can also be used, including but not limited to polycation-condensed DNA linked or unlinked to adenovirus alone (see, e.g., Curiel, Human Gene Therapy (1992) 3:147); ligand-linked DNA (see, e.g., Wu, Journal of Biological Chemistry (1989) 264:16985); eukaryotic cell delivery vehicle cells (see, e.g., U.S. Pat. No. 5,814,482; PCT Publication Nos. WO 95 / 07994; WO 96 / 17072; WO 95 / 30763; and WO 97 / 42338) and nuclear charge neutralization or fusion with cell membranes. Naked DNA can also be used. Exemplary naked DNA introduction methods are described in PCT Publication No. WO 90 / 11092 and U.S. Pat. No. 5,580,859. Liposomes that can serve as gene delivery vehicles are described in U.S. Pat. No. 5,422,120; PCT Publication Nos. WO 95 / 13796; WO 94 / 23697; WO 91 / 14445; and European Patent No. 0524968. Additional methods are described in Philip, Mol. Cell. Biol. (1994) 14:2411, and Woffendin, Proc. Natl. Acad. Sci. USA (1994) 91:1581.

[0231] The specific dosing regimen, ie, dosage, timing, and repetition, used in the methods described herein will depend on the particular subject and the subject's medical history.

[0232] In some embodiments, more than one antibody or a combination of an antibody and another suitable therapeutic agent may be administered to a subject in need of treatment. The antibody may also be used in conjunction with other agents for enhancing and / or supplementing the effectiveness of the agent. The therapeutic efficacy of the target disease / disorder may be assessed by methods well known in the art.

[0233] When any antibody described herein is used to treat cancer, it can be combined with anti-cancer therapy (e.g., anti-cancer therapy known in the art). Additional anti-cancer therapy includes chemotherapy, surgery, radiation, immunotherapy, gene therapy, etc.

[0234] Alternatively, the treatment of the present disclosure can be combined with chemotherapeutic agents, for example, pyrimidine analogs (5-fluorouracil, floxuridine, capecitabine, gemcitabine, and cytarabine), purine analogs, folate antagonists and related inhibitors (mercaptopurine, thioguanine, pentostatin, and 2-chlorodeoxyadenosine (cladribine)); antiproliferative / antimitotic agents, including natural products such as vinca alkaloids (vinblastine, vincristine, and vinorelbine), microtubule disruptors such as taxanes (paclitaxel, docetaxel), vincristine, vinblastine, nocodazole, epothilones and navelbine, epipodophyllotoxins (etoposide, teniposide), DNA damaging agents (actinomycin, amsacrine), , anthracyclines, bleomycin, busulfan, camptothecin, carboplatin, chlorambucil, cisplatin, nedaplatin (cisplatin), cyclophosphamide, cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin, hexamethyhnelamineoxaliplatin, ifosfamide, melphalan, merchlorehtamine, mitomycin, mitoxantrone, nitrosoureas, plicamycin, procarbazine, paclitaxel, taxotere, teniposide, triethylenethiophosphoramide, and etoposide (VP16); antibiotics, such as dactinomycin (actinomycin D), Daunorubicin, doxorubicin (Adriamycin), idarubicin, anthracyclines, mitoxantrone, bleomycin, plicamycin (mithramycin), and mitomycin; enzymes (L-asparaginase, which metabolizes L-asparagine systemically and incapacitates cells that are incapable of synthesizing their own asparagine); antiplatelet agents; antiproliferative / antimitotic alkylating agents such as nitrogen mustards (dichloromethyl diethylamine, cyclophosphamide and its analogs, melphalan, chlorambucil), ethyleneimine and methylmelamines (altretinoin and thiotepa), alkyl sulfonates-busulfan, nitrosoureas (carmustine (BCNU) and analogs, streptozotocin), triamcinol-dacarbazine (DTIC); antiproliferative / antimitotic antimetabolites , such as folic acid analogs (methotrexate); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones, hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide, nilutamide) and aromatase inhibitors (letrozole, anastrozole); anticoagulants (heparin, synthetic heparin salts and other thrombin inhibitors); fibrinolytics (such as tissue prothrombin activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; anticoagulants; antisecretory agents (breveldin); immunosuppressants (cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil);Antiangiogenic compounds (e.g., TNP-470, genistein, bevacizumab) and growth factor inhibitors (e.g., fibroblast growth factor (FGF) inhibitors); angiotensin receptor blockers; nitric oxide donors; antisense oligonucleotides; antibodies (trastuzumab); cell cycle inhibitors and differentiation inducers (retinoic acid); mTOR inhibitors, topoisomerase inhibitors (doxorubicin (adriamycin), amsacrine, camptothecin, daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin and mitoxantrone, topotecan, irinotecan), corticosteroids (cortisone, dexamethasone, hydrocortisone, methylpednisolone, prednisolone and prenisolone); growth factor signaling kinase inhibitors; mitochondrial dysfunction inducers and caspase activators; and chromatin perturbants. ;

[0235] When any of the antibodies described herein are used to treat immune disorders, they can be used together with other immunomodulatory treatments, such as, for example, therapeutic vaccines (including but not limited to GVAX, DC-based vaccines, etc.) or checkpoint inhibitors (including but not limited to agents that block CTLA4, PD1, LAG3, TIM3, etc.). In some cases, the antibody can be combined with another therapy for treating an autoimmune disease. Examples include, but are not limited to: intravenous Ig therapy; nonsteroidal anti-inflammatory drugs (NSAIDs); corticosteroids; cyclosporine, rapamycin, ascomycin; cyclophosphamide; azathioprine; methotrexate; brequinar; FTY 720; leflunomide; mizolibine; mycophenolic acid; mycophenolate mofetil; 15-deoxyarginine; immunosuppressants, or adhesion molecule inhibitors.

[0236] For examples of additional useful agents, see also: Physician's Desk Reference, 59th Supplementary Edition, (2005), Thomson PDR, Montvale NJ; Gennaro et al., eds., Remington's Science and Practice of Pharmacy, 20th Supplementary Edition, (2000), Lippincott Williams and Wilkins, Baltimore Md.; Braunwald et al., eds., Harrison's Principles of Internal Medicine, 15th Supplementary Edition, (2001), McGraw Hill, New York; Berkow et al., eds., The Merck Manual of Diagnosis and Therapy, (1992), Merck Research Laboratories, Rahway, NJ. Laboratories, Rahway NJ).

[0237] When a second therapeutic agent is used, this agent can be administered simultaneously or sequentially (in any order) with the therapeutic agents described herein. When co-administered with additional therapeutic agents, the appropriate therapeutically effective dose of each agent can be reduced based on additive or synergistic effects.

[0238] VI. Kits Comprising the Multispecific Antibodies Disclosed herein

[0239] The present disclosure also provides kits for treating or ameliorating target diseases, such as cancer or immune disorders described herein. Such kits may include one or more containers, the one or more containers including any of the multispecific antibodies disclosed herein, and optionally a second therapeutic agent to be used with the antibody, the second therapeutic agent also being described herein.

[0240] In some embodiments, the kit may include instructions for use according to any of the methods described herein. The included instructions may include a description of administering an antibody for treating, delaying the onset of, or alleviating a target disease such as those described herein, and optionally a second therapeutic agent. The kit may further include a description of selecting an individual suitable for treatment based on identifying whether the individual suffers from the target disease, such as by using a diagnostic method as described herein. In still other embodiments, the instructions include a description of administering the antibody to an individual at risk of the target disease.

[0241] Instructions for use of anti-Cmx antibodies typically contain information about the dosage, dosing regimen, and route of administration for the intended treatment. The container may be a unit dose, bulk package (e.g., multi-dose package), or subunit dose. The instructions provided in the kit of the invention are typically written instructions on a label or package insert (e.g., paper included in the kit), but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.

[0242] The label or package insert indicates that the composition is used to treat, delay the onset of, and / or alleviate a disease, such as cancer or an immune disorder (eg, an autoimmune disease).Instructions can be provided for practicing any of the methods described herein.

[0243] The kit of the present invention is in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), etc. It is also contemplated that packaging used in combination with a specific device (e.g., an inhaler, a nasal application device (e.g., a nebulizer), or an infusion device (e.g., a mini pump)). The kit can have a sterile inlet port (e.g., the container can be an intravenous solution bag or vial with a stopper that can be pierced by a hypodermic injection needle). The container can also have a sterile inlet port (e.g., the container can be an intravenous solution bag or vial with a stopper that can be pierced by a hypodermic injection needle). At least one active agent in the composition is an antibody, such as those described herein.

[0244] The kit may optionally provide additional components such as buffers and interpretative information. Typically, the kit includes a container and a label or package insert on or associated with the container. In some embodiments, the invention provides an article comprising the contents of the kit described above.

[0245] General techniques

[0246] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are fully explained in the following literature, such as: Molecular Cloning: A Laboratory Manual, 2nd Edition (Sambrook et al., 1989) Cold Spring Harbor Press; Oligonucleotide Synthesis (MJ Gait ed. 1984); Methods in Molecular Biology (Humana Press); Cell Biology: A Laboratory Notebook (JE Cellis ed., 1989) Academic Press; Animal Cell Culture (RI Freshney ed., 1987); Introduction to Cell and Tissue Culture (JPather and PE Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (JP Cellis ed., 1998) Academic Press; Procedures (A. Doyle, JB Griffiths and DG Newell, eds. 1993-8) John Wiley and Sons; Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (DM Weir and CC Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, 1987); Current Protocols in Molecular Biology (FM Ausubel et al., eds. 1987); PCR: The Polymerase Chain Reaction (Mullis et al., eds. 1994); Current Protocols in Immunology (JEColigan et al., eds., 1991); Short Protocols in Molecular Biology (John Wiley & Sons, 1999); Immunobiology (CA Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: a practice approach (D. Catty, ed., IRL Press, 1988-1989); Monoclonal antibodies: a practical approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000); Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane, Cold Spring Harbor Laboratory Press, 1999); Antibodies (M. Zanetti and J. D. Capra, eds., Harwood Academic Press, 1996); Publishers, 1995); DNA Cloning: A practical Approach, Volumes I and II (D.N. Glover, ed. 1985); Nucleic Acid Hybridization (B.D. Hames and S.J. Higgins, eds. (1985); Transcription and Translation (B.D. Hames and S.J. Higgins, eds. (1984); Animal Cell Culture (R.I. Freshney, ed. (1986); Immobilized Cells and Enzymes (I.R.L. Press, (1986)); and B. Perbal, A practical Guide To Molecular Cloning (1984); F.M. Ausubel et al. (eds.).

[0247] Without further elaboration, it is believed that those skilled in the art can utilize the present invention to the greatest extent based on the above description. Therefore, the following specific examples are interpreted as being merely illustrative and not limiting the remainder of the present disclosure in any way. For the purposes or themes mentioned herein, all publications cited herein are incorporated by reference.

[0248] Examples

[0249] Example 1: Construction and production of multispecific and multivalent antibodies

[0250] The exemplary multispecific antibodies shown in Table 2 were produced by recombinant techniques and characterized for their antigen binding activity and biological activity as disclosed herein.

[0251] Briefly, the heavy chain variable region (V H ) and light chain variable region (V L ) were used as starting material for preparing multispecific antibodies. The coding sequences of the multiple chains of each exemplary multispecific antibody were cloned into expression vectors, which were transfected into CHO cells for transient expression. The multispecific antibodies produced in CHO cells were purified from the culture supernatant by protein A affinity chromatography. Antibody properties were examined using standard protocols or as described herein.

[0252] Example 2: Effect of flexible peptide linkers on the properties of multispecific antibodies.

[0253] This example explores the effect of a flexible peptide linker, which is a G / S-rich peptide linker, on the characteristics of a multispecific antibody comprising the flexible peptide linker. In this example, multispecific antibodies comprising flexible peptide linkers of different lengths were tested.

[0254] Exemplary multispecific antibodies were produced in CHO cells as described above in Example 1. Binding of the multispecific antibodies to the corresponding target antigens was assessed by ELISA or FCM following standard procedures.

[0255] like Figures 2A-2F As shown in Table 3, the length of the flexible peptide linker has no significant effect on the binding of the binding moieties connected by the flexible peptide linker, nor on the overall mass of these multispecific antibodies including the flexible peptide linker (data not shown). Two groups of multispecific antibodies were tested, and similar results were obtained.

[0256] Table 3: Effect of flexible peptide linkers on the binding of multispecific antibodies

[0257] Antibody Flexible peptide linker B7H3 binding CD3 binding Ly1612 N / A +++++ - Ly305 N / A - +++++ Ly2364 <![CDATA[(G4S)5(SEQ ID NO:7)]]> +++++ +++ Ly1963 <![CDATA[(G4S)4(SEQ ID NO:6)]]> +++++ +++ Ly2365 <![CDATA[(G4S)3(SEQ ID NO:5)]]> +++++ +++ Ly2366 <![CDATA[(G4S)2(SEQ ID NO:4)]]> +++++ +++ Ly2367 <![CDATA[G4S(SEQ ID NO:3)]]> +++++ +++ Ly2368 N / A +++++ +++ Ly2384 <![CDATA[G3S(SEQ ID NO:2)]]> +++++ +++ Ly2385 <![CDATA[G2S]]> +++++ +++ Ly2136 <![CDATA[(G4S)5(SEQ ID NO:7)]]> +++++ +++ Ly2128 <![CDATA[(G4S)4(SEQ ID NO:6)]]> +++++ +++ Ly2137 <![CDATA[(G4S)3(SEQ ID NO:5)]]> +++++ +++ Ly2138 <![CDATA[(G4S)2(SEQ ID NO:4)]]> +++++ +++ Ly2139 <![CDATA[G4S(SEQ ID NO:3)]]> +++++ +++

[0258] Example 3: Effect of rigid peptide linkers on the properties of multispecific antibodies.

[0259] This example explores the effects of rigid peptide linkers, which are capable of forming disulfide bonds between each other, on the characteristics of multispecific antibodies comprising the rigid peptide linkers.

[0260] (i) Effects of disulfide-forming properties of rigid peptide linkers on antibody stability and binding

[0261] In this example, multispecific antibodies comprising an exemplary rigid peptide linker GGGGSDKTHTCPPCPAPEAAGP (SEQ ID NO: 13), which comprises a Cys residue for disulfide bond formation, or a control peptide linker PAPEAAGP (SEQ ID NO: 28), which does not comprise a Cys residue and is therefore unable to form disulfide bonds, were tested.

[0262] As described in Example 1 above, an exemplary multispecific antibody comprising the above peptide linker was produced in CHO cells. Proteins were prepared with reduced or non-reduced LDS sample buffer and loaded onto a Bis-Tris precast gel. The gel was run at 140 volts with MOPS SDS buffer for 40 minutes. After electrophoresis, the gel was stained with Coomassie blue. Figure 3A The mobility of antibodies Ly1891, Ly1899 and Ly1963 with a rigid peptide linker (SEQ ID NO: 13) and antibodies Ly1800, Ly1803 and Ly1961 with a control peptide linker (SEQ ID NO: 28) is shown. Antibodies Ly1891, Ly1899 and Ly1963 show the expected mobility on SDS-PAGE under both reducing and non-reducing conditions. In contrast, although antibodies Ly1800, Ly1803 and Ly1961 show the expected mobility under reducing conditions, only half-mers of the intact molecule are visible under non-reducing conditions, indicating that the latter antibody has poor stability due to the absence of a disulfide-forming segment.

[0263] Next, size exclusion chromatography (SEC) was performed using a high performance liquid chromatography system. DPBS at pH 7.4 was used as the mobile phase and the sample was injected into a Zenix-SEC-300 column or equivalent. SEC-HPLC analysis revealed that the antibody constructs without disulfides (Ly1800, Ly1803 and Ly1961) formed more aggregates compared to their counterparts (Ly1891, Ly1899 and Ly1963) containing disulfides, as demonstrated by the percentage of high molecular weight (HMW) peaks as summarized in Table 4 below.

[0264] Table 4: SEC analysis of constructs without or with a rigid peptide linker

[0265] protein Main peak (%) HMW peak (%) Ly1800 85.1 14.0 Ly1891 93.4 6.45 Ly1803 72.1 21.9 Ly1899 98.8 1.2 Ly1961 81.6 18.4 Ly1963 96.2 3.8

[0266] Binding of these antibody constructs to CD3-expressing Jurkat cells was assessed by flow cytometry (FCM) as in Example 2. FCM analysis revealed that the presence of the disulfide-forming segments of Ly1899 and Ly1891 increased target-dependent binding to the cells compared to antibodies lacking the disulfide-forming segments (Ly1803 and Ly1800) ( Figure 3B ), which is consistent with the above observations of lower stability and more aggregates for constructs without linker disulfides.

[0267] (ii) Contribution of the G4S segment in a rigid peptide linker to antibody stability and aggregation

[0268] To investigate how the G4S motif would affect the properties of multispecific antibodies with a rigid peptide linker comprising the G4S motif, clones Ly2128, Ly1963 and Ly1967 with a linker comprising GGGGSDKTHTCPPCPAPEAAGP (SEQ ID NO: 13) and clones Ly2125, Ly2157 and Ly2167 with a rigid peptide linker DKTHTCPPCPAPEAAGP (SEQ ID NO: 21) were tested.

[0269] SEC-HPLC analysis performed as described in the previous section showed that antibodies without the G4S motif in the rigid peptide linker had a relatively short retention time (RT), indicating that the antibodies could exist in the form of oligomers (Table 5). Native mass spectrometry analysis for Ly2125 revealed a mass of 398 kDa, indicating a dimer structure of the expected intact molecule of the antibody.

[0270] Table 5: SEC analysis of exemplary multispecific antibodies

[0271] Antibody Main peak (%) Main peak RT / min Ly2125 76.4 6.9 Ly2128 89.6 7.7 Ly2157 78.0 7.2 Ly1963 87.5 7.9 Ly2167 83.2 6.2 Ly1967 83.0 7.0

[0272] The binding of these antibody constructs to the CD3 target antigen was assessed by ELISA as in Example 2. Figures 4A-4C As shown, the absence of the G4S motif in the rigid peptide linkers (Ly2125, Ly2157, and Ly2167) increased CD3 binding compared to the rigid peptide linkers with the G4S motif (Ly2128, Ly1963, and Ly1967). The higher binding potency of Ly2125, Ly2157, and Ly2167 may be the result of oligomer formation.

[0273] Example 4: Activity of the central Fv binding portion in a multispecific antibody

[0274] This example evaluates the binding activity of the central Fv fragment in a multispecific antibody.

[0275] CD3 modulators

[0276] Several bispecific or trispecific antibodies were constructed as CD3 modulators targeting B7H3 and / or CD19. The trispecific antibodies had a CD137 or CD28 binding domain and a central (hidden) CD3 binding domain. The binding of these antibodies to CD3 was determined as described in Example 2 and was 1 / 50-1 / 10 of the binding to CD3 of the parent anti-CD3 mAb Ly305 (Table 6 and Table 7 below). Figures 4A-4C ).

[0277] Carry out CD3 reporter gene assay to determine the effectiveness of these antibodies.Use the CD3 reporter gene assay system including Jurkat / NFAT-Luc2P cells (Jurkat cells expressing the luciferase reporter gene driven by NFAT response element).In simple terms, Jurkat / NFAT-Luc2P cells are collected, and 50000 cells / well are divided into 96 well plates, and with or without other target expression cells co-culture.Add test antibody, and plate is incubated for another 6 hours at 37 DEG C, then Bright-GloTM luciferase assay (Promega, catalog number E2620) is carried out.NFAT-mediated luminescence in this assay corresponds to the activation of CD3 by multispecific antibodies in the absence or presence of high-affinity target antigen.

[0278] The CD3 reporter assay showed that the potency of these antibodies was greatly reduced (no activity at 10 μg / mL) in the absence of additional targets compared to the parental anti-CD3 mAb (Table 6). However, in the presence of additional targets for cross-linking (such as tumor antigens or immune receptors), the activity of CD3 was greatly enhanced (Table 6 and Table 6 below). Figures 5A-5I ).

[0279] Table 6: CD3 binding and activation

[0280]

[0281] Cell killing caused by exemplary multispecific antibodies was determined by measuring lactate dehydrogenase (LDH) release. Target cells and PBMC effector cells were seeded into 96-well plates and incubated with test antibodies. The plates were incubated at 37 ° C for 48 hours. According to the manufacturer's instructions, LDH was measured using an LDH assay kit (Promega) to measure LDH released from damaged cells. Additionally, according to the manufacturer's instructions, the activation of immune cells was assessed by measuring IFN-γ levels using an HTRF assay kit from Cisbio (Cisbio). Fig. 6A and 6B CD3 activation induces T cell killing activity against tumor cells expressing specific TA of the multispecific antibody, respectively.

[0282] These examples demonstrate that the central CD3 Fv binding module has significantly reduced CD3 binding and minimal ability to induce CD3 activation by itself. However, in a multispecific format, the CD3 Fv binding module has high aggregation and activation potential due to the presence of a second binding partner and / or a third binding partner, with much higher CD3 activation capacity compared to the parent mAb Ly305.

[0283] CD137 modulators

[0284] Several bispecific or trispecific antibodies (such as Ly2118 and Ly2281) were constructed as CD137 regulators and targeted B7H3 and / or PD-1. The CD137 binding of these bispecific or trispecific antibodies was 1 / 30-1 / 20 of the CD137 binding of the parent anti-CD137 mAb (Table 7 or Figure 7A-7B ).

[0285] CD137 reporter gene assay was performed using GS-H2-huCD137 reporter cells expressing human CD137 to determine the effectiveness of these antibodies, and downstream signaling assays for IL-8 expression were performed. GS-H2-huCD137 reporter gene cells with or without additional target expression cells were seeded in assay plates at 3000 cells / well and 25000 cells / well, respectively. Exemplary multispecific antibodies were added to the assay plate. The plate was incubated in a CO2 (5%) incubator at 37°C for 18-20 hours. 8 μL supernatants from each well of the assay plate were subjected to homogeneous time-resolved fluorescence (HTRF) assay (Cisbio). Human interleukin 8 (CD137 activated reporter gene) detection assay was performed in 16 μL assay volumes using human IL-8 assay kit (Cisbio, catalog number 62IL8PEB). Tecan F200pro was used to read the results.

[0286] Results from the CD137 reporter gene assay showed minimal activity of the antibodies tested. However, when additional targets (such as tumor antigens or immune receptors) were available for cross-linking, activity was greatly enhanced (Table 7 and Table 8 below). Figures 8A-8E ).

[0287] Table 7: CD137 binding and activation

[0288]

[0289] As shown in Table 7 and Figures 7-8, the central Fv CD137 binding portion showed a much lower binding affinity to CD137 than the parental anti-CD137 antibody (Ly1630), and in the presence of GS-H2-huCD137 reporter cells, both the parental clone and the multispecific antibody showed no CD137 activation activity. However, in the presence of cells expressing other target antigens (B7H3 or PD-1), the multispecific antibody showed a high ability to activate CD137, while the parental anti-CD137 did not show this effect.

[0290] These examples demonstrate that the central CD137 Fv binding module has significantly reduced CD137 binding and minimal ability to induce CD137 activation. However, in a multispecific format, the CD137 Fv binding module has high aggregation and activation potential due to the presence of a second binding partner and / or a third binding partner.

[0291] CD40 modulators

[0292] Several bispecific or trispecific antibodies were constructed as CD40 modulators including Ly2121, Ly2279 and Ly2280 and targeting B7H3 and / or PD-1. The CD40 binding of these bispecific or trispecific antibodies was 1 / 6-1 / 3 of the CD40 binding of the parent anti-CD40 mAb (Table 8 or Figures 9A-9B ).

[0293] CD40 reporter assays were performed using reporter cells expressing human CD40 to determine the agonist activity of the exemplary multispecific antibodies, and downstream signaling assays for IL-8 expression were performed. GS-H2-huCD40 reporter cells with or without additional target expressing cells were seeded in assay plates at 1000 cells / well and 25000 cells / well, respectively. Exemplary multispecific antibodies were added to the assay plates. The assay plates were incubated at 37°C in a CO2 (5%) incubator for 18-20 hours. 8 μL of supernatant from each well of the assay plate was subjected to HTRF detection assay (Cisbio). Human interleukin 8 (CD40 activated reporter gene) detection assay (Cisbio, catalog number 62IL8PEB) was performed in a 16 μL assay volume. The results were read using Tecan F200pro.

[0294] Results from the CD40 reporter gene assay showed reduced activity in the CD40 activation reporter gene assay. However, in the presence of additional targets for cross-linking (such as tumor antigens or immune receptors), activity was greatly enhanced (Table 8 and Table 9 below). Figures 10A-10F ).

[0295] Table 8: CD40 binding and activation

[0296]

[0297] These examples demonstrate that the central CD40 Fv binding module has significantly reduced CD40 binding and low ability to induce CD40 activation. However, in a multispecific format, the CD40 Fv binding module has high aggregation and activation potential due to the presence of a second binding partner and / or a third binding partner (including TAA B7H3 or immune checkpoint inhibitor PD-1), suggesting synthetic biology of xLink (cross-linking) activity driven by avidity of high-affinity target antigens and optimally modulating immune responses in situations where multivalent binding can readily occur, such as in the tumor microenvironment.

[0298] Example 5: Contribution of peptide linker sequence to binding in trispecific antibodies

[0299] This example explores the effects of a peptide linker attached to an Fv on the characteristics of a multispecific antibody comprising the peptide linker.

[0300] The trispecific B7H3 / CD3 / CD28 antibodies Ly2132, Ly2133, Ly2134, Ly2135, and Ly2128, all of which contain a terminal Fv CD28 binding module, were examined in this study. H and V LThe fragments were each linked to the Fc fragment via a peptide linker (flexible or rigid) as indicated below:

[0301] Ly2134: GGGGS (SEQ ID NO:3);

[0302] Ly2133:GGGGSGGGGS (SEQ ID NO:4);

[0303] Ly2132: GGGGSGGGSGGGGS (SEQ ID NO: 5);

[0304] Ly2128: GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 6);

[0305] Ly2135: DKTHTCPPCPGGGGSGGGGSGGGGS (SEQ ID NO: 17).

[0306] Fig.11 The effects of these peptide linkers on binding to the target antigen are shown. Longer (G4S)n sequences are associated with higher binding activity (Ly2128>Ly2132>Ly2133>Ly2134), with the shorter G4S in Ly2134 having minimal binding. The presence of the DKTHTCPPCP (SEQ ID NO: 8) peptide sequence in the linker has a negative impact on binding activity because Ly2135 shows lower binding than Ly2132. It was found that the binding affinity of the Fv fragment in the multispecific antibody was about 1 / 100 of that of the parent mAb (in IgG form).

[0307] Figures 12A-12B The agonistic properties of the trispecific antibodies are shown. Longer (G4S)n sequences are associated with agonistic activity (Ly2128>Ly2132>Ly2133>Ly2134). The presence of the DKTHTCPPCP (SEQ ID NO: 8) peptide sequence in the peptide linker has a negative impact on agonistic activity, as Ly2135 shows lower agonistic activity than Ly2132. Similar trends were observed when reporter cells were treated with the antibodies listed above together with CHO cells expressing B7H3.

[0308] In summary, the data demonstrate that the length and structure of the linker connecting the Fv portion can fine-tune the Fv binding potency to further achieve the desired function.

[0309] Example 6: Characterization of multispecific antibodies containing terminal Fv binding portions

[0310] Several multispecific antibodies were constructed at the C-terminus using the Fv CD137, CD40, CD28 or CD3 binding moieties described in the present invention, including Ly1963, Ly1966, Ly1967, Ly1800, Ly1891, Ly2122, Ly2128, Ly2326, Ly2396, Ly2405, Ly2415, Ly2424, Ly2434, Ly2444, Ly2454, Ly2580, Ly2579, Ly2638, Ly2639, Ly2640, Ly2641, Ly2642, Ly2643 and Ly2644. Binding of these multispecific antibodies to the corresponding targets was assessed by FCM or ELISA performed as described above. Activation of CD137, CD40, CD28 or CD3 signaling by these multispecific antibodies was also assessed using appropriate reporter gene systems as described above.

[0311] CD137 modulators

[0312] Several bispecific or trispecific antibodies targeting B7H3, CD19 or PD-1 were constructed using CD137 modulators through their terminal Fv fragments. The binding of these bispecific or trispecific antibodies to CD137 is weaker than that to the parent anti-CD137 mAb (Table 9 and Table 9 below). Figures 17A-17B and 25A-25C).

[0313] As described in the examples above, a CD137 reporter gene assay was performed to determine the efficacy of these antibodies. Results from the CD137 reporter gene assay showed minimal activity of the antibodies tested in the absence of additional targets. However, when additional targets (such as tumor antigens or immune receptors) were available for cross-linking, activity was greatly enhanced (Table 9 and Table 10). Figures 31A-31C ).

[0314] Table 9: CD137 binding and activation

[0315]

[0316]

[0317] Note: N / A = Not Applicable

[0318] like Figures 17A-17B and Figures 25A-25CAs shown, the binding affinity of the terminal Fv CD137 binding part to CD137 is 1 / 100-1 / 20 of the binding affinity of the reference and parent anti-CD137 antibodies (TM173 and Ly1630) to CD137, and in the absence of additional targets, the multispecific antibodies did not show CD137 activation activity. However, in the presence of cells expressing other target antigens (B7H3, CD19, PD-1 or CD3), the multispecific antibodies showed a high ability to activate CD137, while the parent anti-CD137 mAb did not show such a cross-linking effect. See also Figures 31A-31C .

[0319] These examples demonstrate that the terminal CD137 Fv binding module has significantly reduced CD137 binding and minimal ability to induce CD137 activation at the C-terminus. However, in a multispecific format, the CD137 Fv binding module has high aggregation and activation potential due to the presence of a second binding partner and / or a third binding partner.

[0320] CD28 modulators

[0321] Several multispecific antibodies targeting B7H3, BCMA, CEA or HER2 were constructed using CD28 modulators through their terminal Fv fragments.

[0322] like Figures 13A-13D As shown, the binding affinity of the terminal Fv CD28 binding portion to CD28 is 1 / 100-1 / 20 of the binding affinity of the parent anti-CD28 antibody Ly224 to CD28.

[0323] As described in the above examples, Jurkat reporter gene assays were performed to determine the effectiveness of these antibodies. Results from the reporter gene assays showed weak activity of the antibodies tested in the absence of additional targets. However, when additional targets (such as tumor antigens) were available for crosslinking, activity was greatly enhanced ( Figures 13E-13N ).

[0324] These examples demonstrate that the terminal CD28 Fv binding moieties have significantly reduced CD28 binding at the C-terminus. However, in the multispecific format, the CD28 Fv binding moieties have high aggregation and activation potential due to the presence of the second binding partner and / or the third binding partner, as summarized in Table 10 below.

[0325] Table 10: CD28 binding and T cell activation

[0326]

[0327]

[0328] PD-L1 modulators

[0329] Several multispecific antibodies targeting B7H3 were constructed using PD-L1 modulators through their terminal Fv fragments.

[0330] like Fig.14A As shown, the binding affinity of the terminal Fv PD-L1 binding portion to PD-L1 is 1 / 100-1 / 20 of the binding affinity of the parent anti-PD-L1 antibodies Ly076 and Ly2530 to PD-L1.

[0331] Jurkat reporter gene assays were performed to determine the blocking efficacy of the terminal Fv PD-L1 binding moiety. Results from the reporter gene assays showed weak blocking activity of the antibodies tested in the absence of additional targets. However, when additional targets (such as tumor antigens) were available for crosslinking, the activity was slightly enhanced ( Fig. 14B and 14C ).

[0332] These examples demonstrate that the terminal PD-L1 Fv binding module has significantly reduced PD-L1 binding and weak blocking activity at the C-terminus. However, in the multispecific format, the PD-L1 Fv binding module has aggregation and activation potential due to the presence of the second binding partner and / or the third binding partner, as summarized in Table 11 below.

[0333] Table 11: PD-L1 binding and blocking activity

[0334] protein PD-L1 binding Blocking activity without co-culture Blocking activity using additional targets Ly076 +++++ +++ +++ Ly2530 +++++ +++++ +++++ Ly2846 ++ + + Ly2847 +++ ++ ++

[0335] Example 7: Evaluation of multispecific antibodies with hidden Fv modules for cancer immunotherapy

[0336] This example tests the anti-tumor efficacy of exemplary multispecific antibodies with hidden Fv modules and additional binding domains that target the tumor microenvironment.

[0337] A. Multispecific Antibodies Targeting CD3 and CD19 and / or CD20

[0338] (i) Binding to target antigen

[0339] Bispecific antibodies targeting CD3 and CD19 or targeting CD3 and CD20 have been shown to be effective for B cell lymphoma. However, such bispecific antibodies show some disadvantages, including short half-life and high side effects. In order to address these problems, in this example, several multispecific antibodies with one or both of anti-CD3 and anti-CD137 Fvs targeting CD19 and / or CD20 were evaluated, such as Ly1966, Ly1967, Ly2278, Ly2326, Ly2579, Ly2580, Ly2800, Ly2802, Ly2943, Ly2944, Ly2945, Ly2946, Ly2947 and Ly2948. The combination of these multispecific antibodies and the corresponding targets was evaluated by FCM or ELISA as described above, and the combination thereof with tumor cells expressing tumor antigens (e.g., Raji cells (CD20+CD19+)) was also examined. Table 12 and Figure 4C A summary of these data is presented in Figures 15 to 17. These data demonstrate that the binding activity of the Fv binding module has been significantly reduced.

[0340] Table 12: Target binding of anti-CD19 / 20 multispecific antibodies

[0341] protein CD19 binding CD20 binding Raji Combination CD3 binding CD137 binding Ly238 ++++ N / A ++++ N / A N / A Ly239 N / A ++++ +++++ N / A N / A Ly305 N / A N / A N / A ++++ N / A Ly1630 N / A N / A N / A N / A +++++ Ly1966 ++++ N / A ++++ + + Ly1967 ++++ N / A ++++ + + Ly2278 ++++ N / A ++++ + - Ly2326 ++++ N / A ++++ N / A + Ly2800 +++ ++ ++ + + Ly2802 ++ +++ +++ + + Ly2943 +++ ++ ++ + + Ly2944 ++ +++ +++ + +

[0342] (ii) Reporter gene assay

[0343] The reporter gene assay described above was performed to determine activation of CD3 signaling by multispecific antibodies comprising anti-CD19 / CD20 and / or CD137 binding moieties. Figure 5C-5I and Fig.18A These data are summarized in -18L. The presence of CD19, CD20, including tumor cells expressing these antigens (e.g., Raji cells) significantly increased CD3 activation of multispecific antibodies including Ly1966, Ly1967, Ly2278, Ly2800, Ly2802, Ly2943, and Ly2944. Binding to CD137 enhanced CD3 activation of multispecific antibodies Ly1966, Ly1967, Ly2800, Ly2802, Ly2943, and Ly2944, although at higher concentrations compared to CD19 binding, reflecting the lower affinity of the CD137 binding Fv module.

[0344] Table 13: Activation of CD3 signaling by multispecific antibodies targeting CD19 or CD20

[0345]

[0346]

[0347] Reporter gene assays were also used to determine activation of CD137 signaling by multispecific antibodies targeting CD19 or CD20. Figures 19A-19G The results are summarized in .

[0348] Table 14: Activation of CD137 signaling by anti-CD19 / 20 multispecific antibodies

[0349]

[0350] Activation of the immune receptors CD3 or CD137 by the multispecific antibodies was minimal but significantly increased under cross-linking conditions, supporting the designed avidity-mediated effect.

[0351] (iii) Tumor cell killing, pharmacokinetics, and antitumor efficacy

[0352] Tumor cell killing by immune cells induced by anti-CD19 / 20 multispecific antibodies was examined in vitro.

[0353] Raji cells and human PBMCs were mixed and incubated with various test articles for 48 hours, and the release of LDH from damaged cells was measured using a kit from Promega according to the instructions. The cytotoxicity of the test articles was calculated based on the LDH level in the culture supernatant. Ly1966 and Ly1967 showed highly potent activity, with EC 50 The values ​​were 10.8pM and 8.9pM ( Fig. 20A ). The control Ly1963 targeting B7H3 showed no significant activity in this assay, supporting CD19 target-specific cytotoxicity activated by Ly1966 and Ly1967 ( Fig. 20A ).

[0354] Nalm-6-luc cells and human PBMCs were mixed and incubated with various test articles for 48 hours, and the luminescence from tumor cells was measured using a kit from Promega according to the instructions. The cytotoxicity of the test article was negatively correlated with the luminescence intensity. Anti-CD19 ( / CD20) antibodies integrated with anti-CD3 and / or anti-CD137 Fv showed significant tumor cell killing activity comparable to or superior to anti-CD20 / CD3 bsAb reference Ly2309 in this assay ( Fig. 20B ).

[0355] (iv) Pharmacokinetics

[0356] Ly1967 was administered to mice for pharmacokinetic analysis. Briefly, the study used C57BL / 6 mice (6-7 weeks old, 19-20 g, female, purchased from Vital River). The antibody was diluted in DPBS and administered by intraperitoneal injection at 5 mg / kg, 4 mice per group. Blood sampling was performed by continuous bleeding before dosing, 1 day, 4 days, 7 days, 10 days, 14 days, 17 days and 21 days. 10 μL of blood at each time point was added to 40 μL PBS-BSA solution. The samples were then mixed thoroughly and centrifuged at 2000xg for 5 minutes at 4°C. The supernatant was frozen on dry ice and stored at -70°C until analysis. Blood antibody concentrations were determined by ELISA from target recombinant human protein binding. After a single intraperitoneal injection of 5 mg / kg, serum concentrations of active molecules were determined by dual antigen binding ELISA. As Fig.21 As shown, Ly1967 remained in the circulation for 3 weeks after administration, and its PK profile was similar to that of conventional antibodies.

[0357] (v) Anti-tumor effect

[0358] Antitumor efficacy was examined in a syngeneic mouse model using bone marrow transplantation of murine colon cancer cell line MC38 overexpressing human CD19, murine melanoma cell line B16F10, or NCG mouse model transplanted with human PBMC of human Burkitt's lymphoma cell line Raji. Test articles were injected intraperitoneally. Mice were weighed and tumor growth was measured twice a week using a caliper. The formula 0.5x(length x width) was used. 2 ) to estimate tumor volume. Fig.22A As shown, strong antitumor activity was achieved by both Ly1967 and Ly2278. In addition, the following facts collectively indicate the advantages of anti-CD19 / 20 multispecific antibodies over reference anti-CD3 bsAbs (Ly2278, Ly2307, and Ly531) in terms of in vivo antitumor activity: Ly1967 showed stronger antitumor activity than Ly531 (anti-CD19 / CD3 bispecific antibody) (in Fig. 22B Ly1967 is stronger than Ly2278 (in Fig. 22C and Ly2800 / 2802 is stronger than Ly2307 or Ly531 (in Fig.22D and Ly2943 / 2944 is stronger than Ly2307 or Ly531 (in Fig.22E middle).

[0359] B. Multispecific Antibodies Targeting CD3 and B7H3

[0360] B7H3-targeted CD3 bispecific T cell engagers have the potential to mediate immune killing of various solid tumors, in which high levels of B7H3 expression are common. Several anti-B7H3 multispecific antibodies were prepared using the Fv CD3 and CD137, CD28, PD-1, PD-L1 or CTLA4 binding modules described in the present invention, including Ly1965, Ly1963, Ly2128, Ly2122, Ly2936, Ly2937, Ly2939 and Ly2940.

[0361] (i) Binding to target antigen

[0362] The binding of these multispecific antibodies to the corresponding targets was evaluated by FCM or ELISA and is summarized in Table 15 and Figures 4A-4C and Figures 23-29. The multispecific antibodies exhibited affinity binding to the TA target B7H3 and significantly attenuated affinity to the immune targets CD3, CD137, CD28, PD-1, PD-L1, or CTLA4.

[0363] Table 15: Target binding of anti-B7H3 multispecific antibodies

[0364]

[0365] Note: N / A = not applicable; + / - = weak binding; *weak cell binding assessed by FCM, moderate protein binding assessed by ELISA

[0366] (ii) Reporter gene assay

[0367] The activation of CD3 signaling by anti-B7H3 multispecific antibodies was evaluated using a reporter gene system and is summarized in Tables 16 and Figures 5A-5I and 30A-30Q. The presence of the B7H3 target antigen significantly increased CD3 activation of multispecific antibodies containing Ly1963 and Ly1965. Binding to terminal Fv targets such as CD137, CD28, PD-1, or PD-L1 enhanced CD3 activation of the corresponding multispecific antibodies.

[0368] Table 16: Activation of CD3 signaling by anti-B7H3 multispecific antibodies

[0369]

[0370] The activation of CD137 signaling by anti-B7H3 multispecific antibodies was evaluated using a reporter gene system and is summarized in Tables 17 and 18 below. Figures 31A-31F middle.

[0371] Table 17: Activation of CD137 signaling by anti-B7H3 multispecific antibodies

[0372]

[0373]

[0374] Note: N / A = Not Applicable

[0375] The blocking of PD-(L)1 signaling by anti-B7H3 multispecific antibodies was evaluated using a reporter gene system and is summarized in Tables 18 and 19 below. Figures 14B-14C middle.

[0376] Table 18: Blockade of PD-(L)1 signaling by anti-B7H3 multispecific antibodies

[0377] protein PD-(L)1 blockade without co-culture PD-(L)1 blockade using B7H3 Ly2530 +++++ +++++ Ly076 ++++ ++++ Ly711 ++++ ++++ Ly2846 + / - + Ly2847 + ++

[0378] Note: N / A = Not Applicable

[0379] Multispecific antibody activation of immune receptors CD3 or CD137 was minimal, but significantly increased under cross-linking conditions, supporting the designed avidity-mediated effect. The effect of multispecific antibody cross-linking on PD-L1 signaling was also observed in the exemplary anti-B7H3 / CD3 / PD-L1 multispecific antibody.

[0380] (iii) Tumor cell killing, pharmacokinetics, and antitumor efficacy

[0381] Tumor cell killing by immune cells induced by anti-B7H3 multispecific antibodies was examined in vitro. A375 cells or A375-Luc cells and human PBMCs were mixed and incubated with various test antibodies for 48 hours, and LDH release or luminescence intensity was measured as described above.

[0382] Figures 32A-32B Provided is a summary of these results in an in vitro assay for killing A375 cancer cells. Ly2128 and Ly1963 show a trend of stronger cytotoxicity than Ly1965, which indicates the contribution of additional CD28 or CD137 signaling induced by the corresponding terminal Fv. Compared to Ly1963, Ly2128 induces higher cytokine production, but there is no obvious difference in tumor cell killing.

[0383] Figures 32C-32D A summary of these results in an in vitro assay for killing A375-luc cancer cells is provided. Ly2600, Ly2936 and Ly1963 showed a trend towards stronger cytotoxicity than Ly2939, suggesting the contribution of the additional CD137-terminal Fv.

[0384] Figures 32E-32F Results from an in vitro assay of Ly2938 with a CD28-terminal Fv killing A375-luc cancer cells are presented.

[0385] Figures 32G-32H Results of exemplary multispecific antibodies of B7H3 / CD3 / PD-L1 in an in vitro assay for killing A375-luc cancer cells are provided. Ly2846 and Ly2847 showed comparable or stronger cytotoxicity than Ly1963 and higher IFN-γ secretion than Ly1963, indicating the contribution of the additional PD-L1 terminal Fv.

[0386] Figures 32I-32J Results of exemplary multispecific antibodies of B7H3 / CD3 / PD-1 in an in vitro assay for killing A375-luc cancer cells are provided. Ly2904 showed as potent cytotoxicity as Ly1963 in tumor cell killing and IFN-γ secretion, indicating the contribution of the additional PD-1 terminal Fv.

[0387] Figure 32K-32L Results of B7H3 / CD3 / CTLA4 exemplary multispecific antibodies in an in vitro assay for killing A375-luc cancer cells are provided. Ly2901, Ly2902, and Ly2903 showed different and slightly lower levels of cytotoxicity and IFN-γ secretion than Ly1963, indicating the contribution of the additional CTLA4 terminal Fv.

[0388] Pharmacokinetic analysis of these multispecific antibodies was performed using the mouse model as described above. Fig.33 The presence of circulating Ly1963 antibodies over a 21 day period is shown, with a PK profile similar to that of conventional antibodies.

[0389] The anti-tumor efficacy was examined in a mouse model of bone marrow transplantation. Bone marrow from homozygous human CD3 and CD137 knock-in mice was transplanted into wild-type C57 mice that had been subjected to whole-body irradiation 12-24 hours in advance. Three weeks after the bone marrow transplantation, LL2 tumors expressing human B7H3 were inoculated subcutaneously. Five days after tumor inoculation, the mice were grouped and the test article was injected intraperitoneally weekly. The mice were weighed and tumor growth was measured twice a week using a caliper. Tumor volume was estimated as 1 / 2 (length x width 2 ).like Fig.34A As shown, strong antitumor activity was achieved by Ly1963. The trispecific antibody Ly1963, which showed more robust antitumor efficacy than the bispecific antibodies Ly1965 or Ly2122, suggests potential benefits in designing synthetic CD3 and CD137 activities for stronger antitumor immunity.

[0390] Antitumor efficacy was examined in a human PBMC-transplanted mouse model. A375 tumors expressing human B7H3 were inoculated subcutaneously on day 0 and human PBMCs were inoculated intravenously. Four days after tumor inoculation, mice were grouped and injected intraperitoneally with test articles weekly. Mice were weighed and tumor growth was measured twice a week using a caliper. Tumor volume was estimated as 1 / 2 (length x width 2 ).like Figures 34B-34L As shown, anti-tumor activity was achieved by exemplary multispecific antibodies Ly2823, Ly2936, Ly2937, Ly2600, Ly2846, Ly2847, Ly2938, Ly2939 and Ly2940. Notably, the bispecific antibody Ly2940, which showed robust anti-tumor efficacy, indicated the potential benefit of anti-CD137 Fv at the C-terminus.

[0391] C. Multispecific Antibodies Targeting Other Immunomodulators and B7H3

[0392] The anti-tumor efficacy of bispecific antibodies targeting B7H3 and other immunomodulators has been evaluated in clinical trials. Several anti-B7H3 multispecific antibodies were prepared using the Fv CD137 and / or CD40 binding modules described in the present invention, including Ly2279, Ly2424, Ly2428, Ly2434, Ly2641, Ly2642, Ly2512, Ly2513, Ly2514 and Ly2515.

[0393] (i) Binding to target antigen

[0394] The binding of these multispecific antibodies to the corresponding targets was evaluated by FCM or ELISA and is summarized in the following Table 19. The multispecific antibodies exhibited avid binding to the TAA target B7H3 and significantly attenuated affinity to the immune targets CD40 or CD137.

[0395] Table 19: Target binding of anti-B7H3 multispecific antibodies

[0396] protein B7H3 binding CD40 binding CD137 binding TM383 N / A ++++ N / A TM559 N / A ++++ N / A Ly1630 N / A N / A +++++ Ly2279 ++++ +++ N / A Ly2424 ++++ +++ N / A Ly2428 ++++ +++ N / A Ly2434 ++++ +++ N / A

[0397] Note: N / A = Not Applicable

[0398] The activation of CD137 or CD40 signaling by these multispecific antibodies was evaluated using a reporter gene system. Immune cell activation and tumor cell killing induced by these multispecific antibodies were examined in vitro. These multispecific antibodies were administered to mice for pharmacokinetic analysis. The anti-tumor efficacy of these multispecific antibodies was examined in mouse models.

[0399] D. Trispecific and Bispecific Anti-PD-1 Antibodies

[0400] Several anti-PD-1 multispecific antibodies were prepared using the Fv CD137, CD40 or GITR binding moieties described in the present invention, including Ly2281, Ly2396, Ly2638, Ly2280, Ly2405, Ly2409, Ly2415, Ly2639, Ly2640, Ly2505, Ly2506, Ly2509, Ly2510, Ly2511, Ly2578, Ly2507, Ly2508, Ly2576 and Ly2577.

[0401] The binding of these multispecific antibodies to the corresponding targets was evaluated by FCM or ELISA and is summarized in the following Table 20. The multispecific antibodies exhibited avid binding to the target PD-1 and significantly weakened the affinity to the immune targets CD40, CD137 or GITR.

[0402] Table 20: Target binding of anti-PD-1 multispecific antibodies

[0403]

[0404]

[0405] Note: N / A = Not Applicable

[0406] These multispecific antibodies were evaluated for activation of CD137 or CD40 or GITR, or inhibition of PD-1 signaling using the reporter gene systems described above or below.

[0407] A PD-1 reporter gene assay was performed to determine the efficacy of these antibodies. The assay consists of two genetically engineered cell lines: Jurkat T cells expressing human PD-1 and a luciferase reporter gene driven by an NFκB response element, and Raji cells expressing human PD-L1. Jurkat and Raji cells with or without additional target-expressing cells were seeded in assay plates. Exemplary multispecific antibodies were added to the assay plates. The plates were incubated at 37°C in a CO2 (5%) incubator for 6 hours. The luminescent signal was examined with the Bright-glo kit from Promega.

[0408] Tumor cell killing by immune cells induced by these multispecific antibodies was examined in vitro. The pharmacokinetics in mice were evaluated by injecting multispecific antibodies and measuring the circulating levels of these antibodies for at least 21 days. The anti-tumor efficacy of these multispecific antibodies was examined using mouse tumor models.

[0409] E. Trispecific and Bispecific Anti-PD-L1 Antibodies

[0410] Several anti-PD-L1 multispecific antibodies were prepared using the Fv CD137, CD40, CD28 or CD3 binding moieties described in the present invention, including Ly2438, Ly2444, Ly2453, Ly2454, Ly2643, Ly2644, Ly2517, Ly2518, Ly2519, Ly2520, Ly2521, Ly2522, Ly2626, Ly2627, Ly2628, Ly2629, Ly2630, Ly2631, Ly2632, Ly2633, Ly2634, Ly2635, Ly2636 and Ly2637.

[0411] The binding of these multispecific antibodies to the corresponding targets was evaluated by FCM or ELISA and is summarized in the following Table 21. The multispecific antibodies exhibited avid binding to the target PD-L1 and significantly weakened the affinity to the immune targets CD40, CD137, CD3 or CD28.

[0412] Table 21: Target binding of anti-PD-L1 multispecific antibodies

[0413] protein PD-L1 binding CD40 binding CD3 binding CD137 binding CD28 binding Ly2438 ++++ ++++ N / A N / A N / A Ly2444 ++++ ++++ N / A N / A N / A Ly2453 ++++ +++ N / A N / A N / A Ly2454 ++++ +++ N / A N / A N / A

[0414] Note: N / A = Not Applicable

[0415] The activation of CD137, CD40, CD28 or CD3 signaling and the blockade of PD-1 / PD-L1 signaling by these multispecific antibodies were evaluated using appropriate reporter gene systems as described above. Tumor cell killing by immune cells induced by these multispecific antibodies was examined in vitro. The pharmacokinetics in mice were evaluated by injecting the multispecific antibodies and measuring the circulating levels of these antibodies for at least 21 days. The anti-tumor efficacy of these multispecific antibodies was examined using mouse tumor models.

[0416] Example 8: Additional Characterization of Multispecific Antibodies

[0417] Multispecific antibodies can be further characterized as exemplified below:

[0418] (i) Trispecific and bispecific anti-PSMA antibodies

[0419] Several anti-PSMA multispecific antibodies were constructed using the Fv CD3 binding modules described in the present invention, including Ly2083, Ly2084, Ly2086, Ly2606, Ly2607, Ly2608 and Ly2609. The binding of these multispecific antibodies to the corresponding targets was evaluated by FCM or ELISA. The activation of CD3 or CD137 signaling by these multispecific antibodies was evaluated using the appropriate reporter gene system described above. Tumor cell killing caused by immune cells induced by these multispecific antibodies was examined in vitro. The pharmacokinetics in mice were evaluated by injecting the multispecific antibodies and measuring the circulating levels of these antibodies for at least 21 days. The anti-tumor efficacy of these multispecific antibodies was examined using a mouse tumor model.

[0420] (ii) Trispecific and bispecific anti-BCMA antibodies

[0421] Several anti-BCMA multispecific antibodies were prepared using the Fv CD3 binding module described in the present invention, including Ly2312, Ly2315, Ly2602, Ly2603, Ly2604 and Ly2605. The binding of these multispecific antibodies to the corresponding targets was evaluated by FCM or ELISA. The activation of CD3 or CD137 signaling by these multispecific antibodies was evaluated using the appropriate reporter gene system described above. Tumor cell killing caused by immune cells induced by these multispecific antibodies was examined in vitro. The pharmacokinetics in mice were evaluated by injecting multispecific antibodies and measuring the circulating levels of these antibodies for at least 21 days. The anti-tumor efficacy of these multispecific antibodies was examined using a mouse tumor model.

[0422] (iii) Trispecific and bispecific anti-HER2 antibodies

[0423] Several anti-HER2 multispecific antibodies were prepared using the Fv CD3 binding module described in the present invention, including Ly2316, Ly2317, Ly2318, Ly2319, Ly2610, Ly2611, Ly2612, Ly2613, Ly2614, Ly2615, Ly2616 and Ly2617. The binding of these multispecific antibodies to the corresponding targets was evaluated by FCM or ELISA. The activation of CD3 or CD137 signaling by these multispecific antibodies was evaluated using the appropriate reporter gene system described above. Tumor cell killing caused by immune cells induced by these multispecific antibodies was examined in vitro. The pharmacokinetics in mice were evaluated by injecting multispecific antibodies and measuring the circulating levels of these antibodies for at least 21 days. The anti-tumor efficacy of these multispecific antibodies was examined using a mouse tumor model.

[0424] (iv) Trispecific and bispecific anti-CEA antibodies

[0425] Several anti-CEA multispecific antibodies were prepared using the Fv CD3 binding module described in the present invention, including Ly2320, Ly2321, Ly2322, Ly2618, Ly2619, Ly2620, Ly2621, Ly2622 and Ly2623. The binding of these multispecific antibodies to the corresponding targets was evaluated by FCM or ELISA. The activation of CD3 or CD137 signaling by these multispecific antibodies was evaluated using the appropriate reporter gene system described above. Tumor cell killing caused by immune cells induced by these multispecific antibodies was examined in vitro. The pharmacokinetics in mice were evaluated by injecting multispecific antibodies and measuring the circulating levels of these antibodies within at least 21 days. The anti-tumor efficacy of these multispecific antibodies was examined using a mouse tumor model.

[0426] (v) Trispecific and bispecific anti-P53 R175H antibodies

[0427] Several anti-p53 R175H multispecific antibodies, including Ly2288, Ly2624 and Ly2625, were prepared using the Fv CD3 binding module described in the present invention. The binding of these multispecific antibodies to the corresponding targets was evaluated by FCM or ELISA. The binding of these multispecific antibodies to the corresponding targets was evaluated by FCM or ELISA. The activation of CD3 or CD137 signaling by these multispecific antibodies was evaluated using the appropriate reporter gene system described above. Tumor cell killing caused by immune cells induced by these multispecific antibodies was examined in vitro. The pharmacokinetics in mice were evaluated by injecting multispecific antibodies and measuring the circulating levels of these antibodies for at least 21 days. The anti-tumor efficacy of these multispecific antibodies was examined using a mouse tumor model.

[0428] (vi) Trispecific and bispecific anti-MAGE-A4 antibodies

[0429] Several anti-MAGE-A4 multispecific antibodies were prepared using the Fv CD3 binding module described in the present invention. The binding of these multispecific antibodies to the corresponding targets was evaluated by FCM or ELISA. The activation of CD3 or CD137 signaling by these multispecific antibodies was evaluated using the appropriate reporter gene system described above. Tumor cell killing caused by immune cells induced by these multispecific antibodies was examined in vitro. The pharmacokinetics in mice were evaluated by injecting multispecific antibodies and measuring the circulating levels of these antibodies for at least 21 days. The anti-tumor efficacy of these multispecific antibodies was examined using a mouse tumor model.

[0430] (vii) Trispecific and bispecific anti-PRAME antibodies

[0431] Several anti-CEA multispecific antibodies were prepared using the Fv CD3 binding module described in the present invention. The binding of these multispecific antibodies to the corresponding targets was evaluated by FCM or ELISA. The activation of CD3 or CD137 signaling by these multispecific antibodies was evaluated using the appropriate reporter gene system described above. Tumor cell killing caused by immune cells induced by these multispecific antibodies was examined in vitro. The pharmacokinetics in mice were evaluated by injecting multispecific antibodies and measuring the circulating levels of these antibodies in at least 21 days. The anti-tumor efficacy of these multispecific antibodies was examined using a mouse tumor model.

[0432] (viii) Trispecific and bispecific anti-CD47 antibodies

[0433] Several anti-CD47 multispecific antibodies were prepared using the Fv CD47 binding modules described in the present invention, including Ly2147 and Ly2148. The binding of these multispecific antibodies to the corresponding targets was evaluated by FCM or ELISA. The phagocytosis of tumor cells induced by these multispecific antibodies was examined in vitro. The pharmacokinetics in mice were evaluated by injecting the multispecific antibodies and measuring the circulating levels of these antibodies for at least 21 days. The anti-tumor efficacy of these multispecific antibodies was examined using a mouse tumor model.

[0434] Sequence Listing

[0435] Table 1: Components in bi / multispecific antibodies

[0436]

[0437]

[0438]

[0439]

[0440]

[0441]

[0442]

[0443]

[0444] *: may have a (GxS)n fragment located at the N-terminus and / or the C-terminus. X is an integer between 1-6, inclusive, and n is an integer between 1-10, inclusive

[0445] Table 2: Sequences of exemplary bi-multispecific antibodies

[0446]

[0447]

[0448]

[0449]

[0450]

[0451]

[0452]

[0453]

[0454]

[0455]

[0456]

[0457]

[0458]

[0459]

[0460]

[0461]

[0462]

[0463]

[0464]

[0465]

[0466]

[0467]

[0468]

[0469]

[0470]

[0471]

[0472]

[0473]

[0474]

[0475]

[0476]

[0477]

[0478]

[0479]

[0480]

[0481]

[0482]

[0483]

[0484]

[0485]

[0486]

[0487]

[0488]

[0489]

[0490]

[0491]

[0492]

[0493]

[0494]

[0495]

[0496]

[0497]

[0498]

[0499]

[0500]

[0501]

[0502]

[0503]

[0504]

[0505]

[0506]

[0507]

[0508]

[0509]

[0510]

[0511]

[0512]

[0513]

[0514]

[0515]

[0516]

[0517]

[0518]

[0519]

[0520]

[0521]

[0522]

[0523]

[0524]

[0525]

[0526]

[0527]

[0528]

[0529]

[0530]

[0531]

[0532]

[0533]

[0534]

[0535]

[0536]

[0537]

[0538]

[0539]

[0540]

[0541]

[0542]

[0543]

[0544]

[0545]

[0546]

[0547]

[0548]

[0549]

[0550]

[0551]

[0552]

[0553]

[0554]

[0555]

[0556]

[0557]

[0558]

[0559]

[0560]

[0561]

[0562]

[0563]

[0564]

[0565]

[0566]

[0567]

[0568]

[0569]

[0570]

[0571]

[0572]

[0573]

[0574]

[0575]

[0576]

[0577]

[0578]

[0579] Other embodiments

[0580] All features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature having the same, equivalent or similar purpose. Therefore, unless otherwise expressly stated, each feature disclosed is merely an example of a series of general equivalent or similar features.

[0581] Through the above description, those skilled in the art can easily determine the essential characteristics of the present invention, and without departing from the spirit and scope of the present invention, various changes and modifications can be made to the present invention to make it suitable for various uses and conditions. Therefore, other embodiments are also within the scope of the claims.

[0582] Equivalent form

[0583] Although several embodiments of the present invention have been described and shown herein, a person of ordinary skill in the art will readily conceive of various other devices and / or structures for performing the functions described herein and / or obtaining these results and / or one or more of these advantages, and each of such variations and / or modifications is considered to be within the scope of the embodiments of the present invention described herein. More generally, a person of ordinary skill in the art will readily understand that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary, and that actual parameters, dimensions, materials, and / or configurations will depend on one or more specific applications for which the present invention is taught. Using only routine experiments, a person of ordinary skill in the art will recognize or be able to determine many equivalents of the specific embodiments of the present invention described herein. Therefore, it should be understood that the foregoing embodiments are presented only by way of example, and within the scope of the appended claims and their equivalents, embodiments of the present invention may be practiced in a manner different from that specifically described and claimed. The embodiments of the present invention disclosed herein relate to each individual feature, system, article, material, kit, and / or method described herein. In addition, if any combination of two or more such features, systems, articles, materials, kits and / or methods are not mutually inconsistent, then such features, systems, articles, materials, kits and / or methods are included within the inventive scope of the present disclosure.

[0584] All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms.

[0585] All references, patents, and patent applications disclosed herein are hereby incorporated by reference with respect to the subject matter for which each is cited, which in some cases may be incorporated in its entirety.

[0586] Unless clearly indicated to the contrary, the indefinite articles "a" and "an" as used in this specification and claims should be understood to mean "at least one".

[0587] As used herein in the specification and claims, the phrase "and / or" should be understood to mean "either or both" of the elements so combined, i.e., elements that are present in combination in some cases and separately in other cases. Multiple elements listed with "and / or" should be interpreted in the same manner, i.e., "one or more" of the elements so combined. In addition to the elements specifically identified by the "and / or" clause, other elements may optionally be present, whether related or unrelated to those specifically identified. Thus, as a non-limiting example, in one embodiment, when used in conjunction with open language such as "including", a reference to "A and / or B" may refer only to A (optionally including elements other than B); in another embodiment, only to B (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

[0588] As used herein in this specification and claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when the items in the list are separated, "or" or "and / or" should be interpreted as inclusive, i.e., including at least one element in many elements or element lists, but also including more than one element and optionally other unlisted items. Only explicitly indicating the opposite term, such as "only one of..." or "exactly one of..." or when used in the claims, "consisting of..." will refer to including exactly one element in multiple elements or element lists. In general, when there is an exclusive term before, such as "any one", "one of...", "only one of..." or "exactly one of...", as used herein, the term "or" should only be interpreted as indicating exclusive alternatives (i.e., "one or the other but not two"). When used in the claims, "consisting essentially of..." should have the common meaning as used in the field of patent law.

[0589] As used herein in this specification and claims, the phrase "at least one" with respect to a list of one or more elements should be understood to mean at least one element selected from any one or more elements in the list of elements, but not necessarily including at least one element of each element specifically listed in the list of elements, and not excluding any combination of elements in the list of elements. This definition also allows that there may be optionally elements other than the elements specifically identified in the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, in one embodiment, "at least one of A and B" (or equivalently, "at least one of A or B", or equivalently "at least one of A and / or B") may refer to at least one optionally containing more than one A, without B (and optionally containing elements other than B); in another embodiment, may refer to at least one optionally containing more than one B, without A (and optionally containing elements other than A); in yet another embodiment, may refer to at least one optionally containing more than one A, and optionally containing more than one B (and optionally containing other elements); etc.

[0590] It should also be understood that in any method claimed herein that includes more than one step or action, the order of the method steps or actions is not necessarily limited to the order in which the method steps or actions are described unless explicitly stated to the contrary.

Claims

1. A multispecific antibody comprising a first binding moiety specific for a first target antigen and a second binding moiety specific for a second target antigen, wherein the first target antigen is a first immune cell receptor, which is optionally a first T cell receptor; and the second target antigen is (i) a second immune cell receptor, which is optionally a second T cell receptor, which is different from the first immune cell receptor, or (ii) a first tumor-associated antigen (TAA); optionally wherein the first T cell receptor and / or the second T cell receptor is a T cell activating receptor or a T cell checkpoint receptor; The first binding moiety is a first Fv fragment, which includes a first heavy chain variable region (V H ) and the first light chain variable region (V L ); Where the first V H connected to a first flexible peptide linker and a first rigid peptide linker; and the first V L connected to a second flexible peptide linker and a second rigid peptide linker; and The first rigid peptide linker and the second rigid peptide linker form one or more disulfide bonds.

2. The multispecific antibody according to claim 1, wherein the first flexible peptide linker and the second flexible peptide linker are the same, and / or wherein the first rigid peptide linker and the second rigid peptide linker are the same.

3. The multispecific antibody according to claim 1 or claim 2, wherein the first flexible peptide linker, the second flexible peptide linker, or both are G / S-rich peptide linkers, Optionally, wherein the G / S-rich peptide linker comprises the formula (G X S) n , where X is an integer between 1 and 6, inclusive, and n is an integer between 1 and 10, inclusive.

4. The multispecific antibody of any one of claims 1 to 3, wherein the first rigid peptide linker, the second rigid peptide linker, or both comprise the amino acid sequence of DKTHTCPPCPAPEAAGP (SEQ ID NO: 21), DKTHTCPPCPAPELLGP (SEQ ID NO: 9), or DKTHTCPPCPAPELLGGP (SEQ ID NO: 27), optionally linked to a G / S-rich peptide linker.

5. The multispecific antibody of claim 4, wherein the first rigid peptide linker, the second rigid peptide linker, or both comprise (G X S) n The motif is linked to the N-terminus of DKTHTCPPCPAPEAAGP (SEQ ID NO: 21), DKTHTCPPCPAPELLGP (SEQ ID NO: 9) or DKTHTCPPCPAPELLGGP (SEQ ID NO: 27), wherein x is an integer between 1-6, inclusive, and n is an integer between 1-10, inclusive.

6. The multispecific antibody of claim 1 or claim 2, wherein the first rigid peptide linker, the second rigid peptide linker, or both are rigid peptide linkers listed in Table 1.

7. The multispecific antibody according to any one of claims 1 to 6, wherein the second binding moiety is linked to the first V H Connected or connected to the first V through the second flexible peptide linker L connect.

8. The multispecific antibody according to any one of claims 1 to 7, further comprising a third binding moiety specific for a third target antigen.

9. The multispecific antibody of claim 8, wherein the third binding moiety is the same as the second binding moiety, and the third target antigen is the same as the second target antigen.

10. The multispecific antibody of claim 8, wherein the third binding moiety is different from the second binding moiety; and optionally wherein the third target antigen is a second TAA.

11. The multi-chain antibody according to any one of claims 8 to 10, wherein the second binding moiety is connected to the first V H connected, and wherein the third binding moiety is connected to the first V L connect.

12. The multispecific antibody according to any one of claims 7 to 11, wherein the first V H further connected to the first Fc fragment via the first rigid peptide linker, and wherein the first V L Further connected to a second Fc fragment via the second rigid peptide linker; each Fc fragment comprises a CH2 domain and a CH3 domain, optionally wherein the Fc fragment is derived from an IgG1 molecule.

13. The multispecific antibody of claim 12, wherein the first Fc fragment and the second Fc fragment comprise mutations in the CH3 domain that enhance heterodimerization rather than homodimerization of the first Fc fragment and the second Fc fragment relative to their wild-type counterparts and / or reduce protein A binding. The multispecific antibody of claim 13 , wherein the mutation is a knob-in-hole mutation, a charged mutation, or a ZW1 mutation.

15. The multispecific antibody of any one of claims 12 to 14, wherein the first Fc fragment, the second Fc fragment, or both comprise one or more mutations that alter binding activity to an Fc receptor relative to the wild-type counterpart.

16. The multispecific antibody according to any one of claims 12 to 15, wherein the first Fc fragment, the second Fc fragment, or both comprise an amino acid substitution at one or more of positions 239, 265, 297, 329, 330, and 332, Optionally wherein the first Fc fragment, the second Fc fragment or both comprise (i) an amino acid substitution at position 329, which is optionally P329G, (ii) amino acid substitutions at positions 265 and 297, which are optionally D265A and N297A, and / or (iii) amino acid substitutions at positions 239, 330 and 332, optionally S239D, A330L and I332E.

17. The multispecific antibody according to any one of claims 7 to 16, wherein the second binding portion and / or the third binding portion are in the form of a single-chain variable fragment (scFv); in the form of a single domain antibody, which is optionally a single domain antibody; in the form of a Fab; or in the form of a cross-Fab; optionally wherein the single domain antibody is a heavy chain antibody fragment (VHH).

18. The multispecific antibody according to any one of claims 7 to 17, wherein the second binding moiety is a Fab fragment comprising a first VH-CH1 fragment and a first VL-CL fragment, or wherein the second binding moiety is a crossover Fab fragment comprising a first VH-CL fragment and a first VL-CH1 fragment; and optionally wherein the third binding moiety is a Fab fragment comprising a second VH-CH1 fragment and a second VL-CL fragment, or wherein the third binding moiety is a crossover Fab fragment comprising a second VH-CL fragment and a second VL-CH1 fragment.

19. The multispecific antibody according to claim 18, comprising: (a) a first polypeptide, wherein the first polypeptide comprises, from N-terminus to C-terminus, the first VH-CH1 fragment or the first VH-CL fragment of the second binding moiety, the first flexible peptide linker, the first V H , the first rigid peptide linker and the first Fc fragment; (b) a second polypeptide, wherein the second polypeptide comprises, from N-terminus to C-terminus, the second VH-CH1 fragment or the second VH-CL fragment of the third binding moiety, the second flexible peptide linker, the first V L , the second rigid peptide linker and the second Fc fragment; (c) a third polypeptide comprising the first VL-CL fragment or the first VL-CH1 fragment of the second binding moiety; and (d) a fourth polypeptide comprising the second VL-CL fragment or the second VL-CH1 fragment of the third binding moiety.

20. The multispecific antibody of claim 19, wherein the third polypeptide and the fourth polypeptide are identical.

21. The multispecific antibody of any one of claims 12 to 16, further comprising a fourth binding moiety specific for a fourth antigen, wherein the fourth binding moiety is a second Fv fragment comprising a second V H and the second V L ; wherein the second V H The first Fc fragment is connected to the first Fc fragment via a first peptide linker, and the second V L Connected to the second Fc fragment via a second peptide linker; optionally wherein the first peptide linker is the same as the second peptide linker.

22. The multispecific antibody of claim 21, wherein the first peptide linker, the second peptide linker, or both are G / S-rich peptide linkers, Optionally wherein the G / S-rich peptide linker comprises the formula (GXS)n, wherein X is an integer between 1-6, inclusive, and n is an integer between 1-10, inclusive.

23. The multispecific antibody according to claim 21 or claim 22, further comprising a third peptide linker and a fourth peptide linker, wherein the third peptide linker and the fourth peptide linker are respectively connected to the second V H and the second V L Linked, optionally wherein the third peptide linker and the fourth peptide linker are optionally the same pair of rigid peptide linkers, the pair of rigid peptide linkers forming one or more disulfide bonds.

24. The multispecific antibody of claim 23, wherein the third peptide linker, the fourth peptide linker, or both comprise the amino acid sequence of DKTHTCPPCPAPEAAGP (SEQ ID NO: 21), DKTHTCPPCPAPELLGP (SEQ ID NO: 9), DKTHTCPPCPAPELLGGP (SEQ ID NO: 27), optionally linked to a G / S-rich peptide linker.

25. The multispecific antibody of claim 23 or claim 24, wherein the third peptide linker, the fourth peptide linker, or both comprise (G X S) n The motif is linked to the N-terminus of DKTHTCPPCPAPEAAGP (SEQ ID NO: 21), DKTHTCPPCPAPELLGP (SEQ ID NO: 9) or DKTHTCPPCPAPELLGGP (SEQ ID NO: 27), wherein x is an integer between 1-6, inclusive, and n is an integer between 1-10, inclusive.

26. A multispecific antibody according to any one of claims 21 to 25, wherein the fourth target antigen is a third immune receptor, optionally a third T cell receptor, and the third T cell receptor is preferably a T cell activation receptor or a T cell checkpoint receptor; optionally wherein the third immune receptor is different from the first immune receptor and / or the second immune receptor.

27. The multispecific antibody of any one of claims 21 to 25, wherein the fourth target antigen is a third TAA, which is optionally different from the first TAA or the second TAA.

28. The multispecific antibody according to any one of claims 21 to 27, comprising: (a) a first polypeptide, wherein the first polypeptide comprises, from N-terminus to C-terminus, the first VH-CH1 fragment or the first VH-CL fragment of the second binding moiety, the first flexible peptide linker, the first V H , the first rigid peptide linker, the first Fc fragment, the first peptide linker, the second V H and optionally the second peptide linker; (b) a second polypeptide, wherein the second polypeptide comprises, from N-terminus to C-terminus, the second VH-CH1 fragment or the second VH-CL fragment of the third binding moiety, the second flexible peptide linker, the first V L , the second rigid peptide linker, the second Fc fragment, the third peptide linker and the second V L and optionally said fourth peptide linker; (c) a third polypeptide comprising the first VL-CL fragment or the first VL-CH1 of the second binding moiety; and (d) a fourth polypeptide comprising the second VL-CL fragment or the second VL-CH1 fragment of the third binding moiety.

29. The multispecific antibody of claim 28, wherein the third polypeptide is identical to the fourth polypeptide.

30. The multispecific antibody according to any one of claims 1 to 5, further comprising a first heavy chain constant region fragment and a second heavy chain constant region fragment, the first heavy chain constant region fragment is connected to the first flexible peptide linker, and the second heavy chain constant region fragment is connected to the second flexible peptide linker, optionally wherein the first heavy chain constant region fragment and / or the second heavy chain constant region fragment is derived from an IgG1 molecule; wherein each of the first heavy chain constant region fragment and the second heavy chain constant region fragment comprises a hinge domain, a CH2 domain and a CH3 domain, and wherein the second binding moiety is linked to the first heavy chain constant region fragment or the second heavy chain constant region fragment.

31. The multispecific antibody of claim 30, further comprising a third binding moiety specific for a third target antigen, wherein the second binding moiety is linked to the first heavy chain constant region fragment and the third binding moiety is linked to the second heavy chain constant region fragment.

32. The multispecific antibody of claim 31, wherein the third target antigen is the same as the second target antigen, optionally wherein the third binding moiety is the same as the second binding moiety.

33. The multispecific antibody of claim 31 or claim 32, wherein the third binding moiety is different from the second binding moiety; and optionally wherein the third target antigen is a second TAA.

34. A multispecific antibody according to any one of claims 31 to 33, wherein the first heavy chain constant region fragment and the second heavy chain constant region fragment comprise mutations in the CH3 domain, which enhance heterodimerization rather than homodimerization of the first Fc fragment and the second Fc fragment relative to their wild-type counterparts and / or reduce protein A binding.

35. The multispecific antibody of claim 33, wherein the mutation is a knob-in-hole mutation, a charged mutation, or a ZW1 mutation.

36. The multispecific antibody of any one of claims 30 to 35, wherein the first heavy chain constant region fragment, the second heavy chain constant region fragment, or both comprise one or more mutations that alter binding activity to an Fc receptor relative to the wild-type counterpart.

37. The multispecific antibody of any one of claims 30 to 36, wherein the first heavy chain constant region fragment, the second heavy chain constant region fragment, or both comprise (i) a deletion at one or more of positions 236-238, and / or (ii) an amino acid substitution at one or more of positions 239, 265, 297, 329, 330, and 332, Optionally wherein the first heavy chain constant region fragment, the second heavy chain constant region fragment or both comprise (i) a deletion at position 237, (ii) at least two amino acid substitutions selected from the group consisting of L234A, L235A and P329G, (iii) a deletion at position 237 and amino acid substitutions of D265A and N297A, (iv) amino acid substitutions of S239D, A330L and I332E, and / or (v) Deletion at position 237 and the amino acid substitution P329G.

38. The multispecific antibody of any one of claims 31 to 37, wherein the second binding moiety and / or the third binding moiety are in the form of a single-chain variable fragment (scFv); in the form of a single domain antibody, which is optionally a single domain antibody; in the form of a Fab; or in the form of a cross-Fab; optionally wherein the single domain antibody fragment is a heavy chain antibody fragment (VHH).

39. The multispecific antibody according to any one of claims 32 to 38, wherein the second binding moiety is a Fab fragment comprising a first VH-CH1 fragment and a first VL-CL fragment, or wherein the second binding moiety is a crossover Fab fragment comprising a first VH-CL fragment and a first VL-CH1 fragment; and optionally wherein the third binding moiety is a Fab fragment comprising a second VH-CH1 fragment and a second VL-CL fragment, or wherein the third binding moiety is a crossover Fab fragment comprising a second VH-CL fragment and a second VL-CH1 fragment.

40. The multispecific antibody of claim 39, comprising: (a) a first polypeptide, wherein the first polypeptide comprises, from N-terminus to C-terminus, the first VH-CH1 fragment or the first VH-CL fragment of the second binding moiety, the first heavy chain constant region fragment, the first flexible peptide linker, the first V H and said first rigid peptide linker; (b) a second polypeptide, which comprises, from N-terminus to C-terminus, the second VH-CH1 fragment or the second VH-CL fragment of the third binding moiety, the second heavy chain constant region fragment, the second flexible peptide linker and the first V L , the second rigid peptide linker; (c) a third polypeptide comprising the first VL-CL fragment or the first VL-CH1 fragment of the second binding moiety; and (d) a fourth polypeptide comprising the second VL-CL fragment or the second VL-CH1 fragment of the third binding moiety.

41. The multispecific antibody of claim 40, wherein the third polypeptide and the fourth polypeptide are identical.

42. The multispecific antibody of claim 1, which is one of the multispecific antibodies listed in Table 2.

43. A multispecific antibody comprising a first binding moiety specific for a first target antigen and a second binding moiety specific for a second target antigen, wherein the first target antigen is a first immune cell receptor, the first immune cell receptor is optionally a first T cell receptor, preferably a T cell activation receptor or a T cell checkpoint receptor; wherein the second target antigen is a second immune cell receptor or a first tumor-associated antigen (TAA), optionally wherein the second immune cell receptor is a second T cell receptor, preferably a second T cell activating receptor or a second T cell checkpoint receptor, wherein the second immune cell receptor is different from the first immune cell receptor; The first binding moiety is a first Fv fragment, which includes a first heavy chain variable region (V H ) and the first light chain variable region (V L ); Where the first V H is connected to a first peptide linker and a first heavy chain constant region fragment; and the first V L connected to a second peptide linker and a second heavy chain constant region fragment; and wherein the second binding portion is connected to the first binding portion via the first heavy chain constant region fragment or the second heavy chain constant region fragment, each of the first heavy chain constant region and the second heavy chain constant region comprising a hinge domain, a CH2 domain and a CH3 domain; optionally wherein the first heavy chain constant region fragment and / or the second heavy chain constant region fragment are derived from an IgG1 fragment.

44. The multispecific antibody of claim 43, wherein the first peptide linker, the second peptide linker, or both are G / S-rich peptide linkers, Optionally, wherein the G / S-rich peptide linker comprises the formula (G X S) n , where X is an integer between 1 and 6, inclusive, and n is an integer between 1 and 10, inclusive.

45. The multispecific antibody of claim 43 or claim 44, further comprising a third binding moiety specific for a third target antigen.

46. ​​The multispecific antibody of claim 45, wherein the third target antigen is the same as the second target antigen, optionally wherein the third binding moiety is the same as the second binding moiety.

47. The multispecific antibody of claim 45, wherein the third binding moiety is different from the second binding moiety; and optionally wherein the third target antigen is a second TAA.

48. A multispecific antibody according to any one of claims 45 to 47, wherein the first heavy chain constant region fragment and the second heavy chain constant region fragment comprise mutations in the CH3 domain, which enhance heterodimerization rather than homodimerization of the first Fc fragment and the second Fc fragment and / or reduce protein A binding relative to their wild-type counterparts.

49. The multispecific antibody of claim 48, wherein the mutation is a knob-in-hole mutation, a charged mutation, or a ZW1 mutation.

50. The multispecific antibody of any one of claims 45 to 47, wherein the first heavy chain constant region, the second heavy chain constant region, or both comprise one or more mutations that alter binding activity to an Fc receptor relative to the wild-type counterpart.

51. The multispecific antibody of any one of claims 45 to 50, wherein the first heavy chain constant region fragment, the second heavy chain constant region fragment, or both comprise (i) a deletion at one or more of positions 236-238, and / or (ii) an amino acid substitution at one or more of positions 239, 265, 297, 329, 330, and 332, Optionally wherein the first heavy chain constant region fragment, the second heavy chain constant region fragment or both comprise (i) a deletion at position 237, (ii) at least two amino acid substitutions selected from the group consisting of L234A, L235A and P329G, (iii) a deletion at position 237 and the amino acid substitutions D265A and N297A, (iv) the amino acid substitutions S239D, A330L and I332E, and / or (v) Deletion at position 237 and the amino acid substitution P329G.

52. The multispecific antibody of any one of claims 45 to 51, wherein the second binding portion and / or the third binding portion are in the form of a single-chain variable fragment (scFv); in the form of a single domain antibody, which is optionally a heavy chain only (VHH) form; in the form of a Fab; or in the form of a cross-Fab.

53. The multispecific antibody of any one of claims 1 to 52, wherein the first immune receptor, optionally the second immune receptor and / or the third immune receptor is selected from the group consisting of: CD3, CD28, PD-1, PD-L1, CD47 and a member of the tumor necrosis factor receptor superfamily (TNFRSF), optionally wherein the member of the TNFRSF family is selected from the group consisting of: FAS, TNFRSF12A, 4- 1BB / CD137, TNFRSF13B, TNFRSF13C, CD27 / TNFRSF7, CD30 / TNFRSF8, CD40 / TNFRSF5, DR3 / TNFRSF25, DR4 / TNFRSF10A, DR5 / TNFRSF10B, DR6 / TNFRSF21, GITR / TNFRSF18, HVEM / TNFRSF14, L TBR, OX40 / TNFRSF4, TROY / TNFRSF19, RELT / TNFRSF19L, TNFRSF12A, TNFRSF13B, TL1A / TNFSF15, TNFRSF17, TNFRSF1A, TNFRSF11B, RANK / TNFRSF11A, TNFRSF11B, NGFR, EDA2R, and TNFRSF1B.

54. The multispecific antibody according to any one of claims 1 to 53, which binds at least to: (a) CD3 and CD28, (b) CD3 and CD137, (c) CD137 and PD-1, (d) CD40 and PD-1, (e) CD40 and PD-L1, (f) CD137 and GITR, (g) CD137 and PD-L1, (h) CD137 and CD40, (i) CD137 and OX40, (j) CD3 and PD-1, (k) CD3 and PD-L1, or (l)CD3 and CTLA4.

55. The multispecific antibody of any one of claims 1 to 49, wherein the first TAA, optionally the second TAA and the third TAA are selected from the group consisting of: B7H3, CD19, CD20, PSMA, HER2, CEA, BCMA, P53 mutant, DLL3, MET and EGFR.

56. The multispecific antibody according to any one of claims 1 to 50, which binds to: (1) B7H3, CD3 and CD137; (2) CD19, CD3, and CD137; (3) B7H3, CD3, and CD28; (4) CD19, CD3, and CD28; (5) B7H3, CD137, and PD-1; (6) B7H3, CD40, and PD-1; (7)PMSA, CD3 and CD137; (8) B7H3 and CD3; (9) B7H3 and CD137; (10) CD19 and CD3; (11) CD19 and CD137; (12) B7H4 and CD40; (13) HER2, CD3, and CD137; (14) CEA, CD3 and CD137; (15) BCMA, CD3 and CD137; (16) P53 mutants, CD3, and CD137; (17) PD-1 and CD137; (18) PD-1 and CD40; (19) B7H3 and CD40; (20) PD-L1 and CD40; (21) PD-L1 and CD3; (22) PD-L1, CD3, and CD137; (23) PD-L1, CD3, and CD28; (24) PD-L1, CD137, and B7H3; (25) PD-L1, CD40, and B7H3; (26) PD-1, CD40, and CD137; (27) PD-1, CD137, and GITR; (28) CD19, CD20, CD3 and CD137; (29) CEA and CD3; (30) CEA and CD137; (31) P53 mutants and CD3; (32) P53 mutants and CD137; (33) PD-L1, CD40, and CD137; (34) PD-L1 and CD137; (35) MET, EGFR, and CD47; (36) BCMA and CD3; (37) BCMA and CD137; (38) PSMA and CD3; (39) HER2 and CD3; (40) HER2 and CD40; (41) HER2 and CD137; (42) PSMA and CD137; (43) HER2, MET, CD3 and CD137; (44) MAGE-A4, CD3 and CD137; (45) PRAME, CD3 and CD137; (46) HER2, MET, and CD3; (47)MAGE-A4 and CD3; (48)PRAME and CD3; (49) HER2, MET, and CD47; (50)B7H3, CD3 and PD-1; (51) B7H3, CD3 and PD-L1, or (52) B7H3, CD3, and CTLA4; (53) PSMA, CD3, and CD137; (54) PSMA, CD3, and CD28; (55) HER2, CD3, and CD137; (56) HER2, CD3, and CD28; (57) CEA, CD3 and CD137; (58) CEA, CD3 and CD28; (59) BCMA, CD3, and CD137; (60) BCMA, CD3 and CD28; or (61)CD19, CD19, CD3 and CD28.

57. The multispecific antibody according to any one of claims 1 to 56, wherein the multispecific antibody comprises heavy chain complementarity determining regions (CDRs) and light chain CDRs identical to the heavy chain CDRs and light chain CDRs in one or more of the parent antibodies listed in Table 1; optionally wherein the multispecific antibody comprises V sequences identical to those in the one or more parent antibodies. H and V L Same V H and V L .

58. The multispecific antibody of any one of claims 1 to 57, which is bivalent, trivalent or tetravalent.

59. A nucleic acid or group of nucleic acids that together encode the multispecific antibody of any one of claims 1 to 58.

60. The nucleic acid or nucleic acid set according to claim 59, which is an expression vector or an expression vector set.

61. A host cell comprising the nucleic acid or nucleic acid set according to claim 59 or claim 60.

62. The host cell of claim 61 which is a mammalian host cell.

63. A method for producing a multispecific antibody, the method comprising: (i) culturing the host cell according to claim 61 or claim 62 under conditions that allow expression of the antibody; as well as (ii) collecting the antibodies thus produced.

64. A pharmaceutical composition comprising the multispecific antibody or a nucleic acid or a nucleic acid set encoding the multispecific antibody according to any one of claims 1 to 58, and a pharmaceutically acceptable carrier.

65. A method for modulating an immune response in a subject, the method comprising administering to a subject in need thereof an effective amount of a multispecific antibody according to any one of claims 1 to 58, a nucleic acid encoding the multispecific antibody, or a pharmaceutical composition comprising the antibody or encoding nucleic acid.

66. The method of claim 65, wherein the subject is a human patient having or suspected of having cancer.